The pathologist's H&E is like the clinician's H&P (history and physical) - basic exams to be performed on every patient or specimen forming the cornerstone of diagnosis. However, the pathologist is no longer limited to the H&E; there are a wide variety of special studies available to evaluate pathologic processes, from simple histochemical stains to global gene expression patterns. Pathologists are now clinical cell biologists. Familiarity with the types of special studies available is important as the initial processing of the gross specimen may limit the types of studies that can be performed.

HISTOCHEMISTRY {#s0010}
==============

Almost all histochemical stains are suitable for formalin-fixed tissues. Common stains and their uses are listed in [Table 7-1](#t0010){ref-type="table"} . However, numerous other types of stains and modifications are used and pathologists must be aware of individual laboratory practices.TABLE 7--1HISTOCHEMICAL STAINSSTAINCOMPONENTS STAINEDPOSSIBLE USES AND COMMENTSAFOG (acid fuschin orange G; modified Masson's trichrome)Nuclei -- brownConnective tissue -- blueBasement membrane -- blueProteins, fibrin, readsorption droplets in cells, immune complexes -- red/orange/yellowRBCs -- yellowEvaluation of renal biopsiesAlcian blueAcid mucins -- blue (e.g., normal intestinal glands)Nuclei -- redCytoplasm -- pinkSometimes used to identify mucosubstances in mesotheliomas or intestinal metaplasia. Affected by pH. Hyaluronidase digestion can be used to identify hyaluronic acid.Alcian blue/PASIntestinal metaplasia -- dark purpleNormal stomach -- pinkDemonstrates both acid and neutral mucinsAlcian yellowFree mucus -- yellowBacteria -- dark blueIdentification of *H. pylori* in gastric biopsiesAcid-fast bacilli stains (Fite-Faraco, Ziehl-Neelson, Kinyoun)TB -- red and beadedMAI -- red*Nocardia* -- pinkTissue -- blueIdentification of mycobacteria. Modifications are used to demonstrate *M. leprae* or *Nocardia*. Carnoy's fixed tissues cannot be used and B-5 is suboptimal. Slides must be examined under oil.Alizarin red SCalcium -- orange red, polarizesIdentifies calcium in tissuesBileBile -- dark green on a yellow backgroundIdentification of bileBodian'sNerve fibers and neurofibrils -- blackNuclei -- blackTissue -- blueNeural tumors, identification of axonsChloroacetate esterase (Leder; CAE)Mature myeloid cells, mast cells -- red granulesNuclei -- blueEvaluation of leukemiasIdentification of mast cellsCannot be used for tissue fixed in Zenker's or B-5.Congo redAmyloid -- orange red with apple green birefringence after polarizationNuclei -- blueDetection of amyloid. Immunoperoxidase studies can be used to identify specific types. Overstaining can result in false positives.DieterleSpirochetes, *Legionella*, other bacteria -- brown to blackTissue -- pale yellow or tanInfectious lesionsMelanin, chromatin, formalin pigment, and foreign material may also stainDiff Quik (a modified Giemsa stain)*H. pylori* -- dark blueOther bacteria -- blueNuclei -- dark blueCytoplasm -- pinkEvaluation of chronic gastritisElastic stains (Verhoeff--van Gieson)Elastic fibers -- blue black to blackNuclei -- blue to blackCollagen -- redOther tissue -- yellowIdentification of arteries and veins, vasculitis, invasion of lung tumors into visceral pleura, abnormal elastic fibers in elastofibromasFibrin (see Phosphotungstic acid hematoxylin or Mallory PTAH)To demonstrate fibrin in renal biopsiesFontana-MassonMelanin, argentaffin granules, chromaffin granules, some lipofuschin -- blackNuclei -- redIdentification of melanin in melanomas and secretory granules in neuroendocrine tumorsThis stain has largely been replaced by IHCGiemsa (May-Grunwald)Bacteria (e.g., *H. pylori*) -- blueParasites (*Leishmania*, *Plasmodium*) -- blueMast cells -- red to purple granulesNuclei -- blueCytoplasm of leukocytes -- pink to blue depending on cell type and differentiationLymphoproliferative disorders (good nuclear and cytoplasmic detail)Identification of bacteria, rickettsias, and *Toxoplasma gondii*Gram (Brown-Hopps, Brown-Brenn)Gram-positive bacteria -- blueGram-negative bacteria -- redNuclei -- redTissue -- variableIdentification of bacteria, some cases of actinomycetes, *Nocardia*, coccidioidomycosis, blastomycosis, cryptococcosis, aspergillosis, rhinosporidiosis, and amebiasisGrimeliusArgentaffin and argyrophil granules -- dark brown to blackNuclei -- redBackground -- pale yellow-brownEvaluation of neuroendocrine tumors (largely replaced by the use of immunohistochemistry for chromogranin)Hematoxylin and eosin (H&E)Nuclei -- dark blue or purpleCytoplasm -- pink to redStandard stain for the routine evaluation of tissuesIron (colloidal iron)Ferric iron (e.g., hemosiderin) -- blueNuclei -- redBackground -- pinkBone marrow (iron stores, myelodysplasias), liver (hemochromatosis)Chromophobe renal cell carcinomas are positiveJone's silver methenamineBasement membrane -- dark maroon to blackEvaluation of renal biopsiesMelanin bleachRemoves melanin from tissue, usually for IHCMelanin can be difficult to distinguish from IHC positivityMethyl green-pyronin YDNA (nuclei) -- green to blue-greenRNA - redGoblet cells - mint greenPlasma cell and immunoblast cytoplasm - pink to redMast cells - orangeBackground - pale pink to colorlessPlasma cell lesions (largely replaced by IHC)Does not work well on tissues decalcified with formic acid.Mucicarmine (Mayer)Mucin - deep rose to redCapsule of *Cryptococcus* - deep rose to redNuclei - blackTissue - blue or yellowIdentification of adenocarcinomas, identification of *Cryptococcus*Oil red OFat - redNuclei - blueRequires frozen sections (lipids are dissolved by most fixatives or during processing). Tissue fixed in formalin can be used if tissue is frozen.Periodic acid -- Schiff (PAS)Glycogen - redBasement membranes (BM) - redMucins - redColloid - redFungi - redClassification of tumors with glycogen (e.g., Ewing's/PNET, rhabdomyosarcoma, renal cell carcinoma), glomerular diseases (BM), identification of adenocarcinomas (mucin), fungal diseases (especially in argentophic areas -- neutrophils and debris), spironolactone bodies in adrenal adenomas treated with this drugPeriodic acid -- Schiff with diastase digestion (PAS-D)As above except glycogen that has been digested will not be stainedIdentification of glycogen in tumorsIdentification of fungus in glycogen-rich tissue (e.g., skin)PAS-D resistant deposits in liver are present in alpha-1-antitrypsin deficiencyPhosphotungstic acid hematoxylin (Mallory PTAH)Glial fibers - blueNuclei - blueNeurons - salmonMyelin - blueSkeletal muscle cross striations - blueFibrin - blueCollagen - red brownIdentification of neural lesionsSkeletal muscle differentiation (Zenker's fixative is preferred). This stain has been replaced by IHC for muscle markers.Reticular fibers (Gomor's reticulin, Gordon and Sweets, Snook)Reticulin - blackMature collagen, type 1 -- brownImmature collagen, types 3 and 4 - blackBone marrow (myelophthisis), liver (fibrosis, veno-occlusive disease), carcinoma vs. sarcoma (reticular network) (but largely replaced by IHC)Silver stain (Grocott methenamine--silver nitrate -- GMS)Fungi - black*Pneumocystis* - blackMucin - taupe to grayTissue - greenEvaluation of infectious diseasesBacteria will also stain black.SteinerSpirochetes, *H. pylori*, *Legionella*, other bacteria - dark brown to blackTissue - light yellowEvaluation of infectious diseasesSulfated Alcian blueMyocytes -- yellowConnective tissue -- red-purpleAmyloid -- sea-foam greenIdentification of amyloid in cardiac biopsiesToluidine blueMast cells - deep violetBackground - blueMast cell diseases, chronic cystitisTrichrome (Gomori, Masson)Mature collagen, type 1 -- dark blueImmature collagen, types 3 and 4 - light blueMucin - green or blueNuclei - blackCytoplasm, keratin, muscle fibers - redLiver (fibrosis)Trichrome - modifiedViable myocardium - magenta to brick redNonviable myocardium -dusky gray to mauveEvaluation of myocardial biopsiesVon Kossa calciumCalcium - blackTissue - redDemonstration of phosphate and carbonate radicals with calcium in tissues, identification of malakoplakia (Michaelis-Gutmann bodies)Warthin StarrySpirochetes - blackOther bacteria - black(including *Bartonella* sp.)Tissue - pale yellow to light brownInfectious lesions (including syphilis, cat scratch fever, and bacillary angiomatosis)Wright'sEosinophilic granules - pinkNeutrophilic granules - purpleLymphocytic cytoplasm - blueNuclei -blue to purpleBlood smears

The WebPath section of the University of Utah site ([http://library.med.utah.edu/webpath](http://medlib.med.utah.edu){#interref1}) has useful descriptions of special stains and illustrative photographs.

IMMUNOPEROXIDASE STUDIES {#s0015}
========================

The development of methods to detect antigens on tissue sections with antibodies was a major advance in surgical pathology. Immunohistochemical (IHC) studies are most frequently used for the following purposes:•Classification of tumors (e.g., carcinoma vs. lymphoma, B cell vs. T cell lymphoma).•Identification of in situ lesions vs. invasive carcinomas (e.g., myoepithelial markers in breast cancers, basal cell markers in prostate).•Prognostic factors (e.g., Ki-67 in glioblastomas).•Predictive factors to guide specific therapy (e.g., c-KIT, estrogen and progesterone receptors, HER2/neu).•Identification of extracellular material (e.g., β-2 microglobulin amyloid).•Identification of infectious agents (e.g., CMV or HSV).

Use of Immunohistochemistry. {#s0020}
----------------------------

A differential diagnosis is generated after examination of the H&E-stained slides. IHC is then used to gain evidence for or against diagnostic possibilities. "Trolling" cases through an immunohistochemistry laboratory by ordering numerous antibody studies without a clear reason in mind is more likely to lead to misguided diagnosis due to aberrant immunoreactivity than to provide an unexpected correct diagnosis.

Panels. {#s0025}
-------

There are no absolute rules for immunoreactivity in cells and tissues. Aberrant immunoreactivity or loss of immunoreactivity is occasionally observed for all antibodies, either due to biologic variability (e.g., occasional keratin-positive melanomas) or technical factors (e.g., impure antibodies, cross-reaction with other antigens, failure to preserve antigenicity). Thus, immunohistochemical markers are used most effectively as panels of markers with interpretation based on an immunohistochemical profile.

Slides for Immunohistochemistry. {#s0030}
--------------------------------

Tissue is often dislodged from normal glass slides during the treatments required for IHC. Thus, slides must be coated (e.g., with glue, poly-L-lysine, gelatin, albumin) or special commercial slides must be used. If slides are being prepared by another laboratory, the type of glass slide to be used must be specified.

Factors Affecting Immunogenicity. {#s0035}
---------------------------------

There are numerous variables that can affect antigenicity. The most common are listed below. Each laboratory must optimize its procedures for each antibody used. Studies on tissues or slides not prepared in the routine fashion for a laboratory must be interpreted with caution.•**Type of fixative.** Some fixatives destroy some antigens (e.g., Bouin's diminishes ER immunoreactivity, keratins are not well preserved in B5).[@bib1] Most studies are based on formalin-fixed tissue. Results cannot be assumed to be equivalent for other fixatives.•**Length of time of fixation** in formalin causes protein cross-linking, and antigenicity generally decreases with fixation times over 24 hours. To some extent, this effect can be reversed using antigen retrieval methods. Antigenicity can also be reduced if the tissue is fixed for too short a period (e.g., less than 6 hours).•**Prior decalcification in hydrochloric acid.** Decreases antigenicity of some epitopes (predominantly nuclear) but not others (predominantly cytoplasmic).[@bib2] Decalcifying agents using EDTA did not alter immunogenicity.•Decreased: estrogen receptor (ER), progesterone receptor (PR), Ki-67, p53, BerEp4 (tumor cells), H blood group.•Not affected: calcitonin, chromogranin, GCDFP-15, HMB 45, thyroglobulin, S100, prostate-specific antigen (PSA), keratins (CK 20, CAM5.2, AE1/AE3), A and B blood groups, others.•**Temperature** of baking the slide.•**Length of time since the glass slide was cut.** The immunoreactivity of the majority of antigens declines over days to weeks with potential complete loss at one month.[@bib3], [@bib4] The loss may be due to exposure of tissue to air with oxidation of amino acids, as the immunogenicity of tissue deeper in the block can be preserved for many years. Antigen retrieval methods do not completely restore the antigenicity of old slides. Coating slides with paraffin, storing the slides in a nitrogen desiccator, and/or storing at lower temperatures can partially preserve antigenicity. However, studies should be performed on newly cut slides, if possible.•**Antigen retrieval procedures** (e.g., proteolysis, heating \[microwave, steam\], special incubation fluids). To some extent these methods reverse the effects of formalin fixation. Variable effects are observed for different antibodies.•**Type of antibody** (polyclonal vs. monoclonal vs. mixture of different monoclonals, epitope detected, mouse vs. rabbit). Very different results can be obtained with different antibodies to the same protein or different commercial sources of the same antibody.•**Incubation time, incubation temperature, dilution of antibody.**•**Methods of signal amplification.**

Controls. {#s0040}
---------

Controls are essential for the appropriate interpretation of immunohistochemical studies and ensure that all steps of this complicated procedure have been performed adequately.

**Positive controls** consisting of tissues known to be immunoreactive should be included each time an antibody is used for a test case. Internal positive controls should always be evaluated when present, as they control not only for the technique used but also for the antigenicity of the tissue under investigation. The immunoperoxidase table lists normal cells that are generally immunoreactive for each antibody. Some laboratories have used vimentin as a control for immunogenicity as almost all tissue should demonstrate positivity.[@bib5] Given the wide and non-specific distribution of vimentin, smooth muscle alpha actin may be more useful in this context as pericytes, vascular smooth muscle, and myoepithelial cells present in most tissues are immunoreactive.

Examples of internal controls:•S100: Normal nerves, melanocytes, and Langerhans cells in epidermis, cartilage, some myoepithelial cells, skin adnexa•Estrogen and progesterone receptors: Normal luminal cells in ducts and lobules of the breast•CD31, FVIII: Vascular endothelium•c-KIT (CD117): Mast cells•Smooth muscle alpha actin: Blood vessel walls, myoepithelial cells in the breast•Vimentin: Blood vessels, stromal cells•High molecular weight (MW) keratin: Squamous epithelium•Low MW keratin: Glandular epithelium•CD15: Polymorphonuclear leukocytes

**Negative controls** usually consist of replacing the primary antibody with non-immune animal serum diluted to the same concentration as the primary antibody. No positive reaction should be present. If multiple primary antibodies are used reactive with different target antigens, then they may serve as negative controls for each other. Although the best negative control would be to use antibody preabsorbed against the target antigen, this is rarely practical in a diagnostic laboratory. Diagnostic slides should also be evaluated for internal negative controls. Aberrant immunoreactivity of tissues that should not be positive is indicative that the immunoreactivity is nonspecific and the study should not be used for interpretation.

Evaluation of Studies {#s0045}
---------------------

The following features must be taken into consideration when evaluating studies:

###  {#s0050}

####  {#s0055}

##### Location of Immunoreactivity {#s0060}

Antigens are present in specific sites. Some antigens may be present in more than one location or be extracellular.

Nonspecific positivity should be suspected when immunoreactivity is present in atypical locations:•**Background:** Suspect nonspecific positivity if normal cells or noncellular components are positive. This can occur with suboptimal performance of the assay or suboptimal antibodies.•**Edge artifact:** Antibodies can pool at edges or holes in tissue. True positivity should also be present in the center of the tissue.•**Necrosis or crushing of cells:** Nonspecific positivity can be seen in disrupted cells. Although keratin is generally reliable in necrotic tumors, other markers generally should not be interpreted.•**Inappropriate location** (e.g., cytoplasm instead of nucleus): Occasionally ER or PR are present in the cytoplasm instead of the nucleus. This is not interpreted as a positive result. Plasma cells have large amounts of cytoplasmic immunoglobulins that can crossreact with many antibodies.•In rare cases, immunoreactivity in an unusual location is of diagnostic importance:•**TTF-1:** Cytoplasmic (instead of nuclear) positivity in hepatocellular carcinomas.•**Ki-67 (MIB1):** Cytoplasmic and membrane (instead of nuclear) positivity in trabecular hyalinizing adenomas of the thyroid and sclerosing hemangiomas of the lung.•**Beta-catenin:** Nuclear (instead of cytoplasmic) positivity in solid pseudopapillary tumors of the pancreas and pancreatoblastomas. Both nuclear and cytoplasmic positivity is seen in the majority of colon carcinomas. Nuclear positivity is present in about 20% of endometrioid endometrial carcinomas and 70% of cases of desmoid-type fibromatosis.•**ALK:** The pattern of immunoreactivity correlates with the different types of chromosomal translocations in anaplastic large cell lymphomas.•**NPM** (nucleophosmin) shuttles between the cytoplasm and nucleus. NPM1 mutations occur in about 30% of adult AML and cause aberrant cytoplasmic expression of NPM ("NPMc+ AML"). These cases have a specific gene expression profile and distinctive clinical and prognostic features.

Examples of the normal location of antigens are shown in [Figure 7-1](#f0010){ref-type="fig"} .Figure 7--1Location of immunoreactivity (indicated in blue).

##### Identification of Immunoreactive Cells {#s0065}

Immunoreactivity of tumor cells must be distinguished from immunoreactivity of normal entrapped cells (e.g., desmin \[+\] skeletal muscle cells infiltrated by tumor, S100 \[+\] Langerhans cells in tumors, smooth muscle alpha actin \[+\] blood vessels, etc.). Plasma cells have large amounts of cytoplasmic immunoglobulin and can react nonspecifically with many antibodies.

##### Intensity of Immunoreactivity {#s0070}

Some weak immunoreactivity may be present as a nonspecific finding. It is important to compare positive cells with control slides and with normally nonimmunoreactive cells to determine whether the immunoreactivity is significant.

##### Number of Immunoreactive Cells {#s0075}

In some cases, the number of positive cells may be important as a criterion for positivity or as a prognostic marker (e.g., markers of proliferation such as Ki-67, HER2/neu). In other cases, rare weakly positive cells must be distinguished from intermingled normal cells or just nonspecific immunoreactivity.

##### Criteria for a "Positive" Result {#s0080}

Specific criteria for evaluating IHC have been developed for a few antibodies (see [TABLE 7--12](#t0065){ref-type="table"}, [TABLE 7--13](#t0070){ref-type="table"}, [TABLE 7--14](#t0075){ref-type="table"}, [TABLE 7--15](#t0080){ref-type="table"}, [TABLE 7--16](#t0085){ref-type="table"}). However, criteria do not exist for most antibodies or are not universally used by all pathologists. The significance of immunoreactivity varies with the type of lesion, the antibody, and the specific assay. Strong positivity in the majority of cells is easily interpreted as positive. As the number of positive cells decreases, and the intensity of immunoreactivity weakens, the lower threshold of a "positive" result becomes more difficult to determine.

##### Time {#s0085}

Alkaline phosphatase chromogens (red color) fade over time. DAB (a brown color) is more permanent. This is not a problem in evaluating current pathology specimens. However, if slides are reviewed after a period of time, some chromogens may fade and once positive results may appear to be negative.

Common Panels for Immunohistochemical Studies {#s0090}
---------------------------------------------

The following tables include information from the literature as well as the personal experiences of the staff at Brigham and Women's Hospital. Because of the many differences in specific antibodies, laboratory assays, and criteria for considering a result "positive," results may vary for different institutions. The results have been divided into five categories for general markers and four categories for hematopathology markers. Note that "%" refers to the number of tumors reported to be positive, not the number of cells positive within a tumor ([Table 7-2](#t0015){ref-type="table"} ).TABLE 7--2EVALUATION OF POSITIVITY OF IMMUNOHISTOCHEMICAL STUDIES![](fx23.gif)

The actual markers used to evaluate a case will depend upon the differential diagnosis based on the H&E appearance. In some cases, an initial panel, which is often used for typical cases, has been suggested. Not all markers listed would be used for all cases and some markers are included to indicate when they would not be useful for distinguishing the tumors listed in the table.

POSITIVE is defined as the presence of immunoreactive cells and NEGATIVE as the absence of immunoreactive cells. Unfortunately, "positive" has also been used in some studies to mean "absence of immunoreactivity" when this finding supports a diagnosis. For example, the absence of SMAD4 (DPC4) has been reported as a "positive" result for pancreatic carcinoma, as this marker is absent in the majority of these tumors. This method of reporting results becomes confusing as "positive" and "negative" are dependent on the expected diagnosis. It is preferable to report the findings (positive = immunoreactivity present; negative = immunoreactivity absent) and then interpret them as supporting, or not supporting, the diagnoses in the differential diagnosis.

### Cytokeratin 7 and cytokeratin 20 tables {#s0095}

The combination of these two cytokeratins have been found to be useful to divide carcinomas into four main groups (Ck7+/Ck20+, Ck7+/Ck20-, Ck7-/Ck20+, Ck7-/Ck20-).

In [TABLE 7--3](#t0020){ref-type="table"}, [TABLE 7--4](#t0025){ref-type="table"}, [TABLE 7--5](#t0030){ref-type="table"}, [TABLE 7--6](#t0035){ref-type="table"}, [TABLE 7--7](#t0040){ref-type="table"} , other commonly used antibodies have been included to show differences within each group. The most useful additional antibodies will depend on the specific differential diagnosis.[@bib6], [@bib7], [@bib8] TABLE 7--3PREDOMINANTLY CK7+/CK20+![](fx24.gif)TABLE 7--4NO DOMINANT CK7/CK20 PATTERN OR PATTERN UNKNOWN![](fx25.gif)TABLE 7--5PREDOMINANTLY CK7+/CK20−![](fx26.gif)![](fx27.gif)TABLE 7--6CK7−/CK20+![](fx28.gif)TABLE 7--7PREDOMINANTLY CK7−/CK20--![](fx29.gif)![](fx30.gif)

### Small blue cell tumors {#s0100}

See [Table 7-8](#t0045){ref-type="table"} .TABLE 7--8SMALL BLUE CELL TUMORS![](fx31.gif)

### Spindle cell lesions, soft tissue lesions, and sarcomas {#s0105}

See [Table 7-9](#t0050){ref-type="table"} .TABLE 7--9SPINDLE CELL/SOFT TISSUE LESIONS/SARCOMAS![](fx32.gif)![](fx33.gif)![](fx34.gif)![](fx35.gif)

### Metastatic tumors of unknown origin {#s0110}

Pathologists frequently receive specimens with metastatic tumors. Often, the site of origin is known to the clinician, but this information is not provided to the pathologist. A good clinical history is frequently more successful for correct classification than a battery of studies.

The Ck7/Ck20 pattern is generally helpful to narrow down the potential site of origin of carcinomas (see [TABLE 7--3](#t0020){ref-type="table"}, [TABLE 7--4](#t0025){ref-type="table"}, [TABLE 7--5](#t0030){ref-type="table"}, [TABLE 7--6](#t0035){ref-type="table"}, [TABLE 7--7](#t0040){ref-type="table"}). Additional studies can then be used to identify specific types of carcinoma.

The most important tumors to identify are those with specific therapeutic treatments for cure or palliation ([Table 7-10](#t0055){ref-type="table"} ).[@bib10] TABLE 7--10METASTATIC TUMORS OF UNKNOWN ORIGINTYPE OF TUMORIHCCOMMENTSPOTENTIAL TREATMENTBreastER/PRGyn carcinomas can also be positive. Other carcinomas are rarely positive.Palliated with hormonal treatment.HER2/neuIt is unusual for other carcinomas to be strongly positive for HER2/neu.HER2/neu-positive carcinomas can be treated with Herceptin.[a](#tblfn1){ref-type="table-fn"}GCDFP-15GCDFP-15 is not very sensitive, as many breast carcinomas are negative.The most common type of breast carcinoma to present as an occult primary is invasive lobular carcinoma.Rare women present with positive axillary nodes and no known primary. Most of these women will have breast cancer. The prognosis is the same, whether or not the primary is detected.Carcinoid tumorChromograninChromogranin positivity should be strong and diffuse. Focal and/or weak positivity can be seen in many carcinomas.Metastatic breast cancer and prostate cancer can closely resemble carcinoid tumor and both can be positive for chromogranin.Palliation with tumor-directed pharmaceuticals.Germ cell tumorsPLAPPLAP is not specific, but a germ cell tumor is unlikely if it is negative. Inhibin is more likely to be positive in choriocarcinomas.Chemotherapy for possible cure.OCT-4OCT-4 is highly specific for undifferentiated germ cell tumors (embryonal carcinoma and seminoma) among epithelioid and round cell malignant neoplasms. Other types of germ cell tumors (i.e., yolk sac tumor, teratoma, and choriocarcinoma) are negative.FISH can confirm an isochromosome 12p, even if the metastasis has the appearance of adenocarcinoma, sarcoma, or neuroendocrine carcinomaGISTc-kit (CD117)Specific mutations are correlated with treatment response.Treatment with Gleevec.[b](#tblfn2){ref-type="table-fn"}Lung adenocarcinomaTTF-1Thyroid carcinoma should be excluded if TTF-1 is positive.Up to 20% of patients will have specific activating mutations in EGFR (detected by PCR) and these patients may respond well to treatment with gefitinib.[c](#tblfn3){ref-type="table-fn"}LymphomaLCA, B and T cell markersTreatment for cure or long-term palliation.ProstatePSA or PrAPHormonal therapy effective for palliation.Small cell carcinomaTTF-1 (if of lung origin)Diagnosis made by H&E appearance. P63 is usually negative and can be useful to exclude squamous cell carcinoma.Chemotherapy for palliation.Neuroendocrine markersNot necessary for diagnosis, but can exclude other diagnoses.Squamous cell carcinomasCk5/6, p63Not specific, but characteristic. H&E appearance usually sufficient to reveal keratin production or intercellular bridges.Radiation therapy often effective.p16 or HPVHPV or p16 are most commonly present in carcinoma of the cervix, but may be seen in carcinomas at other sites.Vaccine trials are being conducted.About 26-38% of patients with a cervical LN metastasis of unknown primary will have an occult tonsillar carcinoma (usually basaloid type and p16 or HPV positive). Complete sampling of the tonsil may be necessary to identify these small carcinomas.CD5May be positive in thymic carcinomas.Thyroid -- papillary or follicular carcinomaThyroglobulin and TTF-1Lung carcinomas are also TTF-1 positive, but will be thyroglobulin negative.Highly effective treatment for cure with radioactive iodine.Thyroid -- medullary carcinomaCalcitoninIf familial, important for counseling other family members.Palliative treatment with tumor-directed radionucleotides.Trophoblastic tumorsInhibinInhibin is not specific, but a trophoblastic tumor is unlikely if it is negative.Chemotherapy for possible cure.[^1][^2][^3]

### Poorly differentiated tumors {#s0115}

See [Table 7-11](#t0060){ref-type="table"} .TABLE 7--11POORLY DIFFERENTIATED TUMORSTYPE OF TUMORIMMUNOHISTOCHEMICAL MARKERCOMMENTSCarcinomaBroad spectrum keratins AE1/AE3 or PANK (MNF-116)Some carcinomas may express unusual keratin sub-types. If negative, try other keratin types (e.g., CAM5.2). The Ck7/Ck20 pattern may be helpful in determining the likely site of origin.Some non-carcinomas can have an epithelioid appearance and strongly express keratins (e.g., epithelioid angiosarcoma, epithelioid sarcoma, mesothelioma).MelanomaS100 proteinS100 is strongly positive in the vast majority of melanomas.Some carcinomas (especially breast) and sarcomas are also positive for S100 and additional markers may be required.HMB-45 and MART-1 are expressed by most epithelioid melanomas but may be focal or absent in non-epithelioid melanomas (e.g., spindle cell or desmoplastic melanomas).LymphomaLeukocyte common antigen (LCA)Present in almost all non-Hodgkin's lymphomas.May be absent in 30% of anaplastic (Ki-1) large cell lymphomas. These lymphomas are keratin negative but may express EMA. These tumors will be positive for CD30 (Ki-1) and ALK.

### Estrogen and progesterone receptor evaluation {#s0120}

Hormone receptors are routinely determined on all invasive breast carcinomas and DCIS. ER and PR are weak prognostic markers and are more useful to predict the likelihood of response to hormonal therapies.

Many different methods are currently used to report the results of IHC studies for ER and PR. One method that has been used in multiple studies is the Allred score method ([Table 7-12](#t0065){ref-type="table"} ).TABLE 7--12ER AND PR---ALLRED SCOREPROPORTION SCORE (PS)% POSITIVE CELLSINTENSITY SCORE (IS)INTENSITY OF POSITIVITY000None1\<1%1Weak21% to 10%2Intermediate310% to 33%3Strong433% to 66%5\>66%**The PS and IS Are Added Together for a Total Score:Total Score (TS) = PS + ISInterpretation**0, 2Negative3, 4, 5, 6, 7, 8Positive

Patients with carcinomas that scored 3 (\<1% of cells with intermediate intensity or 1% to 10% of cells with weak intensity) or above had improved disease-free survival when treated with endocrine therapy.[@bib11] Patients with carcinomas with a total score of 2 (\<1% weakly positive cells) had a survival rate similar to ER-negative carcinomas (total score of 0).

About 80% of DCIS cases are positive for ER using the same method of scoring. Women with ER-positive DCIS were shown to experience fewer local recurrences, contralateral recurrences, and distant recurrences when treated with tamoxifen (NSABP B24 study).

With optimization of IHC using newer antigen retrieval methods, 99.2% of carcinomas will have scores of 0, 7, or 8.[@bib12] Therefore, many laboratories report results as positive or negative. The value of further subdividing cases by percent positive cells, H-score, or image analysis for either prognosis or to predict response to tamoxifen has not been demonstrated. Intensity of immunoreactivity is difficult to evaluate as most cases show strong reactivity with optimal assay methods and most carcinomas show considerable variability in intensity.

A possible method for reporting results is shown in [Table 7-13](#t0070){ref-type="table"} . The same system can be used for reporting progesterone receptor results. The use of both ER and PR may be helpful for determining the likelihood of response to tamoxifen, as has been shown with data using the biochemical assay ([Table 7-14](#t0075){ref-type="table"} ). Presumably, the presence of the ER-regulated gene product PR is more predictive of an intact ER regulatory pathway.TABLE 7--13REPORTING RESULTS OF ER AND PR EVALUATIONRESULTCRITERIA% OF CASESCOMMENTSPositive\>10% of cells70% to 80%This group corresponds to PS scores of 3 and above. The majority of these carcinomas will have scores of 7 or 8.Borderline or low positive\>0% to 10%\<5% to 10%The clinical significance of this group is unclear. This group may be interpreted as "negative" or "positive" by some laboratories depending on the cut-off point chosen. This group could include cases with Allred scores of 2, 3, 4, or 5.Negative020% to 30%This group corresponds to a TS score of 0.TABLE 7--14RESPONSE TO TAMOXIFENSTATUS OF CARCINOMA% OF CARCINOMAS% OF PATIENTS RESPONDING TO TAMOXIFENER+ PR+63%75% to 80%ER+ PR--15%25% to 30%ER-- PR+5%40% to 45%ER-- PR--17%\<10%

Recent national guidelines for reporting ER and PR have been released and should be consulted for additional information about performing and interpreting these studies (Hammond ME, et al, American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer, J Clin Oncol 2010 Apr 19).False negative results, and to a lesser extent, false positive results, can also be problems. **False negative results** may be due to a large number of causes including:•Low sensitivity of the assay•Errors in performing the assay•Delayed fixation of tissue•Over- or underfixation of tissue•Overheating of tissue (e.g., with cautery during surgery)•Decalcification of tissue

Most cases of false negativity can be suspected, as the normal breast tissue will also be negative. In such cases, the assay should be repeated on the same block, a different block from the same case, or blocks from another case, if available. If the normal tissue remains negative, the possibility of loss of antigenicity in the tissue can be mentioned in the report.

**False positive results** are quite unusual, as the antibody should not crossreact with other antigens.•Entrapped normal ducts or lobules misinterpreted as carcinoma --- this can be a difficult issue for DCIS as some ducts or lobules may be only partially involved by DCIS.•Control placed on same slide misinterpreted as the carcinoma•Sclerosing adenosis or myofibroblastoma (or other benign lesions) misinterpreted as invasive carcinoma

### HER2/neu score {#s0125}

The HER2/neu immunoreactivity scoring system in [Table 7-15](#t0080){ref-type="table"} was recommended by an expert panel.[@bib13] Other panel suggestions:•If cytoplasmic positivity obscures the membrane pattern, repeat the assay or perform FISH.•If normal ducts and lobules show definitive positivity, repeat the assay.•In cases of invasive carcinoma, only the areas of invasion should be scored. In some cases the associated DCIS can show stronger immunoreactivity.•Fixation must be in neutral buffered formalin and should, ideally, be between 6 and 48 hours for excisions, and at least 1 hour for needle biopsies. However, any effect from longer fixation has not been shown.•Unstained slides should not be used if prepared \>6 weeks earlier. Loss of antigenicity has been shown for other antigens, but not specifically for HER2. TABLE 7--15HER2-IHC SCORINGSCORECRITERIA% OF CASES% OF CASES THAT SHOW AMPLIFICATION BY FISH0 (Negative)No immunoreactivity or immunoreactivity in \<10% of tumor cells.\~ 60%0% to 3%1+ (Negative)Faint weak immunoreactivity in \>10% of tumor cells but only a portion of the membrane is positive.\~ 10%0% to 7%2+ (Equivocal)Weak to moderate complete membrane immunoreactivity in \>10% of tumor cells.\~ 5% to 10%25% to 35%3+ (Positive)More than 30% of the tumor cells must show circumferential intense and uniform membrane staining. A homogeneous (chicken wire) pattern should be present.\~15% to 20%75% to 90%

Only membrane immunoreactivity is scored. Marked cytoplasmic immunoreactivity may make interpretation difficult. FISH studies may be preferred for such cases ([Table 7-16](#t0085){ref-type="table"} ).TABLE 7--16FISH RESULTSRESULTCRITERIAcommentPositive for amplification\>6.0 gene copies or \>2.2 ratioEquivocal for amplification4.0 to 6.0 genes or 1.8 to 2.2 ratioGuidelines suggest counting additional cells for FISH, retesting, or performing IHCNegative for amplification\<4.0 genes or \<1.8 ratio[^4]

In \>90% of carcinomas with protein overexpression, the HER2/neu gene has been amplified. In 3% to 5% of cases, protein overexpression can occur due to other mechanisms. In \<5% of cases, there may be gene amplification without protein overexpression. In general, there is a 20% to 40% response to Herceptin alone in patients with cancers showing gene amplification by FISH, and \<5% of patients respond if the gene is not amplified. Therefore, FISH studies may be helpful for cases with 2+ positivity or difficult to interpret cases (e.g., with variable positivity or cytoplasmic positivity).

Well- and moderately differentiated lobular carcinomas are rarely positive (\<5%). However, in some cases there may be edge enhancement of individual tumor cells that may be difficult to interpret. FISH studies may be helpful.

In rare cases, DCIS overexpresses HER2/neu but the accompanying invasive carcinoma does not. This is a source of potential false positive results for IHC or FISH.

### Myoepithelial markers in breast carcinoma {#s0130}

Myoepithelial markers can be useful for the evaluation of breast lesions ([Table 7-17](#t0090){ref-type="table"} ):•Invasive carcinoma vs. sclerosing adenosis (frequently involved by DCIS, LCIS, or apocrine metaplasia).•DCIS vs. DCIS with microinvasion -- Double immunolabeling with p63 (brown nuclear) and cytokeratin (AE1/AE3 -- red cytoplasm) can be useful to highlight small nests of tumor cells lacking myoepithelial cells. A double stain with SMMHC and cytokeratin AE1/AE3 can also be helpful.•DCIS vs. carcinoma invading as circumscribed tumor nests vs. lymphovascular invasion.•Microglandular adenosis is the only "benign" breast lesion that lacks myoepithelial cells. However, this lesion may be a form of well-differentiated non-metastasizing invasive carcinoma. The cells are negative for ER and PR and strongly positive for S100. TABLE 7--17MYOEPITHELIAL MARKERS IN BREAST CARCINOMA![](fx36.gif)

### Epidermal lesions of the nipple {#s0135}

See [Table 7-18](#t0095){ref-type="table"} .TABLE 7--18EPIDERMAL LESIONS OF THE NIPPLE AND PAGET DISEASE AT OTHER SITES![](fx37.gif)

### Breast carcinoma in males versus metastatic prostate carcinoma {#s0140}

See [Table 7-19](#t0100){ref-type="table"} .TABLE 7--19BREAST CARCINOMA IN MALES VERSUS METASTATIC PROSTATE CARCINOMA![](fx38.gif)

### Signet ring cell carcinomas of the stomach and breast (lobular carcinoma) {#s0145}

See [Table 7-20](#t0105){ref-type="table"} and [Fig. 7-2](#f0015){ref-type="fig"} .TABLE 7--20SIGNET RING CELL CARCINOMAS OF THE STOMACH AND BREAST (LOBULAR CARCINOMA)![](fx39.gif)Figure 7--2Metastatic lobular carcinoma of the breast can morphologically resemble primary signet ring cell gastric carcinomas. Both typically lack e-cadherin expression. In addition, lobular breast carcinomas can be clinically occult or can present as distant metastases many years after the initial presentation. Signet ring cells associated with breast carcinoma more commonly have a central mucin vacuole with a targetoid appearance (cell **A**). Gastric signet ring cells usually have many small vacuoles giving the cytoplasm a foamy appearance (cell **B**). These criteria are not reliable in distinguishing these two carcinomas. However, the presence of the first type of signet ring cell in a biopsy from the gastrointestinal tract should raise the possibility of metastatic breast carcinoma.[@bib14] The majority of lobular breast carcinomas will be ER positive, and this is a reliable marker to exclude gastric carcinoma. In the minority of ER-negative cases, PR, GCDFP, MUC1, CDX2, and Hep Par may be helpful markers.[@bib15]

### Fibroblastic/myofibroblastic lesions of the breast {#s0150}

See [Table 7-21](#t0110){ref-type="table"} .TABLE 7--21FIBROBLASTIC/MYOFIBROBLASTIC LESIONS OF THE BREAST![](fx40.gif)

### Ovarian carcinoma versus mesothelioma {#s0155}

See [Table 7-22](#t0115){ref-type="table"} .TABLE 7--22OVARIAN CARCINOMA VERSUS MESOTHELIOMA![](fx41.gif)

### Primary ovarian carcinoma versus metastatic carcinomas {#s0160}

See [Table 7-23](#t0120){ref-type="table"} .TABLE 7--23PRIMARY OVARIAN CARCINOMA VERSUS METASTATIC CARCINOMAS![](fx42.gif)

### Endocervical carcinoma versus endometrial carcinoma {#s0165}

See [Table 7-24](#t0125){ref-type="table"} .TABLE 7--24ENDOCERVICAL CARCINOMA VERSUS ENDOMETRIAL CARCINOMA![](fx43.gif)

### Endometrial stromal sarcoma versus leiomyosarcoma {#s0170}

See [Table 7-25](#t0130){ref-type="table"} .TABLE 7--25ENDOMETRIAL STROMAL SARCOMA VERSUS LEIOMYOSARCOMA![](fx44.gif)

### Trophoblastic lesions {#s0175}

See [Table 7-26](#t0135){ref-type="table"} .TABLE 7--26TROPHOBLASTIC LESIONS![](fx45.gif)

### Metastatic adenocarcinomas in the abdomen {#s0180}

See [Table 7-27](#t0140){ref-type="table"} .TABLE 7--27METASTATIC ADENOCARCINOMAS IN THE ABDOMEN![](fx46.gif)

### CNS neoplasms {#s0185}

See [Table 7-28](#t0145){ref-type="table"} .TABLE 7--28CNS NEOPLASMS![](fx47.gif)

### Hemangioblastoma versus metastatic renal cell carcinoma {#s0190}

See [Table 7-29](#t0150){ref-type="table"} .TABLE 7--29HEMANGIOBLASTOMA VERSUS METASTATIC RENAL CELL CARCINOMA![](fx48.gif)

### Tumors of germ cells and sex-cord stromal tumors {#s0195}

See [Table 7-30](#t0155){ref-type="table"} .TABLE 7--30TUMORS OF GERM CELLS AND SEX-CORD STROMAL TUMORS![](fx49.gif)

### Adrenal and kidney tumors {#s0200}

See [Table 7-31](#t0160){ref-type="table"} .TABLE 7--31ADRENAL AND KIDNEY TUMORS![](fx50.gif)

### Tumors of bladder, prostatic, and renal origin {#s0205}

See [Table 7-32](#t0165){ref-type="table"} .TABLE 7--32TUMORS OF BLADDER, PROSTATIC, AND RENAL ORIGIN![](fx51.gif)

### Prostate carcinoma versus other lesions {#s0210}

See [Table 7-33](#t0170){ref-type="table"} .TABLE 7--33PROSTATE CARCINOMA VERSUS OTHER LESIONS![](fx52.gif)

### Hepatic tumors {#s0215}

See [Table 7-34](#t0175){ref-type="table"} .TABLE 7--34HEPATIC TUMORS![](fx53.gif)

### Thyroid and parathyroid lesions {#s0220}

See [Table 7-35](#t0180){ref-type="table"} .TABLE 7--35THYROID AND PARATHYROID LESIONS![](fx54.gif)

### Differential diagnosis of epithelial mesothelioma and lung adenocarcinoma {#s0225}

See [Table 7-36](#t0185){ref-type="table"} .TABLE 7--36DIFFERENTIAL DIAGNOSIS OF EPITHELIAL MESOTHELIOMA AND LUNG ADENOCARCINOMA![](fx55.gif)

**Initial panel:** AE1/AE3, calretinin, WT-1 (clone 6F-H2), CEA, Leu-M1, and TTF-1 with additional studies ordered in difficult cases.

Other antibodies generally reported as negative in epithelial mesotheliomas and positive in lung adenocarcinomas include the following: MOC-1, B72.3, Ber-EP4, and BG-8. Cytokeratins 5/6 are reported to be positive in mesotheliomas and negative in lung carcinomas. However, in our experience, these markers have proven less useful than the ones listed earlier. The use of EMA is controversial. Strong membrane positivity is characteristic of epithelial mesothelioma, whereas cytoplasmic positivity is characteristic of adenocarcinomas.

Less is known about the immunophenotype of pure sarcomatoid mesotheliomas. The spindle cells are positive for cytokeratin, but are less frequently positive for the other markers as compared to the epithelioid cells. Tumors that can, on occasion, resemble mesotheliomas are generally negative for cytokeratins, with the notable exceptions of some cases of angiosarcoma, epithelioid hemangioendothelioma, synovial sarcoma, epithelioid sarcoma, and leiomyosarcoma (see [Table 7-9](#t0050){ref-type="table"}).[@bib16]

### Lung carcinoma {#s0230}

See [TABLE 7--37](#t0190){ref-type="table"}, [TABLE 7--38](#t0195){ref-type="table"} .TABLE 7--37LUNG CARCINOMAS![](fx56.gif)TABLE 7--38DIFFERENTIAL DIAGNOSIS OF LUNG CARCINOMASDIFFERENTIAL DIAGNOSISMOST USEFUL MARKERSAdenocarcinoma vs. squamous cell carcinomaKeratin 7, keratin 20, TTF-1, p63Small cell carcinoma vs. basaloid squamous cell carcinomaP63, TTF-1Small cell carcinoma vs. carcinoid tumorMitoses, necrosis, amount of cytoplasmLarge cell neuroendocrine carcinoma vs. carcinoid tumorMitoses, necrosisMucinous lung carcinoma vs. metastatic colon cancerTTF-1, CDX2 (mucinous BAC can be focally positive for CDX2)Lung carcinoma vs. metastatic breast carcinomaTTF-1, compare ER/PR/HER2 pattern in primary breast carcinoma and lung tumor

### B-cell neoplasms {#s0235}

See [Table 7-39](#t0200){ref-type="table"} .TABLE 7--39B-CELL NEOPLASMS![](fx57.gif)![](fx58.gif)

### T-cell neoplasms {#s0240}

See [Table 7-40](#t0205){ref-type="table"} .TABLE 7--40T-CELL NEOPLASMS![](fx59.gif)![](fx60.gif)

### Hodgkin lymphoma {#s0245}

See [Table 7-41](#t0210){ref-type="table"} .TABLE 7--41HODGKIN LYMPHOMA![](fx61.gif)

### Amyloid {#s0250}

Amyloidosis (Greek for *amylon* = starch plus *eidos* = resemblance) is seen in many different clinical settings and is associated with many diseases. Pathologists can narrow down the differential diagnosis considerably to help guide clinical decision making. Finding an amyloid deposit in any tissue is similar to finding metastatic carcinoma in a lymph node -- in both settings clinical information (e.g., history, physical examination, radiology studies, results of laboratory tests) is essential in arriving at the correct interpretation. A little immunohistochemistry and a lot of clinical judgment by the pathologist can help establish the cause with a greater degree of certainty.[@bib17]

**Finding and characterizing amyloid deposits:** 1.Examine the H&E slide for noncellular material in the correct location for the suspected disease ([Table 7-42](#t0215){ref-type="table"} ).TABLE 7--42AMYLOIDTYPE OF AMYLOID-RELATED DISEASETYPE OF PROTEIN (AVAILABLE TESTS)UNDERLYING DISEASEORGAN INVOLVEMENTOTHER FEATURESPrimary ALKappa and lambda light chains (IF and IHC)Multiple myeloma (15% have amyloid)Benign monoclonal gammopathyHeart, bone marrow (only amyloid at this site), kidney, neuromuscular, joints, liver, spleen, tongue, larynxMay have Factor X deficiency (binds to light chains)Localized forms of amyloid are not associated with systemic diseaseSecondary AASerum amyloid protein A (IF[b](#tblfn4){ref-type="table-fn"})Chronic inflammation: infection, RA, Crohn's disease, sarcoid, familial Mediterranean fever, malignancy (RCC, HD)Spleen (100% -- sago \[tapioca\] or lardaceous), kidneys (75%), adrenals (40%), heart (symptoms rare), joints (rare)Dialysis-associatedBeta-2-microglobulin (IHC)Long-term hemodialysis, rarely seen in peritoneal dialysis or with chronic renal failureJoints (periarticular tissue), carpal tunnel, rarely systemic (GI, vessels), rarely involves fat, does not involve spleenMedullary carcinoma-associatedCalcitonin (IHC)Medullary carcinoma of the thyroidAssociated with the tumorCalcitonin can also be used to detect C cell hyperplasiaOther tumor-associated amyloidPeptide hormonesEndocrine tumorsAssociated with the tumorAlzheimer'sBeta amyloid (IHC)Alzheimer's diseaseBrain -- senile plaque cores, neuritic plaques, neurofibrillary tanglesAlso seen in Lewy body dementia, Down's syndrome, hereditary cerebral amyloidosis (Dutch type)Other hereditary dieasesTransthyretin (IHC)Familial amyloid polyneuropathy, senile/cardiac amyloidosisHeart (usually without symptoms), joints, prostateAmyloid P component APAssociated with all forms of amyloid. May be used to detect amyloid radiologically.[^5][^6]2.Amyloid deposits will be orange-pink on Congo Red stains or sea-foam green on Sulfated Alcian blue stains. Amyloid may be more apparent on these stains. HOWEVER, beware of overcalling cases in which there is not a histologic correlate for amyloid in the stained tissue. If there is background positivity in normal tissue due to overstaining, the slide cannot be interpreted. Positive controls must show appropriate specific positivity.3.Congo red-positive amyloid should become an apple green color when viewed under polarized light. This may require the high-quality polarizers that are built in to the microscope. Lower quality polarizers (i.e., the cut squares of polarizing material) may not be adequate. Collagen (silver when H&E is polarized) and fibrin (does not polarize) may mimic amyloid.4.The amyloid deposits can be further characterized using immunohistochemistry or immunofluorescence (see [Table 7-42](#t0215){ref-type="table"}) based on the clinical information, the organ or structures involved, and the distribution of amyloid deposits in the tissue. Amyloid can also be identified using EM (non-branching fibrils, 7.5 to 10 nm width and up to 1 micron in length).5.A firm diagnosis is not always possible. The final diagnosis should be based on a combination of histologic, immunohistochemical, and clinical data.

### Antibodies for immunohistochemistry {#s0255}

See [TABLE 7--43](#t0220){ref-type="table"}, [TABLE 7--44](#t0225){ref-type="table"} .TABLE 7--43ANTIBODIES FOR IMMUNOHISTOCHEMISTRYNAME (ALTERNATE NAME)ANTIGEN (LOCATION)NORMAL CELLS AND TISSUESTUMORSUSESCOMMENTSGeneral Markers**Actin (alpha smooth muscle actin)***(SMA, SM-ACT)*Smooth muscle isoform of actin*(Cytoplasm or membrane)*Smooth muscle, myoepithelial cells, blood vessel walls, pericytes, some stromal cells of intestine, testis, and ovary, myofibroblasts in desmoplastic stroma.Not in striated muscle or myocardium.Smooth muscle tumors, myofibroblastic tumors, PEComas, glomus tumors, KS, some spindle cell carcinomas (e.g., with features of myoepithelial cells)ID of smooth muscle differentiation (muscle or myofibroblasts) in tumors.Noninvasive lesions of breast (myoepithelial cells present if benign or DCIS) vs. invasive carcinoma. Microglandular adenosis also lacks myoepithelial cells.Good marker for myoepithelial cells of the breast but also positive in myofibroblasts in stroma. P63 is more specific, but less sensitive for myoepithelial cells.**Actin (muscle-specific actin)** (HHF35, MSA, muscle common actin, EM ACT)Alpha and gamma smooth muscle actins, recognizes a common epitope of alpha skeletal, cardiac, and smooth muscle*(Cytoplasm)*Smooth, striated, and cardiac muscle, smooth muscle of blood vessels, pericytes, myoepithelial cells, myofibroblastsNumerous tumors including tumors of muscle, glomus tumor, PEComa, GIST, DFSP, dermatofibroma, myofibroblastic tumors, spindle cell carcinomas, salivary gland tumors, mesothelioma, othersID of muscle differentiation in tumors.Sensitive but not specific. Present in tumors not of muscle origin.**Alpha fetoprotein** (AFP, alpha 1-fetoprotein)Glycoprotein present in fetal liver(Cytoplasm, granular)Fetal liver, regenerating liver cellsHCC (but not the fibrolamellar variant), hepatoblastomas, yolk sac tumors, embryonal carcinoma (but less commonly)HCC (+/−) vs. other cell types (however, AFP is rarely present in other carcinomas such as breast and ovary).Yolk sac tumors (+) vs. other germ cell tumors (−/+).Correlates with extracellular hyaline eosinophilic globules in yolk sac tumors**Alpha 1-antitrypsin***(AAT, alpha-1-AT)*Glycoprotein that inhibits proteolytic enzymes produced in the liver*(Cytoplasm)*Histiocytes, reticulum cells, mast cells, Paneth cells, salivary glandHCC, germ cell tumors, true histiocytic neoplasms, colon and lung carcinoma, othersAccumulates in liver cells in AAT deficiencyNot specific for tumor type.CD68 is somewhat more specific for macrophages.**AMACR** (*P504S, alpha-methylacyl-CoA racemase*)Mitochondrial and peroxisomal enzyme involved in the metabolism of branched-chain fatty acid and bile acid intermediates(Cytoplasm)Not present in normal tissuesColorectal carcinoma (92%), colonic adenomas (75%), prostate carcinoma (83%), PIN (64%), nephrogenic adenoma (58%), breast cancer (44%), ovarian carcinoma, TCC, lung carcinoma, RCC, lymphoma, melanomaCan be combined with p63 to distinguish prostate carcinoma (AMACR +, p63 absent in basal cells) from benign mimics (AMACR -, p63 present in basal cells). However, \~20% of small cancers on core may be negative for AMACR.**Androgen receptor***(AR)*Mediates the function of androgens *(Nucleus)*Prostate, skin, oral mucosaOsteosarcoma, prostatic carcinoma, breast carcinoma, ovarian carcinoma, others**B72.3** (*Tumor-associated glycoprotein 72, TAG-72, CA 72-4*)Oncofetal glycoprotein, may be a precursor of the MN blood group system, sialosyl-Tn antigen (*Cytoplasm, membrane*)Not present in most benign adult epithelial cells (may be present in secretory endometrium), apocrine metaplasia, and fetal GI tractAdenocarcinomas (especially ovary, colon, breast)Adenocarcinoma (+ \>90%) vs. mesothelioma (5%) or mesothelial cells (-)Other markers are more useful for mesothelioma vs. adenocarcinoma.**bcl-2***(B-cell lymphoma 2)*Protein involved in inhibition of apoptosis (*Membrane, cytoplasm)*Medullary lymphocytes and epithelial cells of the normal thymus, mantle and T zone small lymphocytesSynovial sarcoma, solitary fibrous tumor, myofibroblastic tumors, schwannoma, neurofibroma, granular cell tumor, GIST, KS, melanomaSmall lymphocytic lymphoma/CLL, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma (MALT), some large B-cell lymphomaSynovial sarcoma (+/-) vs. mesothelioma (-)Thymic carcinomas strongly express bcl-2 compared to thymomas.Small lymphocytic lymphoma, mantle cell lymphoma, and marginal zone lymphoma (MALT) (+) vs. reactive follicles (-).The bcl-2 gene is involved in the t(14;18) found in follicular lymphomas.**Ber-EP4***(Epithelial-specific antigen \[ESA\], Ep-CAM)*Glycoprotein *(Membrane)*All epithelial cells except superficial layers of epidermisMost carcinomasAdenocarcinoma (+; strong and diffuse in 60 to 100%) versus mesothelioma (- or focal in 26%)Other markers are better for distinguishing adenocarcinoma vs. mesothelioma**Beta-amyloid***(6F/3D)*Amyloid present in Alzheimer's disease (AD) and in cerebral amyloid angiopathy *(Extracellular)*NoneSenile plaque core in AD, amyloid cores, neuritic plaques, neurofibrillary tanglesDiagnosis of AD, other diseasesFound in AD, Lewy body dementia, Down's syndrome, hereditary cerebral amyloidosis (Dutch type)**Beta-catenin**Component of the adherens junction that binds to e-cadherin and functions in cell adhesion and anchoring the cytoskeleton; signaling molecule of the Wnt/wingless pathway *(Membrane, cytoplasm)*Urothelium, breast epithelium, colon, esophagus, stomach, thyroidTCC, colonic adenocarcinomas and adenomas, breast carcinoma, esophageal squamous cell carcinoma, head and neck squamous cell carcinomas, gastric carcinoma, ovarian carcinoma, thyroid carcinoma, prostate carcinoma, HCC, brain neoplasmsNuclear positivity in solitary fibrous tumor (40%), endometrial stromal sarcoma (40%), synovial sarcoma (28%)Aberrant nuclear expression in solid-pseudopapillary tumors of the pancreas (95%) and pancreatoblastomas (78%)Aberrant nuclear expression in desmoid fibromatosis (80% deep, 56% superficial) vs. low grade myofibroblastic sarcoma (30%), solitary fibrous tumor (22%), infantile fibrosarcoma (20%), desmoplastic fibroblastomas (6%)**Beta-2 micro-globulin**Immunoglobulin-associated protein *(Extracellular deposits of amyloid)*Plasma cellsIdentification of amyloid in patients on dialysisAmyloid tends to accumulate around joints and in the GI tract**BG8**Lewis blood group y antigen *(Cytoplasm)*Red blood cells, endothelial cellsAdenocarcinomas (95%), rare mesotheliomas (about 5%)Other markers are better for distinguishing adenocarcinoma vs. mesothelioma**Blood group antigens**A, B, and H antigens *(Membrane)*Epithelial cells and red blood cells, endothelial cellsLost or abnormally expressed in many carcinomasCan be helpful to identify potentially misidentified specimens if patients' blood types are known.H is diminished by decalcification but not A and B antigens.**CA 125***(OC125)*Mucin-like glycoprotein, antibody to ovarian carcinoma antigen *(Luminal surface)*Epithelial cells, mesothelial cellsAdenocarcinomas of ovary, breast, lung (bronchioloalveolar), and others (rarely colon), TCC, adenomatoid tumor of the uterus, squamous cell carcinoma, seminal vesicle carcinoma, anaplastic lymphomaSeminal vesicle carcinoma (+) vs. prostate carcinoma (-)Used as a serum marker for monitoring ovarian cancer**CA19-9** (*Carbohydrate antigen 19-9*)Antigen of sialyl Lewisa-containing glycoprotein; antibody to colon carcinoma (*Cytoplasm*)Epithelial cells of breast, colon, kidney, liver, lung, pancreas, salivary gland, othersAdenocarcinomas of GI tract, pancreas, ovary, lung, and bladder, rare in mesotheliomasChronic pancreatitisUsed as a serum marker for monitoring gastrointestinal and pancreatic carcinomas**Calcitonin**Peptide hormone produced by C cells *(Cytoplasm and extracellular amyloid)*C cells of the thyroidMedullary carcinoma of the thyroid (within tumor cells and in amyloid)ID of C-cell hyperplasiaID of medullary thyroid carcinomaUsed as a serum marker for medullary carcinoma.**Caldesmon** (*h-caldesmon*)Actin and calmodulin binding protein in smooth muscle (*Cytoplasm*)Vascular and visceral smooth muscle cells, some myoepithelial cells of the breastSmooth muscle tumors, PEComa, GISTSmooth muscle tumors (+) vs. myofibroblastic lesions (-) or endometrial stromal tumors (-)**Calponin***(CALP)*Protein that binds to calmodulin, F-actin, and tropomyosin to regulate smooth muscle contraction *(Cytoplasm)*Vascular and visceral smooth muscle cells, myoepithelial cells of the breast, periacinar and periductal myoepithelial cells of the salivary glandMyoepithelioma, some smooth muscle tumors, myofibroblastic lesionsCan be helpful to identify myoepithelial cells in breast lesions**Calretinin**Intracellular calcium-binding protein of the troponin C superfamily with an EF-hand domain *(Cytoplasm, nucleus)*Subsets of neurons, pineal cells, germinal epithelium of ovary, mesothelial cells, keratinocytes, breast, sweat glands, neuroendocrine cells, thymusEpithelial mesotheliomas (less + in sarcomatoid type), adenomatoid tumor, some lung squamous cell carcinomas, rare adenocarcinomas, mesenchymal tumors (e.g., synovial sarcoma), granular cell tumor, Leydig cell tumor, granulosa cell tumorEpithelial mesotheliomas (\>90%) versus adenocarcinoma (\<10%)Useful positive marker for mesotheliomas.**Carcinoembryonic antigen***(CEA. CD66e)*Glycoproteins with immunoglobulin-like regions found in fetal tissues *(Cytoplasm)*Fetal tissuesAdenocarcinomas (liver, colon, pancreas, bile duct, and lung more than breast, ovary), TCC, medullary carcinoma of the thyroidUsually absent in RCC, prostate carcinoma, and papillary or follicular thyroid carcinomasAdenocarcinoma (+) versus mesothelioma (--)HCC: polyclonal CEA has a canalicular patternDifferent reactivity patterns occur with different antibodies and with polyclonal versus monoclonal antibodies**CD5** (*Leu 1*)Transmembrane glycoprotein (*Membrane*)T cells and B cell subsets (mantle zone)Thymic carcinoma, adenocarcinomas, mesothelioma (cytoplasmic)T-cell leukemias and lymphomas, aberrantly expressed in low-grade B-cell lymphomas (CLL or mantle cell lymphoma).Thymic carcinoma (+/-) vs. thymoma (-).Thymic carcinoma (+/-) vs. metastatic squamous carcinoma (-)Classification of low grade B-cell lymphomas.Evaluation of T-cell lymphomas (this marker is frequently lost).**CD10** (*CALLA* \[*common acute leukemia antigen\], J5*)Cell surface metalloendopeptidase that inactivates peptides *(Membrane)*Precursor B cells, granulocytes, rare cells in reactive follicles, myoepithelial cells of breast, bile canaliculi, fibroblasts, brush border of kidney and gutEndometrial stromal sarcoma, RCC (clear cell and papillary types), HCC, TCC, rhabdomyosarcoma, pancreatic carcinoma, schwannoma, melanomaPrecursor lymphoblastic lymphoma/leukemia, follicular lymphoma, Burkitt lymphoma, CML, angioimmunoblastic lymphomaMyoepithelial cell marker in breastEndometrial stromal sarcoma (+) vs. leiomyosarcoma (-/+) (but caldesmon is preferred for this purpose)Evaluation of low-grade lymphomas.Evaluation of leukemiasNot specific for nonlymphoid neoplasms.**CD15** (*LeuM1*)3-fucosyl-N-acetyllactos-amine, X-hapten - CHO moiety linked to cell membrane protein (*Membrane and cytoplasm*)Granulocytes, monocytesAdenocarcinomasCMV-infected cellsRS cells (not LP HD) in a membranous and golgi pattern, some large T-cell lymphomas, MF, some leukemiasAdenocarcinomas (+) versus mesotheliomas (-)Evaluation of HD**CD30** (*Ki-1*)Single-chain transmembrane glycoprotein homologous to the nerve growth factor superfamily *(Cytoplasm, membrane, and golgi*)Activated B and T cells, some plasma cells, immunoblasts, interdigitating cells, histiocytes, follicular center cells, decidualized endometrium, reactive mesothelial cells, most other tissues negativeEmbryonal carcinoma, some vascular tumors (not KS), some mesotheliomasAnaplastic large cell (CD30+) lymphomas, mediastinal large B-cell lymphoma, primary effusion lymphoma, HD (but not LP HD), some other B- and T-cell lymphomas, EBV transformed B cellsID of anaplastic large cell (CD30+) lymphomas.Evaluation of HD (RS cells are positive except in LP HD).ID of peripheral T-cell lymphoma (large cells may be positive).**CD31** (*PECAM-1, platelet-endothelial cell adhesion molecule)*Transmembrane glycoprotein functioning in cell adhesion *(Cytoplasm, membrane)*Endothelial cells, platelets, megakaryocytes, plasma cells, histiocytes, other hematopoietic cellsVascular tumors (\> 80% of angiosarcomas), KS, histiocytic neoplasms, PEComa, very rarely other tumorsID of endothelial differentiation in tumorsEvaluation of angiogenesisMost sensitive and specific marker for endothelial cells**CD34***(HPCA-1, hematopoietic progenitor cell, class 1, QBEnd10)*Single-chain transmembrane glycoprotein, leukocyte differentiation antigen *(Cytoplasm, membrane)*Hematopoietic progenitor cells (decreases with maturation), endothelial cells, fixed connective tissue cells (e.g., in skin), fibroblastsAcute leukemia, sarcomas of vascular origin, KS, epithelioid sarcoma, GIST, DFSP, solitary fibrous tumor, neurofibroma, schwannoma, spindle cell lipoma, phyllodes tumor, fibroadenomaID of endothelial or fibroblastic differentiation in tumors.Evaluation of angiogenesis.Evaluation of the number of blasts in bone marrow in acute leukemia.Solitary fibrous tumor (+) vs. sarcomatoid mesothelioma (-)DFSP (+) vs. dermatofibroma (-)Not specific but can be useful in context with other features**CD44v3***(CD44 variant 3, H-CAM)*Transmembrane glycoprotein that mediates cell adhesion (*Membrane*)Many, including myometriumMany, including endometrial carcinomasPossibly helpful to distinguish cellular leiomyoma (+) from endometrial stromal sarcoma (-)Many splice variants of CD44 are present in normal and malignant cells.**CD57***(Leu 7, HNK-1)*Lymphocyte antigen that cross reacts with a myelin-associated glycoprotein (*Membrane*)T-cell subsets, NK cells, myelinized nerves, neuroendocrine cells, prostate, pancreatic islets, adrenal medullaNerve sheath tumors (occasional), leiomyosarcoma, synovial sarcoma, rhabdomyosarcoma, neuroblastoma, gliomas, neuroendocrine carcinomas, neurofibromas, some prostate carcinomasAngioimmunoblastic lymphoma, T gamma lymphoproliferative disorder (large granular cell lymphocytic leukemia)ID of neuroendocrine differentiation in tumorsID of angioimmunoblastic T-cell lymphomaEvaluation of NK neoplasms.Not very specific for solid tumors**CD63***(NKI/C3, melanoma-associated antigen, ME491)*Member of the tetraspanin or transmembrane 4 superfamily (TM4SF) found on lysosomes *(Cytoplasm or membrane)*Melanocytes, mast cells, histiocytes, salivary gland cells, sweat gland cells, pancreatic cells, islets of Langerhans, prostatic cells, Paneth cells, peribronchial glands, pituitaryNevi, melanomas, carcinoids, medullary carcinomas of the thyroid, some adenocarcinomasCellular neurothekoma (NKI/C3 + and S100 -) versus melanocytic lesions (NKI/C3 and S100 +)ID of melanocytic lesionsMay be negative in desmoplastic melanomas**CD68***(KP1, CD68-PG-M1, Mac-M)*Intracellular glycoprotein associated with lysosomes *(Cytoplasm, membrane)*Macrophages, monocytes, neutrophils, basophils, large lymphocytes, Kupffer cells, mast cells, osteoclastsNeurofibroma, schwannoma, MPNST, granular cell tumors, PEComa, melanomas, atypical fibroxanthoma, RCCSome lymphomas, histiocytic sarcomas, APML, Langerhans proliferative disordersBest general marker for macrophages, although not specific to this cell type.The antibody PG-M1 does not react with granulocytes.Not very specific for solid tumors.**CD99***(MIC-2, 12E7, Ewing's sarcoma marker, E2 antigen, HuLy-m6, FMC 29, O13 \[different epitope\])*MIC2 gene product -- glycoproteins (p30 and p32) involved in rosette formation with erythrocytes *(Membrane)*(*Membrane* \[immunoreactivity is more specific than cytoplasmic\])Cortical thymocytes, T lymphocytes, granulosa cells of ovary, pancreatic islet cells, Sertoli cells, some endothelial cells, urothelium, ependymal cells, squamous cellsPNET/Ewing's sarcoma, chondroblastoma, mesenchymal chondrosarcoma, synovial sarcoma, solitary fibrous tumors, GIST, some alveolar rhabdomyocarcomas, desmoplastic small cell tumors, small cell carcinomas, granulosa cell tumors, yolk sac components of germ cell tumors, Sertoli-Leydig cell tumors, atypical fibroxanthoma, meningiomaB- and T-cell precursor lymphoblastic lymphoma/leukemiaThymic carcinomas (lymphocytes +) versus other carcinomas.ID of PNET/Ewing's sarcoma (immunoreactivity should be clearly membranous in the majority of the cells)Evaluation of lymphoblastic lymphoma/leukemiaO13 is the most commonly used antibody.Immunoreactivity is highly dependent upon the antigen retrieval system used**CD117***(c-kit, stem cell factor receptor)*Transmembrane tyrosine kinase receptor (ligand is stem cell factor) - apoptosis is inhibited when the ligand is bound *(Cytoplasm, membrane)*Mast cells, interstitial cells of Cajal (ICC - pacemaker cells of the GI tract found through-out the muscle layers and in the myenteric plexus), epidermal melanocytes, mononuclear bone marrow cells (4%), Leydig cells, early spermatogenic cells, trophoblast, breast epitheliumGIST (\>95%), seminomas (\>70%), intratubular germ cell neoplasia, mature teratomas (\>70%), papillary renal cell (cytoplasmic -- associated with mutations), chromophobe renal cell (membrane - not associated with mutations), some melanomas (focal), mast cell tumors, some carcinomas (including adenoid cystic carcinoma), some brain tumors, some PNET/Ewing's sarcoma, some angiosarcomasAML (\>50%), CML in myeloid blast crisisID of GIST (+) vs. leiomyomas (-) and schwannomas (-).ID of seminomasID of mast cells (mastocytosis) -- abnormal mast cells commonly have the imatinib resistant mutation D816V.Mast cells are an excellent internal control.CD117 (+) does not correlate with mutations and/or oncoprotein activity in tumors not known to have activating mutations and is, in general, not of clinical or therapeutic significance in this setting (e.g., to detect tumors likely to respond to therapy directed against the protein, such as Gleevec.**CD123***(interleukin-3 receptor alpha chain)*Alpha chain of the IL-3 receptor (*Membrane*)Myeloid precursors, macrophages, dendritic cells, mast cells, basophils, megakaryocytesPlasmacytoid dendritic cell tumors**CD141***(thrombomodulin, TM)*Transmembrane glycoprotein, receptor for thrombin *(Cytoplasm \[epithelial cells\], membrane \[mesothelial cells\])*Endothelium, platelets, monocytes, synovial cells, syncytiotrophoblast, mesothelial cells, dermal keratinocytes, islet cells, peripheral nervesMesotheliomas, TCC, KS, squamous cell carcinomas, choriocarcinomas, rarely adenocarcinomas, benign and malignant vascular tumorsMesothelioma (+ 80%) vs. adenocarcinoma (+ 10%) (but variable results have been reported in other studies)Other markers are better for distinguishing adenocarcinoma vs. mesothelioma.**CD146***(melanoma cell adherin molecule, MELCAM, MCAM, MN-4, MUC18, A32 antigen, S-Endo-1)*Membrane cell adhesion glycoprotein of the Ig gene superfamily (*Membrane*)Implantation site intermediate trophoblast, myofibroblasts, endothelium, pericytes, Schwann cells, ganglion cells, smooth muscle, cerebellar cortex, breast luminal and myoepithelial cells, external root sheath of hair follicle, subcapsular epithelium of thymus, follicular dendritic cells, basal cells of bronchus and parathyroid, subpopulations of activated T cellsMelanoma, angiosarcoma, KS, leiomyosarcoma, placental site trophoblastic tumor, choriocarcinomaMay be focally positive in squamous cell carcinoma and small cell carcinoma of the lung, mucoepidermoid carcinoma, breast carcinoma, some leukemias, neuroblastomaID of placental site trophoblastic tumors**CD163***(M130)*Endocytic receptor to scavenge haptoglobin and hemoglobin complexes *(Membrane, cytoplasm)*Tissue macrophages (high expression), monocytes (low expression) including Kupffer cells, Hofbauer cells but not follicular dendritic cells or plasmacytoid monocytesNeoplasms of histiocytic differentiationLeukemias of monocytic differentiationSynovial type giant cell tumors of the vertebral columnLangerhans cell histiocytosis (\~60%), benign fibrous histiocytoma (\~67%)Littoral cell angioma of the spleenID of true histiocytic derivation of tumorsMore specific for monocyte/histiocyte derivation than CD68**CDK4***(cylin-dependent kinase 4)*A kinase involved in cell cycle regulation (*Nuclear*)NoneLiposarcoma, glioblastoma, anaplastic astrocytoma, large B-cell lymphoma, osteosarcoma, breast carcinomaAtypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma (\>90% +) vs. benign adipose tumors (\<5% +)MDM2 can also be used for this differential diagnosis**CDX2***(caudal-related homeobox transcription factor, CDX-88)*Homeobox nuclear transcription factor specific for the intestinal tract that regulates MUC2 expression (*Nucleus*)Small intestine, colon, and endocrine pancreasColon carcinomas (usually strong and diffuse), small intestine carcinomas, mucinous ovarian carcinomas, bladder adenocarcinomas, some gastric, esophageal, pancreatic, and bile duct carcinomasHCC, breast, lung, and head and neck carcinomas are usually negativeID of colon carcinomas and other carcinomas of the gastrointestinal tract.However, other carcinomas (e.g., mucinous ovarian carcinoma or mucinous lung bronchioloalveolar carcinoma) can also be positive**Chromogranin A**Acidic glycoprotein in neurosecretory granules *(Cytoplasm, granular)*Islet cells of pancreas, bronchial Kulchitsky cells, parathyroid, adrenal medulla, anterior pituitary, C-cells of thyroidPheochromocytoma, carcinoids (not rectal), small cell carcinoma, neuroblastoma, some breast and prostatic carcinomas, Merkel cell tumors, islet cell tumors, medullary carcinoma of the thyroid, parathyroid lesions, Brenner tumorID of neuroendocrine differentiation in tumors. Not present in pituitary prolactinomas.Pheochromocytoma (+) versus adrenal cortical carcinoma (--).Parathyroid (+) vs. thyroid (--)Most specific marker of neuroendocrine differentiationAlso can be detected in serumBouin's solution or B5 fixation may increase immunogenicity**Claudin**-1 *(CLDN1)*Protein component of the tight junction complex *(Membrane -- not cytoplasmic)*Epithelial cells, perineurial cells, some endothelial cells (venules)Perineurioma (30%), synovial sarcoma (epithelioid areas, lower in spindle cell areas), carcinomasSome perineurial cells may be present in neurofibromas and schwannomasPerineurioma (+ 30%) vs. DFSP (-), fibromatosis (-), low grade fibromyxoid sarcoma (--)Meningiomas -- 50% +**Collagen IV**Major constituent of basement membranes *(Basement membrane)*Mesangial cells within glomeruli, basement membranes, basal lamina of capillariesTumors with external lamina (schwannomas, smooth muscle tumors)Absence or loss may be associated with stromal invasion by carcinomas**D2-40***(podoplanin, M2A)*Oncofetal Membrane O-linked sialoglycoprotein (*Membrane*)Lymphatic endothelium, germ cells of testis, interstitial cells of Cajal, follicular dendritic cells, myoepithelial cells of the breastLymphatic tumors, some angiosarcomas, some epithelioid hemangioendotheliomas, epithelioid mesotheliomas, seminomas, ITGCN, KS, GIST, ovarian serous carcinomasIdentification of LVIID of seminoma (+, diffuse) vs. embryonal carcinoma (- or focal)Epithelioid meso (+) vs. adenocarcinoma (--)ID of follicular dendritic cell sarcomaMyoepithelial cells of the breast can show cytoplasmic positivity --- limiting usefulness in the breast for LVI**Desmin**Intermediate filament in muscle *(Cytoplasm)*All striated muscle (Z bands) and many smooth muscle cells, myofibroblasts, smooth muscle of some BVsRhabdomyosarcoma (80% +), leiomyosarcoma (50-70% +), PEComa, desmoplastic small round cell tumors (usually dot-like), some myofibroblastic tumors, endometrial stromal sarcomaID of muscle differentiation in tumors**DOG1***(discovered On GIST-1)*Protein of unknown function expressed in GIST *(Cytoplasm or membrane)*Interstitial cells of CajalGIST (positivity in other tumor types is \<10%)ID of GIST (may be + in some CD117 neg GIST)Positive in 79% of GIST with PDGFRA mutations, whereas CD117 is positive in 9% of this group**DPC4***(homozy-gously deleted in pancreatic carcinoma, locus 4, Smad4)*Transcriptional regulator interacting with the TGFbeta signaling pathway *(Nucleus)*Normal tissuesExpressed in most carcinomasLost in 31% of Pan IN-3, 55% of pancreatic carcinomas, and 22% of stage IV colon carcinomasMucinous ovarian carcinoma (+) vs. metastatic pancreatic carcinoma (negative in 55%)Mutated in familial juvenile polyposis in 25% to 60% of cases**E-cadherin**Transmembrane cell adhesion molecule that binds to catenins for cell polarization, glandular differentiation, and stratification *(Membrane)*Epithelial cellsMost carcinomas -- may be lost in poorly differentiated carcinomasNot present in LCIS and invasive lobular carcinoma of breast or gastric signet ring cell carcinomasDuctal (+) vs. lobular (--) lesions of the breastCan be helpful to distinguish DCIS from LCIS.**EGFR***(epidermal growth factor receptor, HER1)*Transmembrane protein receptor of the type 1 growth factor family with tyrosine kinase activity *(Membrane positivity scored, cytoplasmic positivity is not scored)*Many types of epithelium, skin eccrine and sebaceous glands, mesenchymal cells, perineurium The strongest membrane positivity is present in hepatocytes, bile ducts, basilar squamous cells, pancreatic ducts, breast epithelium, lung alveolar lining cells, mesothelial cells, prostate epithelium, endometrial glands and stromaAdenocarcinomas (esp. colon), squamous cell carcinomas, TCC, neural tumors, sarcomasExpression is increased in tumors of higher grade and poorer prognosisColon carcinomas (80-90% positive) -- response to cetuximab is not related to IHC scoreLung adenocarcinoma -- specific mutations (but not IHC) predict response to TK inhibitorsGBM -- 40% show gene amplification and overexpression by IHC. TK domain mutations are rare**Epithelial membrane antigen***(EMA, MUC1, HMFG, DF3, CA 15-3, CA 27.29, PEM, many others)*Episialin, glycoprotein found in human milk fat globule membranes *(Cytoplasm \[more common in malignant cells\], membrane \[more common in benign cells\])*Epithelial cells, perineurial cells, meningeal cells, plasma cells, usually negative in non-neoplastic mesothelial cellsCarcinomas, mesotheliomas (thick membrane pattern), some sarcomas (synovial sarcoma, epithelioid sarcoma, leiomyosarcoma, some osteosarcomas), adenomatoid tumor, chordoma, perineurioma, neurofibroma, meningioma, desmoplastic small round cell tumor, Sertoli cell tumor Some anaplastic large cell lymphomas (CD30 +), plasma cell neoplasmsID of epithelial differentiation in tumors -- however, keratin is more specific for this purposeSynovial sarcoma (typically focal positivity) vs. other sarcomasDemonstrates the "inside out" glands of invasive micropapillary breast carcinomaThere are over 50 monoclonal antibodies recognizing different glycosylation patterns in normal tissues and tumors[@bib18]**Epstein-Barr virusEBV-encoded nonpolyadenylated early RNAs***(EBERS)*RNA produced by EBV *(Nucleus)*EBV-infected B cellsAll EBV-related tumorsMost sensitive marker for EBVDetected by in situ hybridization for RNA on paraffin sections**LMP-1**Latent membrane protein *(Membrane)*EBV-infected B cellsNasopharyngeal carcinomas, RS cells (not LP HD), transplant lymphomas, AIDS-related lymphomas, endemic Burkitt lymphoma (rare in sporadic cases)Evaluation of EBV-related neoplasms**EBNA 2***(nuclear antigen 2)*Nuclear protein *(Nucleus)*EBV-infected B cellsTransplant-related lymphomas, AIDS-related lymphomas Not present in Burkitt lymphoma, nasopharyngeal carcinomas, or HDEvaluation of transplant- and AIDS-related lymphomas**Estrogen receptor***(ER, 1D5, SP1, 6F11, H222, others)*Steroid-binding protein *(Nucleus)*Breast epithelial cells (not myoepithelial cells), epithelial and myometrial cells of the uterusBreast carcinomas (\>70%), myofibroblastoma of breast, gynecologic carcinomas, some skin appendage tumors, rare in other carcinomas, present in some meningiomas, smooth muscle tumors, some melanomas, some thyroid tumors, desmoid tumors, vulvovaginal stromal tumorPrognosis and prediction of response to hormonal therapy of breast cancer. Only nuclear positivity is scoredID of metastatic breast cancerABs recognize different epitopes and have varying sensitivities in formalin fixed tissue. Antigenicity may be diminished after decalcification or exposure to heat during surgery.**Factor VIII-related antigen***(VWF, FVIII:RAg, von Willebrand factor)*Glycoprotein involved in coagulation, part of FVIII complex *(Cytoplasm)*Endothelial cells, megakaryocytes, platelets, and mast cells, endocardiumVascular tumors (often absent in angiosarcomas)Not present in KS, PEComaMegakaryocytic AML (M7)ID of endothelial differentiation in tumors (specific but not very sensitive)Evaluation of angiogenesisEvaluation of M7 (megakaryocytic) leukemiasMay not detect smaller blood vessels (see CD 31 and 34). Present in Weibel-Palade bodies. Not a sensitive marker for vascular neoplasms.**Factor XIIIa***(Factor XIII subunit A)*Transglutaminase involved in the coagulation pathway *(Cytoplasm)*Fibroblasts, dendritic reticulum cells in reactive follicles, dermal dendrocytes, liver, placenta, platelets, megakaryocytes, monocytes, macrophagesFibroblastic neoplasms, dermatofibromaNot very specific**Fascin***(p55)*Actin binding protein thought to be involved in the formation of microfilament bundles and cell motility *(Cytoplasm)*Interdigitating reticulum cells in lymph nodes, dendritic cells of lymph node, thymus, spleen and peripheral blood, histiocytes, smooth muscle, endothelial cells, squamous mucosal cells, lining cells of splenic sinuses, neuronsRS cells and their variants (but not LP HD), rare non HD lymphomasReticulum cell tumorsSome sarcomasMany carcinomas, especially those of advanced stageGlial tumors (more common in high-grade tumors)Not very specific**Fibronectin**Glycoproteins found in BMs and extracellular matrix, bind to integrins *(Extracellular)*Stroma of many tumors**FLI-1***(Friend leukemia integrin-site 1)*Transcription factor (ETS family) -- translocation in Ewing's can result in an EWS-FLI-1 fusion protein *(Nucleus)*Endothelial cells (hemangioblasts, angioblasts), small lymphocytesEwing's sarcoma/PNET, vascular tumors (including KS), Merkel cell carcinoma, melanomaCan also be weakly present in lymphomas, synovial sarcoma, some carcinomasID of vascular tumors (unlike other vascular markers, FLI-1 is nuclear).ID of Ewings/PNET -- not specific but very sensitive (70%)Reactivity can be variable with high background and may be difficult to interpret**Galectin-3***(Gal-3)*Lectin with anti-apoptosis function (galactoside-binding protein) *(Nucleus, cytoplasm, membrane, extracellular matrix)*Many epithelial cells, lymphocytes, mesenchymal cells, macrophages, activated endothelial cellsMany carcinomas, adenomas, lymphomas, soft tissue tumorsThyroid carcinomas (papillary and to a lesser extent follicular) show higher expression than benign lesionsIn some carcinomas, expression is diminished in higher grade lesions**Glial fibrillary acidic protein***(GFAP)*Intermediate filament *(Cytoplasm)*Normal and reactive astrocytes, developing and reactive ependymal cells, developing oligodendrocytes, choroid plexus, Schwann cells, enteric glial cells, pituitary cells, chondrocytesTumors of astrocytes, ependymal cells, and oligodendrocytes, MPNST, myoepitheliomas (salivary glands and soft tissue), sweat gland tumors, Merkel cell carcinomas, chordomasID of neural differentiation in tumors (30% of MPNSTs are +). Neuroblastomas are negative, schwannomas may be focally +.Merkel cell carcinoma (+) versus small cell carcinoma (--) (but Ck20 is a better marker for this purpose).ID of myoepithelial neoplasms.**GLUT-1***(glucose transporter 1)*Component of transmembrane glucose transport *(Membrane)*Erythrocytes, perineurium, blood vessels, trophoblasts, renal tubules, germinal center cellsTCC, lung carcinoma, squamous cell carcinoma, adenocarcinomas of colon, lung, bile ducts, kidney, ovary, pancreas, stomach, and endometrium, germ cell tumorsNot very specific**Gross cystic disease fluid protein-15***(GCDFP, CDP, BR-2, BRST-2)*Protein found in breast fluid *(Cytoplasm)*Apocrine sweat glands, apocrine metaplasia of the breastBreast carcinomas (60%), sweat gland carcinomas, some salivary gland tumors, some prostate carcinomasID of apocrine differentiation in tumorsID of breast metastases (however, only positive in about 60%)**HepPar-1***(hepatocyte paraffin-1, HP1)*Mitochondrial protein*(Cytoplasm, coarsely granular)*LiverHCC, some cases of gastric adenocarcinoma, esophageal adenocarcinoma, others negative or only rarely positiveHCC (80--95%) vs. metastatic carcinomas to the liver**HBME-1**Antigen to microvilli on mesothelioma cells *(Membrane and cytoplasm)*Mesothelial cells, epithelial cellsMesotheliomas (epithelial type - thick, membrane staining), adenocarcinomas, chordomas, chondrosarcomasPositivity higher in thyroid carcinomas than in adenomasMay be absent in thyroid carcinomas with Hurthle cell featuresNot a specific marker for mesotheliomas**HER-2/neu***(c-erbB2, A0485, Sp3)*Growth factor receptor (tyrosine kinase) homologous to epidermal growth factor receptor *(Membrane, some cytoplasm)*Absent or rare in normal cellsBreast carcinomas (20 to 30%), Paget disease of nipple (\>90%), less frequently in other carcinomas (ovary, uterus, GI, pancreas), some synovial sarcomasPoor prognostic factor in breast cancerMembrane positivity used to select patients for treatment with Herceptin (scored from 0 to 3+) (see separate table)Only membrane positivity is scored. Gene amplification (detected by FISH) correlates with strong complete membrane immunoreactivity in \>90% of cases**HHV8**Latent nuclear antigen of human herpes virus type 8 *(Nucleus)*Absent in normal tissueKS (endothelial cells and some perivascular cells)Primary effusion lymphoma (PEL), AIDS-associated multicentric Castleman's diseaseEvaluation of KS and PEL**HMB-45***(E-MEL, melanoma specific antigen)*Oligosaccharide side-chain of a melanosomal antigen, gp100/pmel17 *(Cytoplasm)*Fetal melanocytes and some normal adult superficial melanocytes, retinal pigment epitheliumMelanoma (epithelioid but not spindle cell or desmoplastic type), clear cell sarcoma, PEComa, tumors associated with tuberous sclerosis, melanotic schwannoma, othersID of metastatic melanoma. Melanophages can also be positive. Melan-A may be more specific.ID of PEComa.NKI-betab detects the same protein.Tissues fixed in B5 may have high background staining**hMLH1***(human mutS homologue 2),***hMSH2***(human mutL homologue 1),***MSH6, PMS2**Proteins involved in mismatch repair of DNA (the first two genes account for 95% of HNPCC) (*Nucleus*)Most normal tissuesMay be lost in areas of chronic inflammationExpression (or non-expression) is not specific for tumor typeAbsence is associated with germline mutations in HNPCC patients and with gene silencing by methylation in 15% of sporadic colon carcinomas -- correlated with characteristic clinical, pathologic, and treatment response featuresIHC will not detect the 5% of patients with mutations in other genes or rare patients with mutated gene products that are immunoreactiveOther assays for microsatellite instability utilize PCR (90% sensitive for MSI)**Hormones**(ER and PR are listed separately)Insulin, gastrin, glucagon, somatostatin, calcitonin, ACTH, FSH, LH, PRL, TSH, others *(Cytoplasm)*Hormone-producing cellsHormone-producing tumorsID of hormone products in tumors.May not correlate well with serum levels of the same markers.**Human chorionic gonado tropin***(hCG, B-HCG)*Beta chain of the hormone *(Cytoplasm)*SyncytiotrophoblastsChoriocarcinoma, giant cells in seminomas, placental site tumors (weak)ID of trophoblastic differentiation in tumors**Human placental lactogen***(HPL, hPL)*Hormone *(Cytoplasm)*TrophoblastChoriocarcinoma (may be weak), complete moles (strong), partial moles (weak), some lung and stomach carcinomasID of trophoblastic differentiation in tumors.**Inhibin--- alpha subunit**Hormone produced by ovarian granulosa cells and prostate, inhibits FSH production *(Cytoplasm)*Ovarian granulosa cells, Sertoli cells, pregnancy luteomas, ovarian follicles, syncytiotrophoblast, adrenal cortex, hepatocytesGranulosa cell tumors, juvenile granulosa cell tumors, Sertoli and Leydig cell tumors, ovarian stromal cells around other tumors, hydatidiform moles, choriocarcinoma, thecofibroma, adrenal cortical tumor, granular cell tumorID of sex cord stromal differentiation in ovarian tumors.Distinguishes adrenal cortical tumors (\>70% +) vs. HCC (\<5% +) and RCC (\<5% +)**INI-1***(BAF47/Snf5)*Chromatin remodeling complex (*Nucleus*)All normal cellsDeleted or mutated in pediatric rhabdoid tumors (tumors are negative) and CNS atypical teratoid/rhabdoid tumorsLost in 90% of epithelioid sarcomas (conventional and proximal) and lost in 50% of epithelioid MPNSTID of rhabdoid tumors and atypical teratoid/rhabdoid tumors**Keratins**Intermediate filaments *(Cytoplasm)*Epithelial cellsCarcinomas, mesotheliomas, desmoplastic small round cell tumors (dot-like pattern), thymomas, chordomas, synovial sarcomas, epithelioid sarcoma, leiomyosarcoma, trophoblastic tumors, some other sarcomas, rarely melanomasID of poorly differentiated carcinomasCytokeratins 7 and 20 can be used to help identify the site of origin of carcinomas**AE1/AE3**Two monoclonal antibodies. AE1 detects 10, 15, 16, and 19. AE3 detects 1 to 8. *(Cytoplasm)*Epithelial cells, mesothelial cellsMost carcinomas. The only common carcinomas that are frequently negative are HCC (70% negative) and RCC, clear cell type (20% negative)Epithelioid hemangioendothelioma, epithelioid sarcoma, synovial sarcoma, mesothelioma, adenomatoid tumor, germ cell tumorsID of epithelial differentiation in tumorsHCC (--/+) versus cholangiocarcinoma and metastatic carcinomas (+)Good broad spectrum keratin**CAM 5.2**8, 18 *(Cytoplasm)*Simple and glandular epitheliumMost carcinomas including those usually negative for Ck7 and 20: HCC, prostatic carcinoma, thymic carcinoma, gastric carcinoma, renal cell carcinoma, small cell carcinomaCarcinoid tumor, thymoma, germ cell tumors, mesothelioma, dendritic cellsSynovial sarcoma, epithelioid sarcomaMany squamous cell carcinomas are negativeID of carcinomas that may be negative for Ck7 and Ck20Paget disease (+) versus squamous cell carcinoma (-)Positivity for dendritic cells in lymph nodes and elsewhere may be confused for micrometastasesMay be positive when other keratins are negative**Keratin 5/6**5/6 *(Cytoplasm)*Basal cells, stratum spinosum of epidermis, mesothelial cellsSquamous cell carcinomas, TCC, epithelioid mesotheliomas, squamous metaplasia in adenocarcinomas, thymic carcinomaLess frequently present in non-squamous cell carcinomasEpithelioid mesothelioma (+) vs. pulmonary adeno (--)Present in some "triple negative" breast cancers --- may identify a poor prognostic groupHas limited use in routine practice**Keratin 7**7 *(Cytoplasm)*Simple epithelia, respiratory epithelium, transitional epithelium, endothelial cells of small veins and lymphaticsNot present in squamous epitheliumMost adenocarcinomas of glandular epithelial origin, TCC, mesothelioma, neuroendocrine neoplasmsNot Merkel cell carcinoma or colon carcinomaRare in clear cell RCC (but present in other variants), prostate carcinoma, HCC, lung small cell carcinoma, thymoma, carcinoidNot present in squamous cell carcinomas of the skin, but may be present in squamous cell carcinomas arising from non-keratinizing epithelium (e.g., cervical carcinoma)The combination of Ck7 and Ck20 is used to distinguish carcinomas arising at different sites (see [TABLE 7--3](#t0020){ref-type="table"}, [TABLE 7--4](#t0025){ref-type="table"}, [TABLE 7--5](#t0030){ref-type="table"}, [TABLE 7--6](#t0035){ref-type="table"}, [TABLE 7--7](#t0040){ref-type="table"})**Keratin 14**14 *(Cytoplasm)*Squamous cells, myoepithelial cellsSquamous cell carcinomas, thymoma, myoepithelial neoplasms, oncocytic neoplasms (Hurthle cell adenoma of the thyroid), some triple negative ("basaloid") breast cancersID of keratin in spindle cell breast carcinomas and other triple negative breast cancers**Keratin 20**20 *(Cytoplasm)*Gastric foveolar epithelium, intestinal villi and crypt epithelium, Merkel cells, taste buds, umbrella cells of urothelium, subsets of epithelial cellsNot present in nonepithelial cellsColon carcinoma, Merkel cell carcinoma, TCC, adenocarcinoma of the bladder, pancreatic carcinoma, cholangiocarcinoma, mucinous ovarian carcinoma, esophageal adenocarcinomaMerkel cell carcinomas Ck20 positive, whereas most similar tumors are negativeID of metastatic colon carcinomas (the pattern of Ck7 negative, Ck20 positive, is most frequently seen in this carcinoma, but can rarely be seen in other types)**PAN-K***(MNF-116*)Broad-spectrum dectection of keratins including 5, 6, 8, 17, and 18 *(Cytoplasm)*Epithelial cells including simple epithelium and squamous cellsDetection of keratin in all carcinomas, including poorly differentiated carcinomas (especially spindle cell squamous cell carcinomas)May be more sensitive than AE1/AE3 for carcinomas with myoepithelial ("basal") features due to inclusion of the "basal" keratin Ck17**34βE12***(903)*HMW keratins including 1, 5, 10, 14 *(Cytoplasm)*Complex epithelia, basal cells, myoepithelial cellsTCC, cholangiocarcinoma, squamous cell carcinoma, non-mucinous bronchioloalveolar lung carcinoma, RCC (papillary and chromophobe types), mesothelioma, papillary thyroid carcinoma, thymic carcinoma, lymphoepithelial carcinomaTCC (+) versus prostate carcinoma (-) or RCC (-).Prostate carcinoma (no basal cells) versus benign lesions (with some + basal cells present). Can be combined with p63 for this use.ID of keratin 14 in triple negative ("basaloid") breast cancers (Ck14 is also available separately).**Ki-67** (MIB-1)Protein found during the entire cell cycle but not in G0 *(Nucleus)*Any cycling cellAny cycling tumorUsed as a prognostic marker for some tumorsDetects number of cycling cells in Burkitt lymphoma and large B-cell lymphomaAberrant membrane and cytoplasmic immunoreactivity is present in trabecular hyalinizing adenoma of the thyroid and sclerosing hemangioma of the lungMIB-1 recognizes an epitope preserved in formalin-fixed tissue**Laminin**Component of basement membranes *(Basement membrane)*Basement membranesNerve sheath tumors, smooth muscle tumorsLoss associated with stromal invasion by carcinomasPresent in microglandular adenosis of the breast.**Lysozyme***(Ly)*Muramidase (mucolytic enzyme) *(Cytoplasm)*Circulating monocytes, some tissue macrophages, granulocytes, salivary gland, lacrimal gland, stomach and colon epithelial cells (inflamed or regenerative), apocrine glands, Paneth cells, some other epithelial cellsSalivary gland tumors, stomach and colon carcinomasAML with monocytic differentiationMarker for histiocytes but not specific. May mark activated phagocytic macrophages.Evaluation of myeloid leukemias.Not specific for identification of solid tumors**MAC 387***(L1 antigen, calprotectin, calgranulin, cystic fibrosis antigen)*Three polypeptide chains released with activation or death of neutrophils (*Cytoplasm*)Neutrophils, monocytes, some tissue macrophages, eosinophils, squamous mucosa, reactive skin, synovial lining cellsLung carcinomas (not small cell or carcinoid), squamous cell carcinomasHistiocytic neoplasms (but not Langerhans cells)Marker for macrophages (but not as specific as CD68)Belongs to the S100 protein familyCells can passively take up antigen resulting in false positive results**Mammaglobin***(MGB1)*Secretory glycoprotein *(Cytoplasm)*Breast epithelium, sweat glands, endocervix, endometriumBreast cancer (50%), endometrioid adenocarcinoma (\~40%), salivary gland carcinoma (\~20%), melanoma (\~6%)ID of metastatic breast cancer (+ in about 50%)**MDM2***(mouse double minute 2 homolog)*A ubiquitin protein ligase that regulates p53 stability (*Nucleus*)Not seen in normal cellsLiposarcomas (\>90%) and MPNST (60%)Atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma (\>90% +) vs. benign adipose tumors (\<5% +)CDK4 has a similar pattern**MELAN-A or MART-1***(melanoma antigen recognized by T cells, A103, M2-7C10)*Melanocyte differentiation antigen (*Cytoplasm*)Antibody MC-7C10 is positive in melanocytes of skin, uvea, and retinaAntibody A103 is also positive in adrenal cortex, granulosa and theca cells of the ovary, Leydig cellsMelanomas (but \< 50% of spindle cell or desmoplastic melanomas), PEComasAntibody A103 is also positive in adrenocortical tumors, Leydig cell tumor, granulosa cell tumorID of melanomas. The antibodies are not positive in melanophages and may be more specific for the detection of micrometastases in lymph nodes.Antibody A103 distinguishes adrenocortical tumors (≥50% +) vs. HCC (-) and RCC (-).More sensitive than HMB45Peptides are used for melanoma immunotherapyA103 has a broader spectrum of immuno-reactivity than MC-7C10**MITF***(microphthalmia transcription factor, Mit-f, D5, MiTF)*Basic-helix-loop-helix-leucine zipper transcription factor that regulates tyrosinase and other melanogenic proteins (*Nucleus*)Melanocytes, pigmented cells of the retina, mast cells, osteoclastsMelanoma, PEComa, angiomyolipoma, clear cell sarcomaMelanoma vs. other tumors -- not as specific as other melanoma markers (also present in other tumors)Mutations result in autosomal dominant Waardenburg syndrome type 2a (hereditary deafness and skin hypopigmentation)**MUC2** and **MUC1**Mucins *(Cytoplasm)*MUC1 is typical of pancreaticobiliary-type differentiation and MUC2 of intestinal differentiationMany adenocarcinomasIdentification of colonic metastases (expression more conmmon than in lung or ovary)For pancreatic/ampullary tumors, MUC2 positive tumors may have better prognosis than MUC1 tumorsCholangiocarcinoma (MUC1 80%) vs. HCC (negative)IPMN is usually MUC2+/MUC1--, most PanIN are MUC2-/MUC1+, ductal adenoca is MUC1+ except colloid type which is MUC2+MUC2 is a marker of intestinal cells -- similar pattern as CDX2**Myf-4***(MRF4, myogenin)*Human homologue of myogenin - muscle regulatory protein (*Nucleus*)Striated muscleRhabdomyosarcomaID of skeletal muscle differentiation in tumorsBetter than MyoD1**MyoD1**Nuclear phosphoprotein, role in myogenic regulation *(Nucleus)*Developing muscle tissues (myoblasts), adult muscle is negativeRhabdomyosarcoma (especially poorly differentiated tumors), mixed Mullerian tumorsID of skeletal muscle differentiation in tumorsBackground positivity is often high, making interpretation difficult**Myoglobin**Oxygen-binding protein *(Cytoplasm)*Striated muscle (including cardiac muscle), not smooth muscleTumors of striated muscle (rhabdomyosarcoma + 50%), but often negative in poorly differentiated tumorsID of skeletal muscle differentiation in tumorsMore specific but less sensitive than actin and desmin**Myosin -- smooth muscle myosin heavy chain***(SM-MHC; SMMS-1, M3558)*Contractile protein in smooth muscle that interacts with actin *(Cytoplasm)*Visceral and vascular smooth muscle, myoepithelial cells of the breastTumors with myoepithelial cellsMarker for myoepithelial cells in the breast -- may have less positivity in vascular smooth muscle cells and myofibroblastsAntibodies to different isoforms will detect different types of muscle fibers**Myosin -- fast myosin***(MY-32, M4276)*Contractile protein in skeletal muscle that interacts with actin *(Cytoplasm)*Striated muscle - Type 2 fibers (not present in cardiac or smooth muscle)Rhabdomyosarcoma (some; especially pleomorphic variant)ID of skeletal muscle differentiation in tumors**NANOG**Embryonic stem cell transcription factor *(Nucleus)*Embryonic cellsEmbryonal carcinoma, seminoma, CNS germinomaSeminoma and embryonal carcinoma vs. other germ cell tumorsMay detect "stem cells" in tumorsStronger and more diffusely positive compared to OCT3/4. Named after Tir Na Nog, the mythologic Celtic land of eternal youth**Nestin**Intermediate filament *(Cytoplasm)*Neural stem/progenitor cells, embryonic neural cells, neuronal and glial cellsRetina, striated muscle, cardiac muscle, skin, liver, pancreas, kidneys, testes, adrenalsNeurocytomas, neuroblastomas, gliomas, glioblastomas, astrocytomas, ependymomas, medulloblastomas, SchwannomasCarcinomas, GIST, others**NeuN***(NEUronal Nuclei, A60)*DNA binding neuron-specific protein expressed at terminal differentiation *(Nucleus)*Neuronal cells including cerebellum, cerebral cortex, peripheral ganglion cells Not glia, pineocytes, Schwann cellsCentral neurocytomasMay be focally positive in other CNS neoplasmsID of neuronal differentiation**Neuro filaments***(70 + 200kD, NFP)*Intermediate filaments with three subunits (*Cytoplasm*)Neuronal cells, adrenal medullaTumors of neuronal origin or with neuronal differentiation, neuroblastoma, medulloblastoma, retinoblastoma, Ewing's/PNET, esthesioneuroblastoma, Merkel cell carcinoma, some endocrine tumors (carcinoids, pheochromocytomas)ID of neuronal differentiation in tumorsID of Merkel cell carcinomas**Neuron- specific enolase***(NSE -- do not confuse with the enzyme non-specific esterase)*Gamma-gamma enolase isoenzyme (*Cytoplasm*)Neuroectodermal and neuroendocrine cells, more weakly striated and smooth muscle, megakaryocytes, T cells, some platelets, neurons, pituitary cells, hepatocytesNeuroectodermal and neuroendocrine tumors, melanomas (including desmoplastic melanomas), many breast carcinomas, germ cell tumors, alveolar soft part sarcomaID of neuronal or neuroendocrine differentiation in tumorsLacks specificity**OCT4***(OCT3, OCT3/4, POU5F1)*POU-domain transcription factor (POU5F1 gene) (*Nucleus*)Embryonic stem cells and pluripotent germ cellsSeminoma, intratubular germ cell neoplasia, embryonal carcinomaIdentification of seminoma and embryonal carcinoma. Other epithelioid and round cell neoplasms are negativeMore specific than PLAP for this purpose**OLIG2**Member of the basic helix-loop-helix transcription factor family *(Nucleus)*OligodendrocytesDiffuse glioma (100%), may be positive in other CNS tumors. Sparse positivity in ependymomasT-ALL with OLIG2 translocationPrimary CNS tumor (+) vs. metastasis (-)**p16***(MTS1, CDKN2)*Binds to and inhibits the cyclin-dependent kinases cdk4 and cdk6 *(Cytoplasm and nucleus)*AbsentCervical squamous cell carcinomas and adenocarcinomas (both in situ and invasive), endocervical carcinoma, endometrial carcinomaSome basaloid squamous cell carcinomas of the tonsil in young patients that are associated with HPV16.Evaluation of cervical lesionsPossible use predicting tonsillar site for metastatic squamous cell carcinoma of the head and neckOverexpression is due to HPV-induced cell cycle dysregulation**p53** (*multiple antibodies to wild type and mutant forms)*Tumor suppressor gene product -- probably most frequently mutated gene in malignancy (*Nucleus*)Overexpression uncommon or absent in normal cells or benign tumorsMany malignant tumors -- but not specific for malignancyOverexpression may be used as a prognostic factorDifferent antibodies recognize different wild type and mutant forms of the protein and will give different results**p57***(kip2, p57^KIP2^*)Cyclin-dependent kinase inhibitor (CDKI) acting to inhibit cell proliferation, paternally imprinted (*Nucleus*)Cytotrophoblast, intermediate trophoblast, villous stromal cells, decidual stromal cells, absent in syncytiotrophoblastDiploid complete moles show absent or low expression in cytotrophoblast and villous stromal cells (may be present in villous intermediate trophoblast and decidual stromal cells), partial moles and hydropic abortions have normal expression**p63**Protein with at least six major isotypes, including deltaNp63, member of the p53 family *(Nucleus)*Proliferating basal cells of cervix, urothelium, prostate, and myoepithelial cells of breast, basal squamous cells, squamous metaplasiaSquamous cell carcinomas, TCC, adenomyoepithelioma, adenoid cystic carcinoma, nasopharyngeal carcinoma, "basal type" breast carcinomas, papillary carcinoma of the thyroid, othersID of myoepithelial cells in breast lesionsDiagnosis of prostatic carcinoma by showing absence of basal cells (more sensitive when combined with 34BE12)Basaloid squamous lung cancer (+) vs. small cell (-)ID of metastatic poorly differentiated squamous cell carcinomasEasier to interpret than SMA in breast lesions as myofibroblasts are negative**Placental alkaline phosphatase***(PLAP)*Alkaline phosphatase secreted by trophoblast *(Cytoplasm)*Placenta (trophoblast)Germ cell tumors (but not spermatocytic seminoma), intratubular germ cell neoplasia, partial moles, some carcinomas of breast, ovary, lung, stomach, and pancreas, some rhabdomyo-sarcomas (esp. alveolar type)Absence of immunoreactivity makes a germ cell tumor unlikely. However, spermatocytic seminomas and immature teratomas are negative.ID of intratubular germ cell neoplasia.**Progesterone receptor***(PR, PgR, PgR636)*Steroid binding protein *(Nucleus)*Normal breast epithelial cells, endometrial cells, many smooth muscle cells, breast lobular stromaBreast carcinomas, gynecologic carcinomas, some skin adnexal tumors, secretory meningiomas, endometrial stromal sarcomas, some leiomyomas, myofibroblastic tumors, rarely other tumorsPrognosis and treatment of breast cancerID of metastatic breast cancer**Prealbumin***(Transthyretin, TTR)*Plasma transport protein for retinol and thyroxine (*Cytoplasm*)Pancreatic islet cells, choroid plexus, retinal pigment epithelium, liverPancreatic islet cell tumors, carcinoid tumors, choroid plexus papillomas, choroid plexus carcinomas (may be focal or absent)ID of choroid plexus neoplasmsEvaluation of some forms of amyloidosisMajor subunit protein in some forms of inherited systemic amyloidosis**Prostate specific antigen***(PSA)*Member of kallikrein family of serine protease isolated from human seminal plasma *(Cytoplasm)*Normal prostatic epithelium, urachal remnants, endometrium, transitional cells of bladderProstatic carcinomas, some breast carcinomasID of prostatic carcinomas (may be lost in some poorly differentiated carcinomas). Seminal vesicle carcinomas are negativeMore specific than PAPUsed as a serum screening test for prostate cancer**Prostate acid phosphatase***(PrAP, PAP)*Isoenzyme of acid phosphatase *(Cytoplasm)*Normal prostatic epithelium, periurethral glands, anal glands, macrophagesProstatic carcinomas, TCC, rectal carcinoidsID of prostatic carcinomas (may be lost in some poorly differentiated carcinomas)**RCC***(Renal cell carcinoma marker, gp200)*Glycoprotein on surface of renal tubules, breast epitethelial cells, epididymis *(Cytoplasm, membrane)*Renal tubules, breast, epididymisClear cell and papillary RCC, breast carcinoma, embryonal carcinomaClear cell and papillary RCC (+) vs. chromophobe carcinoma (--/+) and oncocytoma (-)**RET***(Rearranged during transfection)*RET-proto-oncogene -- surface glycoprotein of the receptor tyrosine kinase family (*Cytoplasm*)Neurons, embyronic kidneyPapillary thyroid carcinomas (78%), follicular variant of papillary carcinoma (63%), Hurthle cell carcinoma (57%), insular carcinoma (50%), medullary carcinoma, not present in follicular carcinomas or benign lesionsNeuroblastoma, pheochromocytomaEvaluation of thyroid tumorsGermline mutations occur in MEN2A and 2B (10q11.2), familial medullary thyroid carcinoma, and some cases of Hirschsprung's disease**S-100 protein**Calcium-binding protein isolated from the CNS (member of the EF hand family) *(Nucleus and cytoplasm)*Glial and Schwann cells, melanocytes, chondrocytes, adipocytes, myoepithelial cells, Langerhans cells, macrophages, reticulum cells of lymph nodes, eccrine glands, othersMelanoma (including spindle cell and desmoplastic types), clear cell sarcoma, schwannoma, chordoma, ependymoma, astroglioma, Langerhans proliferative disorders, some carcinomas (e.g., breast, ovary endometrial, thyroid), granular cell tumor, histiocytic sarcoma, myoepitheliomaID of melanoma (if negative, melanoma is highly unlikely)ID of Langerhans proliferative disordersSustentacular cells in pheochromocytomas (loss may be poor prognostic factor)ID of neural tumorsID of cellular schwannomas (more strongly and diffusely positive than in MPNST)Langerhans cells and macrophages in tumors may be misinterpreted as positivity in the tumor itselfS100 is very soluble and may be eluted from frozen tissues**Smoothelin**Smooth muscle specific cytoskeletal protein *(Cytoplasm)*Fully differentiated smooth muscle cells (not present in noncontractile smooth muscle cells or myofibroblasts), weak in perivascular smooth muscleMay distinguish muscularis propria (+, strong, diffuse) vs. muscularis mucosaae (− or weak and focal) in urinary bladder biopsies**SOX2**Embryonic stem cell transcription factor *(Nucleus)*Embryonal carcinomaEmbryonal carcinoma (+) vs. seminoma (--)**Synaptophysin**Transmembrane glycoprotein found in presynaptic vesicles *(Cytoplasm)*Neuroectodermal and neuroendocrine cells, neuronsMedulloblastoma, neuroblastoma, pheochromocytoma, paragangliomas, carcinoids, small cell carcinoma, medullary carcinoma of the thyroid, neural neoplasms, pancreatic islet cell tumorsID of neuroendocrine differentiation in tumorsID of neuronal differentiation in CNS tumors**Synuclein-1**Neuron-specific protein associated with synaptosomes *(Lewy bodies)*BrainPresent in Lewy bodies (Lewy body dementia and Parkinson's disease)**Tau**Microtubule-associated protein *(Cytoplasm, extracellular)*Normal neuronal cell bodies and dendrites, neuropil, glial cellsAbnormal amounts in Alzheimer's disease in neurofibrillary tangles and senile plaquesEvaluation of Alzheimer's disease, Pick's disease, supranuclear palsy corticobasal degeneration, others**TFE3**Transcription factor *(Nucleus)*Not reportedAlveolar soft part sarcoma, Xp11.2 or TFE3 translocation renal carcinomas in children and young adultsOther tumors and normal adult tissues are negativeThese carcinomas have translocations involving the TFE3 gene resulting in its overexpression**Thyroglobulin**Glycoprotein produced by thyroid follicular cells *(Cytoplasm)*Thyroid folliclesThyroid carcinomas (papillary, follicular, and Hurthle cell types, rarely present in medullary carcinomas)ID of metastatic thyroid carcinomaLoss may be a poor prognostic factorThyroglobulin can diffuse into metastatic tumors to the thyroid.**TTF-1***(thyroid transcription factor 1)*Transcription factor for thyroglobulin, thyroid peroxidase, Clara cell secretory protein, and surfactant proteins *(Nucleus; aberrant cytoplasm positivity in HCC)*Thyroid, lung, and some brain tissuesThyroid carcinomas (including medullary carcinoma; may be negative in anaplastic carcinoma), lung adenocarcinomas (75% -- but lower in mucinous bronchioloalveolar carcinomas), small cell carcinoma of lung (\>90%), HCC (cytoplasmic), absent or focal in most other adenocarcinomasMesothelioma (--) vs. adenocarcinoma (+/--)Lung adenocarcinoma (+/--) vs. metastatic breast carcinoma (--)Small cell carcinoma of lung (+) vs. metastasis from other sites (--), but some extrapulmonary small cell carcinomas can also be (+)HCC (cytoplasmic 71%), rare in other tumor typesThe detection of cytoplasmic TTF-1 may depend on the specific antibody used and the antigen-retrieval method**Tyrosinase**Melanogenic protein *(Cytoplasm)*MelanocytesMelanoma vs. other tumors (sensitivity similar to MART-1 and HMB-45)**Ulex***(Ulex Europaeus I lectin, UEA 1)*Lectin, fucose residues on blood group H *(Cytoplasm)*Endothelial cellsVascular tumors, some carcinomasEvaluation of angiogenesisNot very specific**Vimentin**Intermediate filament *(Cytoplasm)*Mesenchymal cells, fibroblasts, endothelial cells, chondrocytes, histiocytes, lymphocytes, many glial cells, myoepithelial cells, smooth muscleAll mesenchymal tumors, neural tumors, melanomas, meningiomas, chordoma, Leydig cell tumor, granulosa cell tumor, Sertoli cell tumor, adrenal cortical adenomaMay be co-expressed with keratin in carcinomas of endometrium, thyroid, kidney (clear cell), adrenal cortex, lung, salivary gland, ovary, and liverMay be poor prognostic factor if co-expressed with keratin or GFAPCan be used as an internal control for immunogenicityNot a specific marker for tumor type or line of differentation**WT1***(Wilms tumor 1 protein)*Zinc finger transcription factor *(Cytoplasm, nucleus)*Sertoli cells, decidual cells of uterus, granulosa cells of ovary, blood vessels, myelocytic cellsWilms tumors (epithelial and blastemal components), epithelial mesotheliomas (nuclei -- 80% to 90%), acute leukemia (nuclei), adenocarcinomas (cytoplasmic; especially breast (mucinous breast cancers can have nuclear positivity (64%), ovary), desmoplastic small cell tumors (nuclear and cytoplasmic), rhabdomyosarcomaMesothelioma (+, nuclear) vs. adenocarcinoma (adenocarcinoma usually negative for nuclear positivity except for ovarian) -- use mouse monoclonal antibodyDesmoplastic small cell tumorsGene located on 11p13 and is inactivated in 5 to 10% of sporadic Wilms tumors and nearly 100% of Denys-Drash syndrome patientsABs detect epitopes at different ends of the protein and may give different results. Not very specific.Hematopathology Markers**ALK protein***(Anaplastic lymphoma kinase, ALK-1, p80, CD246)*The ALK gene (2p23) (a tyrosine kinase receptor) is translocated to part of the nucleophosmin (NPM) gene (5q35) to form the fusion protein p80 and is overexpressed *(Cytoplasm, nucleus)*Nervous system, T cellsAnaplastic (CD30+) large cell lymphomas (about one third have t\[2;5\]\[p23; q35\]). ALK negative anaplastic lymphomas may have trisomy 2.Some inflammatory myofibroblastic tumorsID of anaplastic large cell lymphomasThe pattern of immunoreactivity varies with the translocation present**Alpha-1-antichymo-trypsin***(ACH)*Serine protease inhibitor *(Cytoplasm)*Histiocytes, granulocytes, othersHistiocytic tumors, many adenocarcinomas, melanomas, many sarcomasMarker for histiocytes but CD68 is more specificNot specific for tumor type**Alpha-1-antitrypsin***(AAT, alpha-1-AT)*Glycoprotein synthesized in the liver that inhibits proteolytic enzymes (especially elastase) *(Cytoplasm)*Histiocytes, reticulum cells, mast cells, Paneth cells, salivary glandHCC, germ cell tumors, histiocytic neoplasms, colon and lung carcinomas, othersAccumulates in liver cells in AAT deficiencyNot specific for tumor typeCD68 is a more specific marker for macrophages**Bcl-2**Protein involved in inhibition of apoptosis *(Membrane, cytoplasm)*Medullary lymphocytes and epithelial cells of the normal thymus, mantle and T zone small lymphocytesCLL, mantle cell lymphoma, follicular center cell (FCC) lymphoma, marginal zone lymphomaSynovial sarcoma, other soft tissue tumorsFCC lymphomas (+) vs. reactive follicles (--). Hyperplastic marginal zones of the spleen, abdominal LNs, and ilial lymphoid tissue are (+)Malignant thymomas may have greater reactivity than other thymomasSynovial sarcoma is more frequently positive compared to mesotheliomaInvolved in the t(14;18) found in 90% of FCC lymphomasNot specific for ID of solid tumors**Bcl-6**Proto-oncogene -- Kruppel-type zinc finger protein with homology to transcription factors *(Nucleus)*Normal germinal center B cellsFollicular lymphomas, diffuse large B-cell lymphomas, Burkitt lymphoma, mediastinal large B-cell lymphoma, LP HDNot present in B-CLL, hairy cell leukemia, mantle cell lymphoma, and marginal zone lymphomasEvaluation of B-cell lymphomasInvolved in gene rearrangements at 3q27 in lymphomas**Blood group antigens**A, B, and H antigens *(Membrane)*Epithelial cells, endothelial cells, erythrocytesAbnormally expressed or lost in many carcinomasSometimes helpful in identifying specimensH is diminished by decalcification but not A and B antigens**BOB.1***(B-cell Oct-binding protein 1)*Coactivator that interacts with Oct transcription factors in B cells (*Cytoplasm*)B cells (including plasma cells)B-cell lymphomas and leukemiasReed-Sternberg cells in LP HD, usually absent in other HD typesEvaluation of HDBOB.1 and Oct2 are necessary (but not sufficient) for Ig expression**BSAP***(B-cell specific activator protein, Pax-5)*Transcription factor encoded by the Pax-5 gene that regulates B-lineage specific genes (? *Nuclear*)B cellsAll B-cell neoplasms and HDMerkel cell tumors and pulmonary small cell carcinomas have been reported to be positiveNot reliable in Zenker's fixed tissue**CD1a***(T6)*Membrane glycoprotein (*Membrane*)Cortical thymocytes (immature T cells), Langerhans cells, dendritic cellsLangerhans proliferative disorders, lymphoblastic lymphomaEvaluation of Langerhans proliferative disordersEvaluation of lymphoblastic lymphoma**CD2***(TE, T11, rT3, Leu 5a + b, LFA-2)*Glycoprotein mediating adhesion of activated T cells and thymocytes with antigen presenting cells and target cells, functions in E rosette formation (*Membrane*)T cells, NK cells, cortical thymocytesT-cell neoplasms, may be aberrantly lost in peripheral T-cell neoplasmsPan T-cell marker**CD3** (*T3*)C3 antigen (five polypeptide chains) *(Membrane, cytoplasm)*T cells, cortical thymocytesT-cell neoplasms, may be aberrantly lost in peripheral T-cell neoplasmsAnaplastic large cell lymphoma is often negativeBest pan T-cell markerIn paraffin sections, NK cells may also be positive**CD4***(TH, T4, Leu 3)*Transmembrane glycoprotein, HIV receptor (*Membrane*)T helper/inducer cells, macrophages, Langerhans cellsMF, other T-cell neoplasmsEvaluation of MFEvaluation of T-cell neoplasms**CD5***(Leu 1)*Transmembrane glycoprotein (*Membrane*)T cells and B cell subsets (mantle zone)T-cell leukemias and lymphomas, aberrantly expressed in low-grade B-cell lymphomas (CLL or mantle cell lymphoma)Thymic carcinoma, adenocarcinomas, mesothelioma (cytoplasmic)Classification of low-grade B-cell lymphomasEvaluation of T-cell lymphomas (this marker is frequently lost)Thymic carcinoma (\~40%) vs. thymoma (\<10%) vs. pulmonary squamous cell carcinoma (\<5%)**CD7***(Leu 9)*Membrane-bound glycoprotein (*Membrane*)Precursor T cells, T cell subsets, NK cells, thymocytesT-cell lymphomas and leukemiasFrequently (50%) lost in T-cell lymphomas versus reactive T cells (+)Evaluation of T-cell leukemias**CD8***(T8, Leu 2)*Two glycoprotein chains (*Membrane*)T cell subsets, NK cells, T cytotoxic/suppressor cellsT-cell lymphomas and leukemiasEvaluation of MF and T-cell lymphomas (this marker is frequently lost)**CD10***(CALLA \[common acute leukemia antigen\], J5, neprilysin)*Cell surface metalloendopeptidase that inactivates peptides *(Membrane)*Precursor B cells, granulocytes, rare cells in reactive follicles, myoepithelial cells of breast, bile canaliculi, fibroblasts, brush border of kidney and gutFollicular lymphomas, pre-B-ALL, Burkitt lymphoma, CML, angioimmunoblastic lymphomaRCC (clear cell and papillary), HCC, rhabdomyosarcoma, endometrial stromal sarcomaEvaluation of follicular center cell lymphomasEvaluation of leukemiasMyoepithelial cell marker in breastEndometrial stromal sarcoma (+) vs. leiomyosarcoma (−) (but caldesmon is preferred for this purpose)**CD11b***(Mac-1)*Cell surface receptor for the C3bi complement fragment (*Membrane*)Granulocytes, monocytes, macrophagesMyelomonocytic leukemias**CD11c**Member of the beta(2) integrin family that mediates adhesion to vascular endothelium, transendothelial migration, chemotaxis, and phagocytosis *(Membrane)*Myeloid cells, NK cells, dendritic cells, activated lymphoid cellsHairy cell leukemia, B-cell prolymphocytic leukemia, some B-CLL, marginal zone lymphoma (MALT)**CD13***(My 7)*Aminopeptidase-N, a type II integral membrane metalloprotease functioning in cell surface antigen presentation, receptor for coronaviruses *(Membrane, cytoplasm)*Granulocytes, macrophages, bone marrow stromal cells, osteoclasts, renal tubules, intestinal brush border, cells lining bile duct canaliculi, endothelial cells, fibroblasts, brain cellsAML, CML with blast crisis, some ALLClassification of leukemiasRequires frozen tissue**CD15***(Leu-M1)*3-fucosyl-N-acetyllactosa-mine, X-hapten - CHO moiety linked to cell membrane protein *(Membrane and granular perinuclear)*Granulocytes, monocytesReed-Sternberg cells (not LP HD), some large T-cell lymphomas, MF, some leukemias, some epithelial cells (adenocarcinomas), CMV-infected cellsAdenocarcinomas (+) versus mesotheliomas (−)Evaluation of HD**CD16**Low affinity transmembrane Fc receptor for IgG *(Membrane)*NK cells, granulocytes, activated macrophages, subsets of T cellsExtranodal NK/T-cell lymphoma, some hepatosplenic T-cell lymphomas**CD19***(B4)*B cell type I integral membrane glycoprotein *(Membrane)*B cells, follicular dendritic cells, early myelomonocytic cellspre-B-ALL and B-cell neoplasms (but not plasma cell lesions)Good pan B-cell markerFresh or frozen tissue required**CD20***(L26, B1, Leu16)*B cell non-glycosylated phosphoprotein functioning as a receptor during B cell activation and differentiation *(Membrane, cytoplasm)*B cells, monocytes, not plasma cellsB-cell lymphomas, Reed-Sternberg cells in LP HD, not plasmacytomasBest pan B-cell markerEvaluation of B-cell lymphomasEvaluation of HDUnder investigation as a target for clinical treatment of B-cell lymphomasL26 is best for formalin-fixed tissueMay be preserved in necrotic tissue**CD21***(B2)*Type I integral membrane glycoprotein functioning as the receptor for the C3d fragment of complement C3, CR2, receptor for EBV (*Membrane*)Follicular dendritic cells, mature B cellsMarginal zone (MALT) lymphomas, CLL (B cell), some T-cell ALL, follicular dendritic cell tumorsID of residual follicular structure in LP HD and other diseasesEvaluation of low-grade B-cell lymphomasID of follicular dendritic cell sarcoma**CD22***(BL-CAM)*Type I integral membrane glycoprotein *(Membrane. cytoplasm)*B cells, precursor B cellsB-cell neoplasms (but not plasma cell lesions)Pan B-cell marker**CD23**Membrane glycoprotein, low affinity IgE receptor (*Membrane*)Subpopulation of peripheral B cells, follicular dendritic cellsCLL, but usually not mantle zone lymphoma, Maltomas, or follicular lymphomasEvaluation of low-grade B-cell lymphomas**CD25***(IL-2 receptor)*Interleukin-2 receptor *(Membrane, cytoplasm)*Subpopulation of T cells, myeloid precursors, oligodendrocytesHTLV-1 transformed T and B cellsHairy cell leukemia, adult T-cell lymphoma/leukemia, some T-cell prolymphocytic leukemia, precursor lymphoblastic lymphoma, and anaplastic large cell lymphomaEvaluation of cutaneous T-cell lymphomas for potential anti-CD25 therapyAberrant expression by a subset of neoplastic mast cells**CD30***(Ki-1, BERH2)*Single chain transmembrane glycoprotein, homologous to the nerve growth factor superfamily *(Cytoplasm, membrane and golgi)*Activated B and T cells, some plasma cells, immunoblasts, interdigitating cells, histiocytes, follicular center cells, decidualized endometrium, reactive mesothelial cells, most other tissues negativeAnaplastic (CD30+) large cell lymphomas, large B-cell lymphoma, primary effusion lymphoma, mediastinal large B-cell lymphoma, Reed-Sternberg cells (not LP HD), enteropathy T-cell lymphoma, peripheral T-cell lymphoma, EBV transformed B cellsEmbryonal carcinoma, vascular tumors (not KS), some mesotheliomas, rarely carcinomas are positiveEvaluation of anaplastic (CD30+) lymphomasEvaluation of HD (Reed-Sternberg cells are positive except in LP HD)Evaluation of peripheral T-cell lymphoma (large cells may be positive)**CD33***(My 9)*Myeloid specific receptor (sialic acid--binding immunoglobulin-like lectin or Siglec-3) (*Membrane*)Granulocytes, monocytesAMLEvaluation of leukemiasGemtuzumab ozogamicin is a humanized CD33 antibody linked to an antitumor antibiotic calicheaminin for the treatment of AML**CD34***(HPCA-1, QBEnd10)*Single chain transmembrane glycoprotein *(Cytoplasm, membrane)*Lymphoid and myeloid hematopoietic progenitor cells, endothelial cells, some skin cells, myofibroblastsAcute leukemiaNeurofibroma, angiosarcoma,KS, epithelioid hemangioendothelioma, solitary fibrous tumor, DFSP, epithelioid sarcoma, GIST, myofibroblastic tumorsID of endothelial or myofibroblastic differentiation in tumorsEvaluation of angiogenesisEvaluation of the number of blasts in bone marrow in acute leukemiaNot specific for endothelial cells**CD35***(CR1, C3b/C4b R)*Transmembrane protein that binds complement components C3b and C4b and mediates phagocytosis (*Membrane*)Erythrocytes, B cells, a subset of T cells, monocytes, neutrophils, eosinophils, glomerular podocytes, follicular dendritic cellsMarginal zone (MALT) lymphoma, follicular dendritic cell tumorsDetects follicular dendritic cellsID of follicular dendritic cell sarcomas**CD38**Type II transmembrane glycoprotein with enzymatic action for the formation and hydrolysis of cADPR *(Membrane)*Immature B and T lymphocytes, thymocytes, mitogen-activated T cells, Ig-secreting plasma cells,monocytes, NK cells, erythroid and myeloid progenitors, brain cellsAcute leukemias, plasma cell lesionsNeurofibrillary tangles in Alzheimer's diseaseID of plasma cell lesionsImmunoreactivity may be a poor prognostic marker for patients with CLL**CD43***(Leu 22, L60)*Cell surface glycoprotein *(Membrane)*T cells, macrophages, granulocytesAML (chloromas), T cell neoplasms, aberrant expression in some low-grade B-cell neoplasms (e.g., mantle cell lymphoma, SLL/CLL, marginal zone lymphoma), some MALT lymphomasEvaluation of T-cell lymphomas and leukemiasEvaluation of low-grade B-cell lymphomasLess specific than UCHL-1 for T cells**CD45, Leukocyte common antigen***(LCA, CLA)* Note: CLA also refers to a different antigen, HECA-452Five or more membrane glycoproteins *(Membrane, cytoplasm)*Lymphocytes, leukocytes, histiocytes, not plasma cells, erythrocytes, plateletsNon-Hodgkin's lymphomas, some anaplastic (CD30+) large cell lymphomas, Reed-Sternberg cells in LP HD (but not other types)ID of poorly differentiated neoplasms as lymphomas. However, some anaplastic lymphomas and plasmacytomas may be negativePreserved in necrotic tissueBest general marker for hematologic neoplasms**CD45RA***(DPB)*Restricted form of leukocyte common antigen *(Membrane, cytoplasm)*B cells, monocytes, some T cellsB-cell neoplasms, Hairy cells (not specific)Pan B-cell marker that can be used in Zenker's fixed tissueNot completely specific - other B-cell markers are preferred**CD45RO***(UCHL-1)*Isoform of CD45 (leukocyte common antigen) *(Membrane, cytoplasm)*T cells (memory), granulocytes, monocytesT-cell neoplasms, histiocytic sarcoma, some B-cell lymphomas (plasmacytic, HIV-associated)Good pan T-cell marker (CD3 is more specific)**CD56** (*NCAM*)Neural cell adhesion molecule -- cell surface glycoprotein (*Membrane*)Neurons, astrocytes, Schwann cells, NK cells, subset of activated T cellsSome T/NK-cell lymphomas, plasmacytomasNeuroblastomaEvaluation of panniculitis-like T-cell lymphoma (both CD56+ and CD56-) and T/NK lymphomas**CD57***(Leu 7, HNK-1)*Lymphocyte antigen that cross reacts with a myelin-associated glycoprotein (*Membrane*)T cell subsets, NK cells, myelinized nerves, neuroendocrine cells, prostate, pancreatic islets, adrenal medullaAngioimmunoblastic T-cell lymphomaNerve sheath tumors (occasional), leiomyosarcoma, synovial sarcoma, rhabdomyosarcoma, neuroblastoma, gliomas, neuroendocrine carcinomas, neurofibromas, some prostate carcinomasID of T gamma lymphoproliferative disorder (large granular cell lymphocytic leukemia)ID of neuroendocrine differentiation in tumorsEvaluation of NK neoplasmsNot very specific for solid tumors**CD61***(GPIIIa, platelet glycoprotein IIIa)*Glycoprotein, receptor for fibrinogen, fibronectin, von Willebrand factor, and vitronectin (*Cytoplasm*)Megakaryocytes, plateletsMegakaryocytic leukemiasID of megakaryocytic differentiation**CD68***(KP1, CD68-PGM1, Mac-M)*Intracellular glycoprotein associated with lysosomes *(Cytoplasm, membrane)*Macrophages, monocytes, neutrophils, basophils, large lymphocytes, Kupffer cells, mast cells, osteoclastsSome lymphomas, histiocytic sarcomas, APML, Langerhans proliferative disordersNeurofibroma, schwannoma, MPNST, granular cell tumors, PEComa, melanomas, atypical fibroxanthoma, RCCBest general marker for macrophages, although not specific to this cell typeThe antibody PG-M1 does not react with granulocytes**CD74***(LN2)*Subunit of MHC II--associated invariant chain (*Membrane*)B cells, monocytes, histiocytesB-cell neoplasms, hairy cell leukemia, plasma cell lesionsPan B-cell marker**CDw75***(LN1)*Sialylated glycoconjugate present in surface Ig-positive B cells *(Membrane, cytoplasm)*Mature B cells, T-cell subsets, fetal colon, epithelial cellsReed-Sternberg cells of LP HD (not other types), follicular lymphomasColon carcinomas (50%), gastric carcinomasEvaluation of HD**CD77***(BLA.36, PK antigen)*Globotriaosylceramide, glycolipic membrane from Burkitt lymphoma cell line *(Cytoplasm, membrane)*Tonsillar B cells, dendritic reticulum cells, sinus-lining cells, macrophages, endothelial cell, epithelial cellsHD, Burkitt lymphoma, rarely other B- and T-cell lymphomasEvaluation of RS cells**CD79a***(mb-1 protein)*Heterodimer of mb-1 (CD79a) and B29 (CD79b) polypeptides, B cell antigen receptor *(Membrane)*B cells, plasma cellsPrecursor B-cell ALL, B-cell lymphomas, plasma cell lesions, but not primary effusion lymphomaEvaluation of B-cell neoplasms (may be the only B-cell marker present)**CD79b**See above *(Membrane)*Absent from CLL, hairy cell leukemia**CD95**Transmembrane glycoprotein member of the nerve growth factor receptor/tumor necrosis factor superfamily -- mediates apoptosis *(Membrane)*Activated T and B cells, epithelial cellsPanniculitis-like T-cell lymphoma (if CD56+)**CD99***(MIC-2, 12E7, Ewing's sarcoma marker, E2 antigen, HuLy-m6, FMC 29, O13 \[different epitope\])*MIC2 gene product -- glycoproteins (p30 and p32) involved in rosette formation with erythrocytes (*Membrane* \[*immunoreactivity is more specific than cytoplasmic*\])Cortical thymocytes, T lymphocytes, granulosa cells of ovary, pancreatic islet cells, Sertoli cells, some endothelial cells, urothelium, ependymal cells, squamous cellsB and T cell precursor lymphoblastic lymphoma/leukemiaPNET/Ewing's sarcoma, chondroblastoma, synovial sarcoma, solitary fibrous tumors, GIST, some alveolar rhabdomyocarcomas, desmoplastic small cell tumors, small cell carcinomas, granulosa cell tumors, yolk sac components of germ cell tumors, Sertoli-Leydig cell tumors, atypical fibroxanthoma, meningiomaEvaluation of lymphoblastic lymphoma/leukemiaThymic carcinomas (lymphocytes +) versus other carcinomasID of PNET/Ewing's sarcoma (immunoreactivity should be clearly membranous in the majority of the cells)O13 is the most commonly used antibodyImmunoreactivity is highly dependent upon the antigen retrieval system used**CD103**Mucosal integrin alphaEbeta7 with specificity for e-cadherin (*Cytoplasm*)T cellsEnteropathy type T-cell lymphoma, hairy cell leukemiaRequires frozen tissue or cell suspension**CD117***(c-kit, stem cell factor receptor)*Transmembrane tyrosine kinase receptor (ligand is stem cell factor) -- apoptosis is inhibited when the ligand is bound *(Cytoplasm, membrane)*Mast cells, interstitial cells of Cajal (ICC -- pacemaker cells of the GI tract found throughout the muscle layers and in the myenteric plexus), epidermal melanocytes, mononuclear bone marrow cells (4%), Leydig cells, early spermatogenic cells, trophoblast, breast epitheliumGIST (\>95%), seminomas (\>70%), intratubular germ cell neoplasia, mature teratomas (\>70%), some melanomas (focal), mast cell tumors, some carcinomas, some brain tumors, some PNET/Ewing's sarcoma, some angiosarcomasAML (\>50%), CML in myeloid blast crisisID of GIST (+) vs. leiomyomas (−) and schwannomas (−)ID of seminomasID of mast cells (mastocytosis)Mast cells are an excellent internal controlCD117 positivity does not correlate with mutations and/or oncoprotein activity in tumors not known to have activating mutations and is, in general, not of clinical or therapeutic significance in this setting (e.g., to detect tumors likely to respond to therapy directed against the protein (e.g., Gleevec)**CD123**Alpha chain of the IL-3 receptor *(Membrane)*Myeloid precursors, macrophages, dendritic cells, mast cells, basophils, megakaryocytesPlasmacytoid dendritic cell tumors**CD138***(Syndecan-1)*Transmembrane heparin sulphate glycoprotein that interacts with extracellular matrix and growth factors *(Membrane)*Pre-B cells, immature B cells, Ig-producing plasma cells, basolateral surface of epithelial cells, vascular smooth muscle, endothelium, neural cellsPlasma cell lesions, primary effusion lymphoma, plasma cell component of other B-cell lymphomasSquamous cell carcinomas, other carcinomasID of plasma cells and their neoplasmsExpression may be diminished or lost in poorly differentiated carcinomas**CD163***(M130)*Endocytic receptor to scavenge haptoglobin and hemoglobin complexes *(Membrane, cytoplasm)*Tissue macrophages (high expression), monocytes (low expression) including Kupffer cells, Hofbauer cells but not follicular dendritic cells or plasmacytoid monocytesNeoplasms of histiocytic differentiationLeukemias of monocytic differentiationSynovial type giant cell tumors of the vertebral columnLangerhans cell histiocytosis (\~60%), benign fibrous histiocytoma (\~67%)Littoral cell angioma of the spleenID of true histiocytic derivation of tumorsMore specific for monocyte/histiocyte derivation than CD68**CD207** (*langerin*)Langerhans cell specific C-type lectin (*Cytoplasm*)Langerhans cells of epidermis and epitheliaLangerhans cell histiocytosisInduces formation of Birbeck granules**Clusterin***(Apolipoprotein J, complement lysis inhibitor, gp80, SGP-2, SP40, TRPM2, T64, ApoJ)*Multifunctional protein involved in lipid transport, complement regulation, immune regulation, cell adhesion, other functions *(Membrane, cytoplasm, nucleus)*Many tissuesAnaplastic large cell lymphoma (Golgi pattern)Alzheimer's disease -- present in amyloid plaques and cerebrovascular depositsMany types of carcinomas**Cyclin D1***(PRAD1, bcl-1)*Cyclin regulating cyclin dependent kinases during G1 in the cell cycle, phosphorylates and inactivates the retinoblastoma tumor suppressor protein (*Nucleus*)Cycling cells (however, lymphocytes usually express only cyclins D2 and D3)Mantle cell lymphomaBreast cancer (especially lobular carcinomas and other ER positive carcinomas), esophageal cancer, bladder cancer, lung cancer, HCC, colon carcinoma, pancreatic carcinoma, head and neck squamous cell carcinomas, pituitary tumors, sarcomasParathyroid adenomas (inversion involving cyclin D1 gene and the parathormone receptor)ID of mantle cell lymphomaInvolved in t(11;14)(q13;q32) translocation in mantle cell lymphoma**DBA.44***(HCL)*B cell antigen *(Cytoplasm, membrane)*Mantle zone B cells, some immunoblastsHairy cell leukemia (\>95%), B-cell lymphomas (30%)Evaluation of hairy cell leukemia**Epithelial membrane antigen***(EMA, MUC1, HMFG, DF3, CA 15-3, CA 27.29, PEM, many others)*Episialin, glycoprotein found in human milk fat globule membranes *(Cytoplasm \[more common in malignant cells\], membrane \[more common in benign cells\])*Epithelial cells, perineurial cells, meningeal cells, plasma cells, usually negative in mesothelial cells, monocytesSome anaplastic large cell lymphomas (CD30+), plasma cell neoplasms, malignant histiocytosis, erythroleukemia, AML (M4 and M5), LP HDCarcinomas, mesotheliomas, some sarcomas (synovial sarcoma, epithelioid sarcoma), adenomatoid tumor, chordomas, perineurioma, neurofibroma, meningiomas, desmoplastic small round cell tumor, Sertoli cell tumorID of epithelial differentiation in tumors -- however, keratin is more specific for this purpose. Beware of EMA in some large cell lymphomasSynovial sarcoma typically shows focal positivityThere are over 50 monoclonal antibodies recognizing different glycosylation patterns in normal tissues and tumors[@bib18]**Epstein-Barr virusEBV-encoded nonpolyadenylated early RNAs***(EBERS*)RNA produced by EBV *(Nucleus)*EBV-infected B cellsAll EBV-related tumorsMost sensitive marker for EBVDetected by in situ hybridization for RNA on paraffin sections**LMP-1**Latent membrane protein *(Membrane)*EBV-infected B cellsNasopharyngeal carcinomas, Reed-Sternberg cells (not LP HD), transplant lymphomas, AIDS-related lymphomas, endemic Burkitt lymphoma (rare in sporadic cases)Evaluation of EBV-related neoplasms**EBNA 2***(nuclear antigen 2)*Nuclear protein (*Nucleus)*EBV-infected B cellsTransplant-related lymphomas, AIDS-related lymphomas. Not present in Burkitt lymphoma or nasopharyngeal carcinomasEvaluation of transplant- and AIDS-related lymphomas**Fascin**Actin bundling protein regulated by phosphorylation *(Cytoplasm)*Interdigitating reticulin cells from the T-cell zones, dendritic cells, reticular network, histiocytes, smooth muscle, endothelium, squamous cells, splenic sinusesReed-Sternberg cells (but not in LP HD)High-grade breast carcinomasID of Reed-Sternberg cells in classical HD. Fascin positivity has also been reported in anaplastic large cell lymphoma**FMC7**Antigen on subgroups of mature B cells, epitope of CD20 *(Cytoplasm)*B cellsB-cell lymphomasNot expressed by CLLPan B-cell markerEpitope of CD20 but reactivity low in cells with low cholesterol**Glycophorin A***(GPA)*A glycosylated erythrocyte membrane protein *(Membrane)*Erythroid elements at all stagesErythroleukemiaID of erythroid elements (normal and neoplastic)**Granzyme B**Neutral serine proteases stored in granules in cytotoxic T cells and in NK cells involved in target cell apoptosis by exocytosis *(Cytoplasm)*Cytotoxic T cells and NK cellsSome T-cell lymphomas, Reed-Sternberg cells of some cases of EBV-positive HD**Heavy immuno-globulin chains***(G, A, M, D)*Heavy chain of immunoglobulins *(Cytoplasm \[plasma cells\], membrane \[lymphocytes\])*Plasma cells (G\>A\>M\>D)Plasma cell tumors (monotypic expression of usually G or A), mantle zone lymphomas and WDLL/CLL may coexpress M and D, lymphoplasmocytic lymphoma (M)ID of monoclonal populations of plasma or plasmacytoid cells**HECA-452***(endothelial cell antigen, cutaneous lymphocyte-associated antigen, CLA)*Cell surface glycoprotein *(Membrane)*T cells, more common in cutaneous T cellsMycosis fungoides and other cutaneous T-cell lymphomasNote: CLA is also used to refer to CD45**Hemoglobin***(Hb)*Hemoglobin *(Cytoplasm)*Erythroid cellsSome leukemiasMarker for erythroid cells**HHV8**Latent nuclear antigen of human herpes virus type 8 *(Nucleus)*Absent in normal tissuePrimary effusion lymphoma (PEL), AIDS-associated multicentric Castleman's diseaseKaposi's sarcoma (endothelial cells and some perivascular cells)Evaluation of Kaposi sarcoma and primary effusion lymphoma**HLA**-**DR**Major histocompatibility complex Class II gene *(Membrane)*B lymphocytes, macrophages, Langerhans cells, dendritic cells, activated T cells, some endothelial and epithelial cellsLeukemic myeloblastsNot very specific for cell type**Light immuno-globulin chains***(lambda \[L\], kappa \[K\])*Light chain of immunoglobulins *(Cytoplasm)*Plasma cells (normally K \> L), B cellsPlasma cell tumors, B-cell lymphomasID of monoclonal populations of plasma cells and B cellsID of some types of amyloidMay require frozen tissue for assessment of B lymphoid cellsExcellent Ig preservation in plasma cells in B5 or Zenker's fixed tissue**Lysozyme***(Ly)*Muramidase *(Cytoplasm)*Circulating monocytes, some tissue macrophages, granulocytes, salivary gland, lacrimal gland, stomach and colon epithelial cells (inflamed or regenerative), apocrine glands, some other epithelial cellsAML with monocytic differentiation, salivary gland tumors, stomach and colon carcinomasMarker for histiocytes but not specific. May mark activated phagocytic macrophagesEvaluation of myeloid leukemiasStrongly positive in monocytoid leukemiasNot specific for solid tumor identification**Mast cell tryptase**Serine protease *(Cytoplasm)*Mast cellsMast cell neoplasmsID of mast cell differentiation**Myeloperoxidase *(MPO)***Enzyme in primary granules of myeloid cells *(Cytoplasm)*Myeloid cells, monocytesAML, chloromasClassification of leukemiasCan be used with tissue fixed in Zenker's fixative**Oct2***(Octomer transcription factor)*Transcription factor of the POU homeo-domain family binding to the Ig gene octomer sites regulating B-specific genes (*Nucleus*)B cellsB cell lymphomas and leukemiasReed-Sternberg cells in LP HD (but not other types)Evaluation of HDInteracts with the transcriptional coactivator BOB.1. BOB.1 and Oct are necessary (but not sufficient) for Ig expression**Perforin**Pore-forming protein in cytoplasmic granules of cytotoxic T cells (*Cytoplasm*)NK cells, large granular lymphocytes, gamma/delta T cellsNK-cell lymphomas, anaplastic large cell lymphomaEvaluation of T-cell lymphomas**TCR***(T-cell antigen receptor, JOVI 1)*Two polypeptide chains (alpha and beta)Peripheral T cellsMany T-cell lymphomasEvaluation of T-cell lymphomasAlpha/beta and gamma/delta T-cell receptors can be evaluated in frozen tissue**Terminal deoxytransferase** (*TdT*)Enzyme that catalyzes addition of nucleotides to ss DNA (*Nucleus*)Immature T and B cellsLymphoblastic lymphoma/ALLLymphoblastic lymphoma (+) vs. Burkitt lymphoma (-)**TIA-1***(T-cell intracellular antigen)*A cytolytic granule-associated protein expressed in some CD8+ T cells (*Cytoplasm*)T cells, mast cells, polymorphonuclear leukocytes, eosinophilsMany T-cell lymphomasEvaluation of T-cell lymphomas**traf-1***(Tumor necrosis factor receptor-associated factor)*Membrane-bound proteins that activate the nuclear factor-кB (NF-кB) transcription factor resulting in cell proliferation (*Cytoplasm*)Usually absentHodgkin lymphoma, primary mediastinal large B-cell lymphomaNegative in most DLBCL and ALCLMay interact with LMP1[^7][^8][^9][^10][^11][^12][^13][^14][^15][^16][^17]TABLE 7--44ALTERNATIVE NAMES FOR ANTIGENSLOOKING FOR?FIND IT UNDER:1D5Estrogen receptor (G)6F/3DBeta-amyloid12E7CD99 (G, H)34βE12Keratins (G)38.13CD77(H)70 kD NFNeurofilaments (G)200 kD NFNeurofilaments (G)903Keratins\--34βE12 (G)A (blood group antigen)Blood group antigens (G)A (Ig heavy chain alpha)Heavy chain immunoglobulins (H)A32 antigenCD146 (G)A103MELAN-A (G)AATAlpha 1-antitrypsin (G, H)ACHAlpha-1 antichymotrypsin (H)AE1/AE3Keratins (G)AFPAlpha-fetoprotein (G)Alpha 1-antitrypsinAlpha 1-antitrypsin (G, H)Alpha 1-antichymotrypsinAlpha 1-antichymotrypsin (H)Alpha 1-fetoproteinAlpha fetoprotein (G)Alpha fetoproteinAlpha fetoprotein (G)Alpha-methylacyl-CoA racemaseAMACR (G)Alpha smooth muscle actinAlpha smooth muscle actin (G)AMACRAMACR (G)AmyloidBeta-amyloid (G)Androgen receptorAndrogen receptor (G)Apolipoprotein JClusterin (H)ARAndrogen receptor (G)B (blood group antigen)Blood group antigens (G)B1CD20 (H)B2CD21 (H)B4CD19 (H)B72.3B72.3 (G)bcl-1Cyclin D1 (H)bcl-2bcl-2 (H, G)B-cell specific activator proteinBSAP (H)BER-EP4BER-EP4 (G)BERH2CD30 (G, H)Beta-amyloidBeta-amyloid (G)Beta-cateninBeta-catenin (G)Beta-2 microglobulinBeta-2 microglobulin (G)BG8BG8 (G)B-HCGHuman chorionic gonadotropin (G)BLA.36CD77 (H)BL-CAMCD22 (H)Blood group antigensBlood group antigens (G, H)BR-2Gross cystic disease fluid protein-15 (G)BRST-2Gross cystic disease fluid protein-15 (G)C3b/C4bRCD35 (H)C5b-9C5b-9 (G)c-kitCD117 (G)CA 15-3Epithelial membrane antigen (G, H)CA 19-9CA 19-9 (G)CA 27.28Epithelial membrane antigen (G, H)CA 72-4B72.3 (G)CA125CA125 (G)CA19-9CA19-9 (G)CalcitoninCalcitonin (G), Hormones (G)CaldesmonCaldesmon (G)CalgranulinMAC 387 (G)CALLACD10 (G, H)CALPCalponin (G)CalponinCalponin (G)CalprotectinMAC 387 (G)CalretininCalretinin (G)CAM5.2Keratins (G)Carbohydrate antigen 19-9CA19-9 (G)Carcinoembryonic antigenCarcinoembryonic antigen (G)CD1aCD1a (H)CD2CD2 (H)CD3CD3 (H)CD4CD4 (H)CD5CD5 (G, H)CD7CD7 (H)CD8CD8 (H)CD10CD10 (G, H)CD11bCD11b (H)CD11cCD11c (H)CD13CD13 (H)CD15CD15 (G, H)CD16CD16 (H)CD19CD19 (H)CD20CD20 (H)CD21CD21 (H)CD22CD22 (H)CD23CD23 (H)CD25CD25 (H)CD30CD30 (G, H)CD31CD31 (G)CD33CD33 (H)CD34CD34 (G, H)CD35CD35 (H)CD38CD38 (H)CD43CD43 (H)CD44v3CD44v3 (G)CD45CD45 (H)CD45RACD45RA (H)CD45RoCD45Ro (H)CD56CD56 (H)CD57CD57 (G)CD61CD61 (H)CD68CD68 (G, H)CD74CD74 (H)CDw75CDw75 (H)CD77CD77 (H)CD79aCD79a (H)CD79bCD79b (H)CD95CD95 (H)CD99CD99 (G, H)CD117CD117 (G)CD141CD141 (G)CDXCDX (G)CDKN2p16 (G)CDPGross cystic disease fluid protein-15 (G)CEACarcinoembryonic antigen (G)c-erbB2HER-2/neu (G)Chromogranin AChromogranin A (G)c-kitCD117 (G)CLACD45 (H) or HECA-452 (H)CLDN1Claudin (G)ClusterinClusterin (H)Collagen IVCollagen IV (G)Common acute leukemia antigenCD10 (G, H)Complement lysis inhibitorClusterin (H)CR1CD35 (H)Cyclin D1Cyclin D1 (H)Cystic fibrosis antigenMAC 387 (G)D (Ig heavy chain delta)Heavy chain immunoglobulins (H)DBA.44DBA.44 (H)DesminDesmin (G)DF3Epithelial membrane antigen (G, H)DPBCD45RA (H)E2 antigenCD99 (G, H)EBERSEpstein-Barr virus (G, H)EBNAEpstein-Barr virus (G, H)E-cadherinE-cadherin (G)EGFREGFR (G)EM ACTHHF-35 (G)EMAEpithelial membrane antigen (G)E-MELHMB-45 (G)Endothelial cell antigenHECA-452 (H)Ep-CAMBER-EP4 (G)Epidermal growth factor receptorEGFR (G)Epithelial membrane antigenEpithelial membrane antigen (G, H)Epithelial specific antigenBER-EP4 (G)Epstein-Barr virusEpstein-Barr virus (G, H)EREstrogen receptor (G)erbB2HER-2/neu (G)ESABER-EP4 (G)Estrogen receptorEstrogen receptor (G)Ewing's sarcoma markerCD99 (G, H)Factor VIII related antigenFactor VIII (G)FVIII:RAgFactor VIII (G)Factor XIIIaFactor XIIIa (G)FascinFascin (H)Fast myosinMyosin heavy chain (G)FibronectinFibronectin (G)Fli-1Fli-1 (G)FMC7FMC7 (H)FMC 29CD99 (G, H)Friend leukemia integrin-site 1Fli-1 (G)FVIII:gFactor VIII (G)G (Ig heavy chain gamma)Heavy chain immunoglobulins (H)Gal-3Galectin-3 (G)Galectin-3Galectin-3 (G)GastrinHormones (G)GCDFPGross cystic disease fluid protein-15 (G)GFAPGlial fibriallary acidic protein (G)Glial fibrillary acidic proteinGlial fibriallary acidic protein (G)GlucagonHormones (G)Glucose transporter 1GLUT-1 (G)GLUT-1GLUT-1 (G)GPIIIaCD61 (H)gp80Clusterin (H)gp200RCC (G)GPAGlycophorin A (H)Granzyme BGranzyme B (H)Gross cystic disease fluid disease-15Gross cystic disease fluid protein-15 (G)H (blood group antigen)Blood group antigens (G)H222Estrogen receptor (G)HbHemoglobin (H)HBME-1HBME-1 (G)h-caldesmonCaldesmon (G)H-CAMCD44v3 (G)HCGHuman chorionic gonadotropin (G)HCLDBA.44 (H)HBME-1HBME-1 (G)Heavy chain immunoglobulinsHeavy chain immunoglobulins (H)HECA-452HECA-452 (H)Hematopoietic progenitor cell, class 1CD34HemoglobinHemoglobin (H)HepPar-1HepPar-1 (G)Hepatocyte paraffin-1HepPar-1 (G)HER-2/neuHER-2/neu (G)HHF-35HHF-35 (G)HHV8HHV8 (H)HLA-DRHLA-DR (H)HMB-45HMB-45 (G)HMFGEpithelial membrane antigen (G, H)hMLH1hMLH1 (G)hMSH2hMLH1 (G)HNK-1CD57 (G)HP1HepPar-1 (G)HPCA-1CD34 (G, H)HPLHuman placental lactogen (G)HuLy-m6CD99 (G, H)Human chorionic gonadotropinHuman chorionic gonadotropin (G)Human herpes virus 8HHV8 (G, H)Human mutL homologue 1hMLH1 (G)Human mutS homologue 2hMLH1 (G)Human placental lactogenHuman placental lactogen (G)IL-2 receptorCD25 (H)Inhibin-alpha subunitInhibin-alpha subunit (G)InsulinHormones (G)J5CD10 (G, H)JOVI 1TCR (H)K (Ig lighit chain kappa)Light chain immunoglobulins (H)Keratin 5/6Keratins (G)Keratin 7Keratins (G)Keratin 20Keratins (G)KeratinsKeratins (G)Ki-1CD30 (G, H)Ki-67Ki-67 (G)kip2p57 (G)KitCD117 (G)KP-1CD68 (G, H)L (Ig light chain lambda)Light chain immunoglobulins (H)L1 antigenMAC 387 (G)L26CD20 (H)L60CD43 (H)LamininLaminin (G)LCACD45 (H)Leu 1CD5 (H)Leu 2CD8 (H)Leu 3CD4 (H)Leu 5a + bCD2 (H)Leu 7CD57 (G, H)Leu 9CD7 (H)Leu16CD20 (H)Leu 22CD43 (H)Leukocyte common antigenCD45 (H)Leu-M1CD15 (G, H)Light chain immunoglobulinsLight chain immunoglobulins (H)LFA-2CD2 (H)LMP-1Epstein-Barr virus (G, H)LN1CDw75 (H)LN2CD74 (H)LysozymeLysozyme (H, G)M (Ig heavy chain mu)Heavy chain immunoglobulins (H)Mac-1CD11b (H)MAC 387MAC 387 (G)Mac-MCD68 (G, H)MART 1MELAN A (G)Mast cell tryptaseMast cell tryptase (H)mb-1CD79a (H)MCAMCD146 (G)ME491CD63 (G)MELAN-AMELAN-A (G)Melanoma antigen recognized by T cellsMELAN-A (G)Melanoma-associated antigenCD63 (G)Melanoma cell adhesion moleculeCD146 (G)Melanoma-specific antigenHMB-45 (G)MELCAM (or Mel-CAM)CD146 (G)MIB-1Ki-67 (G)MIC-2CD99 (G, H)MLH1hMLH1MN-4CD146 (G)MNF-116Keratin\--Pan-K (G)MPOMyeloperoxidase (H)MRF4Myf-4 (G)MSAHHF-35 (G)MSH2 or MSH6hMLH1MTS1p16 (G)MUC1Epithelial membrane antigen (G, H)MUC18CD146 (G)Muscle common actinHHF-35 (G)Muscle specific actinHHF-35 (G)My 7CD13 (H)My 9CD33 (H)MyeloperoxidaseMyeloperoxidase (H)Myf-4Myf-4 (G)MyoD1MyoD1 (G)MyogeninMyf-4 (G)MyoglobinMyoglobin (G)Myosin heavy chainMyosin heavy chain (G)NCAMCD56 (H)NeprilysinCD10 (G, H)NEU NNEU N (G)NeurofilamentsNeurofilaments (G)Neuron specific enolaseNeuron specific enolase (G)NFPNeurofilaments (G)NKI-betabHMB-45 (G)NKI/C3CD63 (G)NSENeuron specific enolase (G)O13CD99 (G, H)OC125CA125 (G)Oct2Oct2 (H)Octomer transcription factorOct2 (H)p16p16 (G)p27^kip1^p27^kip1^ (G)p53p53 (G)p57p57 (G)p63p63 (G)P504SAMACR (G)PAN-KKeratins (G)PAPProstate acid phosphatase (G)PECAM-1CD31 (G)PEMEpithelial membrane antigen (G, H)PerforinPerforin (H)PGM1CD68 (G, H)PgRProgesterone receptor (G)PK antigenCD77 (H)Placental alkaline phosphatasePlacental alkaline phosphatase (G)PLAPPlacental alkaline phosphatase (G)Platelet glycoprotein IIIaCD61 (H)PMS2hMLH1PodoplaninD2-40PRProgesterone receptor (G)PRAD1Cyclin D1 (H)PrAPProstate acid phosphatase (G)PrealbuminPrealbumin (G)Progesterone receptorProgesterone receptor (G)Prostate acid phosphataseProstate acid phosphatase (G)Prostate specific antigenProstate specific antigen (G)PSAProstate specific antigen (G)QBEnd10CD34 (G, H)Renal cell carcinoma markerRCC (G)retret (G)RCCRCC (G)rT3CD2 (H)S-100S-100 (G)S-Endo-1CD146 (G)SGP-2Clusterin (H)SMAAlpha smooth muscle actin (G)SM-ACTAlpha smooth muscle actin (G)Smad4DPC4 (G)SM-MHCMyosin heavy chain (G)SomatostatinHormones (G)SP40Clusterin (H)Stem cell factor receptorCD117 (G)SynaptophysinSynaptophysin (G)Syndecan-1CD138 (H)Synuclein-1Synuclein-1 (G)T3CD3 (H)T4CD4 (H)T6CD1a (H)T8CD8 (H)T11CD2 (H)T64Clusterin (H)TAG-72B72.3 (G)TauTau (G)T cell antigen receptorTCR (H)T cell intracellular antigenTIA-1 (H)TCRTCR (H)TdTTerminal deoxytransferase (H)TECD2 (H)Terminal deoxytransferaseTerminal deoxytransferase (H)THCD4 (H)ThrombomodulinCD141 (G)ThyroglobulinThyroglobulin (G)Thyroid transcription factor 1TTF-1 (G)TIA-1TIA-1 (H)TMCD141 (G)traf-1traf-1 (H)TransthyretinPrealbumin (G)TRPM2Clusterin (H)TTF-1TTF-1 (G)TTRPrealbumin (G)Tumor-associated glycoprotein 72B72.3 (G)Tumor necrosis factor receptor--associated factortraf-1 (H)UCHL-1CD45Ro (H)UEA 1Ulex (G)UlexUlex (G)VimentinVimentin (G)von Willebrand's factorFactor VIII (G)VWFFactor VIII (G)Wilms' tumor 1 proteinWT1 (G)WT1WT1 (G)[^18]

Results {#s0260}
-------

The results of studies are incorporated into the surgical pathology report. The following information is included:1.The type of tissue studied: formalin-fixed (or other fixatives) tissue, cryostat sections, cytology preparations, etc.2.The type of immunoagents used, being as specific as possible. For example, do not just list keratin but specify the type of keratin (e.g., AE1/AE3).3.The results of the studies in great enough detail to allow interpretation. For example the type of cell that is immunoreactive (e.g., tumor vs. nontumor), intensity of immunoreactivity (e.g., weak, strong) and/or the number of cells immunoreactive (e.g., focal vs. diffuse).4.Integration of the results into the final diagnosis specifying whether they confirm or support a diagnosis, make one diagnosis more likely than others, or exclude one or more diagnoses.

ELECTRON MICROSCOPY {#s0265}
===================

 {#s0270}

###  {#s0275}

####  {#s0280}

##### Indications for EM Studies {#s0285}

•Diagnostic renal biopsies for glomerular disease•Adenocarcinoma versus mesothelioma (see [Table 7-36](#t0185){ref-type="table"})•Difficult to classify tumors ([TABLE 7--45](#t0230){ref-type="table"}, [TABLE 7--46](#t0235){ref-type="table"} )TABLE 7--45ELECTRON MICROSCOPIC FEATURES OF POORLY DIFFERENTIATED TUMORSTUMORULTRASTRUCTUREADDITIONAL TESTSCOMMENTSCarcinomaWell-developed desmosomes (pentalayered with a dense central line in the intracellular space) with intermediate filament attachment.Tonofilaments and bundles of filaments (keratin).Adenocarcinomas:•Intercellular lumina (but also present in vascular tumors)•Microvilli•Intracellular lumina (mucin vacuoles in signet ring cells)Squamous cell carcinomas•Numerous intermediate filaments (keratin) and desmosomesIHC: Cytokeratins are present in almost all carcinomas if broad spectrum antibodies are used.EMA is present in almost all carcinomas, but is less specific and sensitive.Additional markers can be used to identify specific carcinomas.Other tumors can also be keratin positive and have desmosomes, filaments, and cytokeratin (mesothelioma, meningioma, synovial sarcoma, and epithelioid sarcoma)MelanomaMelanosomes in various stages of development -- indicative of a melanin-forming cell type.Abnormal pleomorphic melanosomes may be present in melanomas.Desmoplastic melanomas lack melanosomes.IHC: S100, HMB45, MART-1HMB45 and MART-1 may be absent in non-epithelioid melanomas.The HMB-45 epitope (gp100) is present in immature melanosomes or premelanosomes, but is not specific to these structures.Melanosomes are also seen in clear cell sarcoma, pigmented schwannomas, PEComa, and other rare tumors. Mature forms can be taken up by melanophages, keratinocytes, and carcinomas.LymphomaNo specific features are present. The cells lack cellular junctions and there is a paucity of cytoplasmic organelles.IHC: LCALCA may be absent in 30% of anaplastic (ALK1) lymphomas. These tumors can be EMA (+) but are keratin (-).SarcomaSome types have specific diagnostic features of cell type (e.g., neural, smooth muscle, striated muscle).No well-developed desmosomes.IHC: May be helpful for identifying specific types.Keratin negative except for synovial sarcoma and epithelioid sarcoma (or rarely in other types).TABLE 7--46CELLS, TUMORS, AND STRUCTURES WITH CHARACTERISTIC FINDINGS BY ELECTRON MICROSCOPYTUMOREM FINDINGSCORRELATIONS AND OTHER DIAGNOSTIC TESTSAlveolar soft part sarcomaRhomboid, rod-shaped, or spiculated crystals in a regular latttice pattern.The characteristic cytoplasmic crystals are composed of monocarboxylate transporter 1 (MCT1) and its chaperone CD147. These proteins are found in many other cell types and are not specific for this tumor.Cytogenetics: t(X;17) creates a ASPL-TFE3 fusion protein.IHC: TFE3 positive (as well as rare pediatric renal tumors with the same translocation). Nuclear immunoreactivity is not present in other tumors or normal tissues.Histo: The crystals are PAS with diastase positive.AmyloidNon-branching fibrils, 7.5 to 10 nm in width and up to 1 micron in length.May be present associated with plasma cell tumors, medullary carcinoma of the thyroid, Alzheimer's disease, or as an isolated finding (primary amyloidosis).IHC: Can be used to identify specific types of amyloid (e.g., lambda or kappa chains, beta2 microglobulin, calcitonin, tau)Bronchioloalveolar carcinoma of the lung (BAL)Lamellar (surfactant) "myelin-like" granules in the supranuclear cytoplasm (typical of Type II pneumocytes).Clara-like electron-dense granules in supranuclear cytoplasm.Intranuclear inclusions comprised of parallel microtubular arrays.These features can also be seen in metastatic BAL.Cytogenetics: These carcinomas are less likely to be associated with smoking and have fewer cytogenetic changes.Bronchioloalveolar carcinomas or adenocarcinomas with features of BAL are more likely to respond to Iressa (38%) as compared to other lung carcinomas (14%) due to specific mutations in EGFR.Mucinous BAL has intranuclear inclusions but generally lacks the other EM features.ChordomaDesmosomes, large vacuoles, glycogen, dilated ER, cytoplasmic invaginations, and intermediate filamentsThe physaliphorous (= having bubbles or vacuoles) appearance is due to dilated ER, glycogen, and cytoplasmic invaginations.IHC: Keratin (corresponds to intermediate filaments), EMA, S100Clear cell sarcomaMelanosomes in various stages of development.Glycogen (resulting in clear cytoplasm).Cytogenetics: t(12;22) EWS;ATF1 fusion proteinIHC: S100, HMB45Dense core granulesDense core granules (vesicle bound by a single membrane with a dense center -- 60 to 300 nm) -- cytoplasmic organelles involved in regulated exocytosis of cell products.Examples:Pancreatic beta cells (insulin): angular crystalline inclusionsPheochromocytoma (epinephrine and norepinephrine): Large, pleomorphic, often clear or only partially filledCarcinoid:•Foregut -- small, round•Midgut -- larger, pleomorphic•Hindgut -- mixedFound in tumors of neuronal or neuroendocrine origin.Vesicles are comprised of granins (predominantly chromogranin A, chromogranin B, and secretogranin II) and various peptide hormones and transmitters, ATP, and biogenic aminesIHC: Chromogranin A (most specific). Specific products of tumors can also be detected.Note: Prostate cancers and breast cancers can also show strong chromogranin positivity and can be mistaken for neuroendocrine tumors, particularly at metastatic sites.Desmoplastic small round cell tumorNumerous desmosomes and tight junctions, numerous cell processes, large number of organelles (mitochondria and RER), microfilaments, small neurosecretory granulesCytogenetics: t(11;22) EWS;WT1 fusion proteinIHC: Keratin, desmin, WT-1, actin, EMA, NSEEndothelial cellsWeibel-Palade bodies (cigar-shaped membrane-bound structures filled with tubules in parallel arrays).Intracytoplasmic lumina may be present in normal cells and in epithelioid vascular neoplasms.Weibel-Palade bodies are frequently absent in tumors arising from endothelial cells (e.g., angiosarcomas). IHC markers are more sensitive to detect endothelial derivation. The membranes are formed by P-selectin and the tubules contain FVIII.IHC: Vascular markers (CD34, CD31, FVIII)Ewing sarcoma (PNET)Homogeneous cell population characterized by the lack of specialized features, large pools of glycogen, no organelles, no extracellular matrix, variable numbers of neurosecretory granules and cell processes.Cytogenetics: t(11;22) EWS;FLI1 fusion protein (and other less common variants)IHC: CD99. FLI1 is also present, but is less specific.Histo: PAS +/− diastase can detect glycogen, but is not currently used for diagnosis.Granular cell tumorNumerous lysosomes (filled with tubular, vesicular, and amorphous material), phagosomes, and granules (correlating with the "granular" cytoplasm), reduplicated basal lamina surrounding groups of cells.IHC: S100, inhibin, CD68, calretininLangerhans cell histiocytosisBirbeck granules (rod-or tennis racket-shaped) structures of variable length with a central periodically striated lamella.May serve as a reservoir for Langerin (a transmembrane type II Ca2+-dependent lectin) and CD1a in the endosomal recycling compartment.IHC: CD1a, Langerin, S100Mast cellsLameller or scroll-like membrane pattern, granules of variable size.IHC: CD117 (c-kit), mast cell tryptaseMedullary carcinoma of the thyroidNumerous neurosecretory granules (calcitonin) associated with stromal amyloid (calcitonin).Cytogenetics: Mutations in the RET gene (sporadic and germline)IHC: Calcitonin (in tumor cells and amyloid), chromograninMerkel cell carcinomaNeurosecretory granules in processes or along cell membranes (subplasmalemmal).IHC: Chromogranin, NSE, cytokeratin 20MesotheliomaElongated, serpiginous, and branched microvilli (generally 10 to 16 length: 1 width) apical without a glycocalyx or actin rootlets.Cytogenetics: Characteristic chromosome deletions and loss of 9 and 22IHC: Calretinin, WT-1NeuroblastomaCellular processes with microtubules (neuropil), dense core granules, Homer-Wright rosettes (the center is comprised of a tangle of cell processes), synaptic vesicles, no glycogenCytogenetics: Changes are linked to prognosisIHC: Chromogranin, NSE, NFP, synaptophysinOncocytomaNumerous mitochondria packed in the cytoplasm (correlating with the granular appearance of the cytoplasm). In contrast, chromophobe renal cell carcinoma has fewer mitochondria and more microvesicles.Cytogenetics: Monosomy with loss of X or Y, 11q13. Chromophobe carcinomas have different cytogenetic changes.IHC: RCC is negative in oncocytomas but positive in 45% to 50% of chromophobe renal cell carcinomas.PerineuriomaLong cell processes wrapping around adjacent cellsIHC: Claudin-1 (a component of tight junctions), EMARhabdoid tumor of the kidneyLarge paranuclear whorls of intermediate filaments (corresponding to cytokeratin and vimentin) and occasional tonofilamentsCytogenetics: hSNF5/INI1 deletions and mutations on chromosome 22IHC: Cytokeratin (+), vimentin (+), absence of INI1 nuclear proteinRhabdomyosarcomaParallel thick (12 to 15 cm) and thin (6 to 8 nm) myosin-actin filaments, Z-bands, filament ribosomal complexes.Spider cells may be seen in cardiac tumors (clear cytoplasm divided by cytoplasmic processes and cross striations formed by leptofibrils).Cytogenetics: Characteristic changes in alveolar and embryonal typesIHC: Muscle markers (HHF-35, desmin, myf4)SchwannomaBasal lamina prominent, often reduplicated. Luse bodies (long spacing collagen, extracellular), myelin figures, long cell processes wrapping around collagen, may rarely have melanosomes (melanotic schwannoma)Cytogenetics: Deletion of 2q (NF2 inactivation)IHC: S100[^19]•Nerve (e.g., toxic or drug-induced neuropathy) and muscle biopsies (e.g., inclusion body or nemaline myopathy)•Bullous skin diseases (e.g., epidermolysis bullosa)•Ciliary dysmorphology (primary ciliary dyskinesia or Kartagener syndrome)•Endomyocardial biopsies (e.g., adriamycin toxicity, amyloid, nemaline myopathy)•Liver biopsies for microvesicular fat in acute fatty liver of pregnancy•Small bowel biopsies to look for pathogens (e.g., Whipple disease)•Congenital, inherited, and metabolic diseases (e.g., ceroid lipofuscinoses)•Prion diseases

##### Method {#s0290}

Ultrastructural details of tissues are lost rapidly. Therefore, fresh tissue must be fixed rapidly and well for EM. Tissues are usually fixed in special fixatives for EM to preserve lipids and glycogen (e.g., 2% paraformaldehyde and 2.5% glutaraldehyde in 0.1 M cacodylate buffer, pH 7.4).1.Place a small fragment of tissue in a drop of fixative on a cutting surface.2.Cut the tissue into multiple tiny fragments, each no greater than 0.1 cm in any dimension.3.Place the tissue into the vial of fixative. Shake the vial to make sure all the tissue fragments are covered by fixative.

Note: If tissue from a small biopsy is found to be nondiagnostic on H&E, any tissue saved for EM should be retrieved for examination by light microscopy.

##### Results {#s0295}

A separate electron microscopy report is usually issued. The results should be incorporated into the final diagnosis.[@bib19]

SNAP FROZEN TISSUE {#s0300}
==================

Frozen tissue is useful for staining (some antibodies only detect antigens in frozen tissue), enzyme studies (muscle biopsies), and to save tissue for DNA or RNA studies.

 {#s0305}

###  {#s0310}

####  {#s0315}

##### Indications {#s0320}

All specimens with a question of a lymphoproliferative disorder, sarcomas, unusual tumors, muscle biopsies.

##### Methods {#s0325}

Small (approximately 0.5 × 0.5 × 0.3 cm^3^) portions of tissue are placed in a clean specimen container moistened with a small amount of normal saline until they can be frozen. Specimens should be snap frozen using liquid nitrogen or dry ice and stored at --20°C.

##### Results {#s0330}

The results of studies on frozen tissue are usually incorporated into the surgical pathology report.

IMMUNOFLUORESCENCE {#s0335}
==================

Like immunoperoxidase studies, immunofluorescence (IF) detects antigens in tissues. However, because amplification of the signal is not used, it is better suited for precise localization of antigen/antibody complexes in tissues or for determining the deposition pattern of immune complexes (e.g., linear vs. granular). Thus, it is most useful for the investigation of diseases related to immune complex deposition such as glomerular diseases and bullous diseases of the skin.

Tissue for IF may be snap frozen (see instructions earlier) or stored in special fixatives for IF. If the specimen is not frozen, special care must be taken to ensure that the biopsy is kept moist in a sealed container.•**Direct IF:** Uses antibodies to detect antigens in the patient's **tissues**.•**Indirect IF:** Uses control tissues to detect antibodies (e.g., anti-BM) in the patient's **serum**.

 {#s0340}

###  {#s0345}

####  {#s0350}

##### Indications {#s0355}

Some skin biopsies (e.g., lupus, pemphigus, pemphigoid, and dermatitis herpetiformis), all diagnostic nontransplant renal biopsies, some transplant renal biopsies, identification of amyloid in cardiac biopsies, and the evaluation of vasculitis in nerve biopsies.

##### Method {#s0360}

Tissue must be submitted fresh.

##### Results {#s0365}

The results of the examination are usually incorporated into the surgical pathology report.

Immunofluorescence of Skin Lesions {#s0370}
----------------------------------

•**SLE (lupus band test)**: linear or granular staining along dermal epidermal junction for multiple immunoreactants in about 80% of cases (most commonly IgG and less often IgM or C3). The specificity increases with the number of positive immunoreactants. Uninvolved sun-exposed skin shows positivity in most patients with active systemic lupus. Uninvolved skin in patients with discoid lupus is usually negative for this test.•**Herpes gestationis:** perilesional skin shows linear BM zone C3 and sometimes IgG.•**Dermatitis herpetiformis:** granular IgA at tips of dermal papillae of uninvolved skin.•**Pemphigus:** IgG and C3 between epidermal cells creating a net-like pattern. In pemphigus vulgaris, a split just above the basal cell layer creates a "tombstone" appearance to the row of basal cells at the base of the vesicle. In pemphigus foliaceus and related disorders, the split occurs near the granular cell layer.•**Pemphigoid:** Ig and C3 along basement membrane but not between cells. Indirect IF reveals an anti-BM antibody.

MOLECULAR GENETIC PATHOLOGY {#s0375}
===========================

Molecular genetic pathology is the newest subspeciality in pathology with board certification. Molecular diagnostics incorporates many types of techniques for the investigation of genetic alterations in cells and viruses (e.g., Southern blotting, PCR analysis, FISH). It has applications in three main areas:

**Inherited diseases:** •Identification of inherited diseases (e.g., cystic fibrosis, hemochromatosis, Factor V Leiden, Prothrombin 20210A, Fragile X syndrome).•Identification of genes conferring susceptibility to diseases (e.g., microsatellite instability \[MSI\], BRCA1 and 2)

**Infectious diseases:** •Detection of organisms•Identification of specific organisms•Quantitation of viral infection (e.g., HIV viral load)

**Cancer**:•Identification of specific genetic alterations associated with tumors•Identification of gene mutations associated with susceptibility to treatment (e.g., EGFR mutations in lung cancer, c-kit mutations in GIST)•Identification of clonality in hematolymphoid proliferations•Detection of minimal residual disease after treatment

These studies are especially helpful for hematolymphoid proliferations that are difficult to classify because of the frequent and characteristic rearrangements that occur in many of these disorders. Unlike cytogenetics, the cells need not be viable. However, it is preferable that the nucleic acids are relatively intact. Southern blot and RNA-based PCR (RT-PCR) assays are best performed on fresh or frozen tissues. Formalin-fixed, paraffin-embedded tissue is amenable to DNA-based PCR assays. Some fixatives (e.g., Bouin's) cause extensive breakage of DNA and may preclude genetic analysis of the tissue.

 {#s0380}

###  {#s0385}

####  {#s0390}

##### Indications {#s0395}

•B-cell proliferations -- clonal rearrangements of the immunoglobulin heavy and light chain genes; specific translocations•T-cell proliferations -- rearrangements of the γ and β T-cell receptor genes•Leukemias•Post-transplant lymphoproliferative disorders -- clonal populations of EBV-infected cells•Oligodendrogliomas -- PCR-based LOH analysis for 1p/19q deletions.•Colon cancers possibly associated with hereditary non-polyposis colorectal carcinoma syndrome (HNPCC): microsatellite instability (MSI) testing of colon cancers occurring in patients 50 years of age or younger.•Human papilloma virus testing: cervical PAP smears, squamous cell carcinomas of the head and neck (see subsequent section).•GIST -- most have mutations in the KIT tyrosine kinase gene. A smaller group (5% to 7%) have mutations in the KIT-homologous tyrosine kinase PDGFRA. About 10% to 15% of GISTs are negative for KIT and PDGFRA mutations (termed "wild-type GISTs"). The specific type of mutation is correlated with prognosis and the respone to specific types of treatment.•Lung adenocarcinoma -- some cancers have mutations in EGFR that predict response to the tyrosine kinase inhibitor gefitinib.

##### Method of Submitting Tissue {#s0400}

Fresh or frozen tissue (e.g., snap frozen tissue) as well as fluids may be used. Cytologic preparations can be used for FISH. Paraffin blocks can also be used.

##### Results {#s0405}

The results are usually either reported separately or incorporated into the surgical pathology report.

CYTOGENETICS {#s0410}
============

Cytogenetic studies have been demonstrated to be useful in several areas important to pathology:•**Tumor classification:** Particularly sarcomas (e.g., Ewing's sarcoma and synovial sarcoma), lymphomas, leukemias, kidney tumors, brain tumors, and other unusual tumors.•**Benign vs. malignant lesions:** •Reactive mesothelial cells vs. mesothelioma•Lipoma vs. liposarcoma•**Prognosis:** Neuroblastoma, oligodendroglioma, multiple myeloma, chronic lymphocytic leukemia.•**Treatment:** Amplification of HER2/neu to predict response to Herceptin.•**Research:** Translocations are common to many tumors and usually identify genes important to the pathogenesis of the tumor

Cells may be cultured to perform complete karyotype analysis or tissues can be analyzed for specific chromosomal alterations by fluorescence in situ hybridization (FISH).

FISH studies can be performed on cultured cells, cytology specimens, touch preparations, and paraffin-embedded tissues.

 {#s0415}

###  {#s0420}

####  {#s0425}

##### Indications {#s0430}

•**For karyotype analysis:** Soft tissue tumors, mesotheliomas (tissue or pleural fluid), unusual tumors, poorly differentiated tumors, all subcutaneous lipomas \>10 cm or of unusual gross appearance, all deep-seated lipomas (subfascial, intramuscular, intraabdominal, retroperitoneal, clinically apparent cord tumors), unusual uterine masses.•**For FISH:** Oligodendroglioma, neuroblastoma.

##### Method for Submitting Tissue {#s0435}

Tissue for karyotyping must be fresh, viable, and relatively sterile. However, tissue may be submitted even if it has not been handled under strictly sterile conditions (contamination is not usually a problem). If specimens are to be held overnight, the tissue should be minced (into 0.1 cm cubes) in a sterile specimen container, covered with culture medium, and held overnight in the refrigerator. Fluids may also be submitted for analysis (especially pleural effusions with a suspicion of mesothelioma).

##### Results {#s0440}

The results of the cytogenetic analysis should be incorporated into the final diagnosis or reported separately ([TABLE 7--47](#t0240){ref-type="table"}, [TABLE 7--48](#t0245){ref-type="table"} ).TABLE 7--47COMMON CYTOGENETIC AND GENETIC CHANGES IN SOLID TUMORS OF DIAGNOSTIC OR THERAPEUTIC SIGNIFICANCETUMOR TYPECHARACTERISTIC CYTOGENETIC CHANGESGENETIC CHANGESFREQUENCYCOMMENTS**Adenoid cystic carcinoma**6q translocations and deletions\>50%**Adrenal cortical carcinomas**2p16 loss\>90%This area is close to the region associated with Carney complex type 2.17p13 LOH85%These changes are less common in localized tumors (25% to 35%) but, if present, such tumors are more likely to metastasize. The 11p15 imprinted region is also involved in Beckwith-Wiedemann syndrome.11p15 LOH with duplication of the active paternal allele leading to IGF-II overexpression85%**Aggressive angiomyxoma**t (12q15)HMGA2 involvement\>20%**Alveolar soft part sarcoma**t(X;17)(p11.2;q25)ASPL-TFE3 fusion\>90%TFE3 can be detected by IHC. This translocation is also present in rare papillary-like renal tumors in young adults (see "Renal tumors").**Aneurysmal bone cyst**t(16;17)(q22;p13)CDH11-USP6 fusion20%t(17p13.2)USP6 fusions\>50%**Angiomatoid fibrous histiocytoma**t(12;16)(q13;p11)FUS-ATF1 fusionUnknownt(12;22)(q13;q12)EWSR1-ATF1 fusionEWSR1-ATF1 translocation also present in clear cell sarcomat(2;22)(q33;q12)CREB1-EWSR1 fusion**Bizarre parosteal osteochondromatous proliferation** (Nora's lesion)t(1;17)(q32;q21)A breakpoint in 1q32 was found in 100% of lesions. A breakpoint in 17q21 was found in 4 or 5 cases.t(1;17)(q42;q23)Only one case with different breakpoints**Breast carcinoma**HER2/neu amplification15-20%Detected by FISH (gene amplification) or IHC (protein overexpression). Positive carcinomas are more likely to respond to Herceptin.[a](#tblfn47){ref-type="table-fn"}BRCA1 and BRCA2 germline mutations\<5%Patients are more likely to be young and have multiple carcinomas. BRCA1 carcinomas are frequently high grade, have "medullary" features, and lack ER, PR, HER2. BRCA2 carcinomas have no specific pathologic features.t(12;15)ETV6-NTRK3 fusion100% (secretory carcinoma)This translocation is found in secretory carcinomas. The same translocation is found in infantile fibrosarcoma and cellular mesoblastic nephroma.**Carcinoma of the upper aerodigestive tract in children**t(15;19)(q13;p13.2)BRD4-NUT fusionPatients with this translocation have a poor prognosis.**Chondromyxoid fibroma**Deletion of 6q\>75%**Clear cell hidradenoma**t(11;19)(q21;p13)MECT1-MAML 2 fusionSame translocations as mucoepidermoid carcinoma and Warthin tumor**Clear cell sarcoma**t(12;22)(q13;q12)EWSR1-ATF1 fusion\>75%t(2;22)(q33;q12)EWSR1-CREB1 fusionUnknown**Colon carcinoma**hMLH1 and hMSH2 mutations15% of sporadic carcinomas95% of HNPCC patients have germline mutations in these genes. Absence can be detected by IHC or by PCR assays for microsatellite instability. Mutations are correlated with characteristic clinical, pathologic, and treatment response features.EGFR (HER1) overexpression82% of all carcinomasApproximately 23% of patients treated with cetuximab[b](#tblfn95){ref-type="table-fn"} and chemotherapy respond.APC mutations80% of all carcinomasAlso present as a germline mutation in familial adenomatous polyposis syndrome.LKB1/STK11 LOH\~ 15%Germline mutations occur in some cases of Peutz-Jeghers syndrome. Mutations appear to be rare in sporadic colon carcinoma but LOH is observed in some.DPC4 (Smad4 or MADH4) mutations (18q21.1)10--20%Germline mutations in occur in some cases of juvenile polyposis syndrome. Mutations in sporadic carcinomas are uncommon.**Desmoplastic fibroblastoma**t(2;11)(q31;q12)Unknown**Desmoplastic small round cell tumor**t(11;22)(p13;q12)EWSR1-WT1 fusion\>95%WT1 can be detected by IHC.**Dermatofibrosarcoma protuberans/giant cell fibroblastoma**+r(17;22)(q21;q13) t(17;22)(q21;q13),COL1A1-PDGFB fusionCOL1A1-PDGFB fusion\>75%The same translocation is present in giant cell fibroblastoma, but without formation of a ring chromosome.**Endometrial stromal sarcoma**t(7;17)(p15;q21)JAZF1-JJAZ1 fusion30%t(6;7)(p21;p15)JAZF1-PHF1 fusion10%t(6;10)(p21;p11)EPC1-PHF1 fusionRare**Epithelioid hemangioendothelioma**t(1;3)((p36.3;q25)**Epithelioid sarcoma**t/del(22q11.2)INI1 deletion, mutationsAbsence can be detected by IHC.**Ewing sarcoma/PNET**t(11;22)(q24;q12)EWSR1-FLI1 fusion\>80%FLI1 can be detected by IHC but is not specific for Ewing's. FISH can detect fusion genes.The type of fusion is correlated with prognosis (e.g., Type I exon 6 has \>100 month survival, Type II exon 5 has 2 year survival).t(21;22)(q22;q12)EWSR1-ERG fusion5-10%t(2;22)(q33;q12)EWSR1-FEV fusion\<5%t(7;22)(p22;q12)EWSR1-ETV1 fusion\<5%t(17;22)(q12;q12)EWSR1-E1AF fusion\<5%inv(22)(q12)(q12)EWSR1-ZSG fusion\<5%t(16;21)(p11;q22)FUS-ERG fusionUnknownt(2;22)(q31;q12)EWSR1-SP3 fusiont(2;16)(q33;p11)FUS-FEV fusion**Extraskeletal myxoid chondrosarcoma**t(9;22)(q22;q12)EWS-NR4A3 fusion\>75%t(9;17)(q22;q11)TAF2N-NR4A3 fusion\<10%t(9;15)(q22;q21)TCF12-NR4A3 fusion\<10%t(3;9)(q11;q22)TGF-NR4A3 fusion**Fibromatosis (desmoid)**Trisomies of 8 and 2030%Deletion of 5q21APC inactivation10%Beta-catenin mutations50%Nuclear beta-catenin can be detected by IHC.**Fibromyxoid sarcoma, low grade**t(7;16)(q32-34; p11.2)FUS-CREB3L2 fusion96%t(11;16)(p11;p11)FUS-CREB3L1 fusionRare**Fibrosarcoma, infantile**t(12;15)(p13;q25)ETV6-NTRK3 fusion\>75%The same translocation is seen in cellular mesoblastic nephroma and secretory breast carcinoma.Trisomies 8, 11, 17,20\>75%**Gastrointestinal stromal tumor**Monosomies 14 and 22\>75%Deletion of 1p\>25%KIT or PDGFRA mutation\>90%CD117 (KIT) is detected by IHC and is useful for diagnosis. Gleevec[c](#tblfn96){ref-type="table-fn"} is effective against tumors with activating mutations in either gene. The type of mutation correlates with treatment response.**Germ cell tumors**Isochromosome 12p\>80-90%Includes all histologic subtypes in males and dysgerminomas of ovaryKIT mutations25-70%Seminomas**Giant cell tumor**Telomeric changes\>50%**Giant cell tumor, diffuse type** (PVNS)t(1;2)(p13;q37)COL6A3-CSF1 fusion\>25%Trisomies 5 and 7Unknown**Glioblastoma multiforme** (anaplastic mixed glioma)EGFR (HER1) amplification40%Detected by ISH. IHC is not helpful for detecting overexpression. The co-deletion of 1p36 and 19q13.3 is absent.**Hepatoblastoma**Trisomies 2q and 20\>75%**Hibernoma**11q13 rearrangement\>50%**Inflammatory myofibroblastic tumor**t(1;2)(q22;p23)TPM3-ALK fusionUnknownALK can be detected by IHC in one third of cases. There are other partners for ALK fusion.t(2;19)(p23;p13)TPM4-ALK fusiont(2;17)(;23;q13)CLTC-ALK fusiont(2;2)(p23;q13)RANB2-ALK fusion**Leiomyoma, uterine**t(12;14)(q15;q24)\
Deletion of 7q\
Deletion of 1pHMGA2 rearrangement40%Uterine leiomyosarcomas have more complex karyotypes.These tumors are cellular and have gene expression patterns similar to leiomyosarcomas.**Lipoblastoma**8q12 rearrangementPLAG1 oncogene\>80%Polysomy 8**Lipoma**Typicalt(12q15)HMGA2 rearrangement40%t(6p21)HMGA1 rearrangement10%t(8q12)PLAG15%Deletion 13q5%Spindle cell or pleomorphicDeletion of 13q or 16q\>75%t(11;16)(q13;p12-13)Unknown**Liposarcoma**Well-differentiatedRing /giant markers (12q13-q15)HMGA2, MDM2 amplification\>75%Similar ring/giant markers are seen in dedifferentiated liposarcomas, with additional aberrationsMyxoid/round cellt(12;16)(q13;p11)t(12;22)(q13;q12)FUS-DDIT3(CHOP) fusionEWS-CHOP fusion\>75%\<5%PleomorphicComplex90%DedifferentiatedRing /giant markers (12q13-q15)HMGA2, MDM2 amplification**Lung adenocarcinomas that respond to gefitinib** (most in women, nonsmokers, with features of BAC)Fewer changes than seen in carcinomas associated with smokingEGFR - small deletions or amino acid substitutions10-20% of all lung carcinomasMutations predict response (gain of function) to the tyrosine kinase inhibitor gefitinib (Iressa).[d](#tblfn50){ref-type="table-fn"}40% to 80% of lung carcinomas show EGFR overexpression by IHC, but only carcinomas with specific mutations respond to gefitinib.**Medulloblastoma**Isochromosome 17q\>25%**Meningioma**Monosomy 2290%1p deletion25%**Mesothelioma**Deletion of 1p? BCL10 inactivation\>50%Cytogenetic changes are less complex than those seen in carcinomas.Cytogenetic analysis of cytologic specimens (e.g., pleural fluid) can be of value if larger biopsies are not available.Deletion of 9pp15, p16, and p19 inactivation\>75%Deletion of 22qNF2 inactivation\>50%Deletions of 3p and 6q\>50%**Mucoepidermoid carcinoma**t(11;19)(q21;p13)MECT1-MAML 2 fusion\>50%Same translocation as Warthin tumor and clear cell hidradenoma**Neuroblastoma**Hyperdiploid, no 1p deletion40%Good prognosis1p deletion40%Poor prognosisDouble minute chromosomesN-MYC amplification\>25%Poor prognosis**Oligodendroglioma**Co-deletion of 1p36 and 19q13.350%Useful for diagnosis and to predict response to radiation and/or chemotherapy. EGFR amplification is absent.9p21 deletionCDKN2A (p16) deletionOccurs in some anaplastic oligodendrogliomas. Poor prognostic factor.**Osteochondroma**Deletion of 8qEXT1 inactivation\>25%**Osteosarcoma**Low gradeRing chromosomes\>50%High gradeComplexRB and P53 inactivation\>80%**Pheochromocytoma**Sporadic (70%)Losses on 1p\>80%Hereditary (30%)Germline mutations in RET, VHL, NF1, SDHB, SDHD, MEN2A, MEN2B\>90% of hereditary casesPatients are more likely to be young (\<50), have multiple tumors, and have a family history of pheochromocytoma, paraganglioma, or medullary carcinoma of the thyroid.**Pleomorphic adenoma** (salivary)t(3;8)(p21;q12)CTNNB1-PLAG1 fusion\>50%t(8q12)PLAG1 fusions\<20%t(9;12)(p12;q15)NFB1-HMGA2 fusion**Prostate cancer**t(21;21)(q22.2;q22.3)TMPRS2-ERG fusionUnknownt(7;21)(p21.2;q22.2)TMPRSS2-ETV1 fusionUnknown**Renal TumorsClear cell carcinoma**Deletion of 3p90%VHL70%Deletion or inactivation**Papillary carcinoma -- adult**Trisomies 3, 7, 12, 16, 17, and 20\>90%KIT mutations\>90%CD117 (c-kit) present by IHC in cytoplasm and is associated with activating mutations.Xp11.2 or TFE3 translocation carcinomas (young adults \[\<1% of all adults\] and children \[30% to 50% of pediatric cases\], female \> male, 10% to 15% have prior treatment)t(X;17)(p11.2;q25.3)ASPL/TFE3 fusionTumors have voluminous cytoplasm.The ASPL-TFE3 fusion is also present in alveolar soft part sarcoma. TFE3 and TFEB can be detected by IHC.t(X;1)(p11.2;q21)PRCC/TFE3 fusiont(X;1)(p11.2;p34)TFE3-PSF fusioninv(X)(p11.2q12)TFE3/*NonO* fusiont(6;11)(p21.1;q12)TFEB-*Alpha* fusionTumors have a more solid, compact architecture, less voluminous cytoplasm, less frequent psammoma bodies and hyaline nodules, and less prominent nucleoli.Oncocytoma-1, -X or -Y\>25%11q13 rearrangement\>25%Chromophobe carcinomaMonosomies 1, 2, 3, 6, 10, 13, 17, and 21\>75%CD117 (c-kit) is present by IHC on membranes, but activating mutations have not been detected.Mesoblastic nephromat(12;15)(p13;q25)ETV6-NTRK3 fusionThe same translocation is seen in infantile fibrosarcoma and secretory breast carcinoma.**Retinoblastoma**13q14 deletionRB1 inactivation\>75%40% of cases are due to germline mutations in RB1.Isochromosome 6p25%**Rhabdoid tumor of the kidney and atypical teratoid/rhabdoid tumor (AT/RT)**Normal karyotypehSNF5/INI1 (22q11.2) deletions and mutations\>90%Infants and children with both tumors have a germline mutation in INI1 (rhabdoid predisposition syndrome).\
Choroid plexus carcinomas are also associated with non-function of this gene (70%).del/t(22)(q11.2)hSNF5/INI1 deletions and mutations**Rhabdomyosarcoma**Alveolart(2;13)(q35;q14)PAX3-FKHR fusion\>75%Poor 4-yr survival if metastatic (8%)t(1;13)(p36;q14), double minutesPAX7-FKHR fusion10-20%Better 4-yr survival if metastatic (75%)t(2:2)(q35;23)PAX3-NCOA1 fusionraret(X;2)(q35;q13)PAX3-AFX fusionrareEmbryonalTrisomies 2q, 8, and 20\>75%LOH 11p15.5\>75%**Schwannoma and perineurioma**Deletion of 22qNF2 inactivation\>80%5% of cases of vestibular schwannomas are associated with neurofibromatosis type 2 (germline NF2 mutations).**Subungual exostosis**t(X;6)(q13-14;q22)COL4A5 and COL12A1 involvement**Synovial sarcoma**Monophasict(X;18)(p11;q11)SYT with SSX1, SSX2, or SSX4 fusion\>90%Biphasict(X;18)(p11;q11)SYT-SSX1 fusion\>90%**Thyroid carcinoma**Papillary10q11 rearrangementRET/PTC rearrangements20%Most common in younger patients (avg 26) and radiation-associated carcinomas, all have psammoma bodiesRAS mutations15%All follicular variant, rare LN mets, 6 women to 1 man, larger tumors1q21 rearrangementNTRK1 fusion oncogenes\>10%BRAF point mutation44%Older patients (avg 48), some anaplastic and poorly differentiated carcinomas (15% are tall cell), higher stage, more extrathyroidal invasionFolliculart(2;3)(q13;p25)PAX8-PPARG fusion\>40%45% have RAS mutationsMedullarySporadic (75%)RET activating mutations\>90%Hereditary (25%)Germline RET, MEN2A, or MEN2B mutations\>90%Indication for screening for pheochromocytoma and screening family members**Wilms tumor, pediatric**Deletion 11p13WT1 inactivation25%Germline mutations occur in several syndromes. WT1 mutations also occur in sporadic tumors.Trisomy 1240%WTXWTX is inactivated in approximately one-third of Wilms tumors[^20][^21][^22][^23][^24]For additional information on specific genes, see Online Mendelian Inheritance in Man (OMIM; [www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov){#interref3}).TABLE 7--48COMMON CYTOGENETIC CHANGES IN LYMPHOMAS AND LEUKEMIASTUMOR TYPECYTOGENETIC CHANGESMOLECULAR EVENTSFREQUENCYCOMMENTSChronic Leukemias and MastocytosisCML (Ph^1^)t(9;22)(q34;q11.2)BCR-ABL fusion (usually p210, but also p190 and p230 fusion proteins)90-95%Philadelphia chromosome. Also present in 5% of children and 15-30% of adults with ALL and 2% of patients with AML.Treated with the ABL tyrosine kinase inhibitor imatinib (Gleevec)[a](#tblfn98){ref-type="table-fn"}. Mutations in BCR-ABL are associated with resistance. RT-PCR is used to detect minimal residual disease.Other variants or cryptic translocationsBCR-ABL fusion (usually p210, but also p190 and p230 fusion proteins)5-10%CML, accelerated phase or blast phaseAdditional changes: extra Ph, +8, or i(17)(q10)80%May be myeloid (70%) or lymphoid (30%).Juvenile myelomonocytic leukemiaPTPN11 mutation35%11% of patients have neurofibromatosis type 1.NF1 mutation20%NRAS and KRAS2 mutations20%Chronic eosinophilic leukemiat(5;12)(q33;p13)ETV6 (also called TEL) - PDGFRB fusionRareWith eosinophilia.Excellent response to imatinib.[a](#tblfn98){ref-type="table-fn"}t(5q33)Several PDGFRB fusions?rareExcellent response to imatinib.[a](#tblfn98){ref-type="table-fn"}Cryptic del(4)(q12) -- interstitial 800 kb deletionFIP1L1-PDGFRA fusion\~ 50%The fusion protein is an activated tyrosine kinase. Excellent response with the tyrosine kinase inhibitor imatinib.^a^FIP1L1-PDGFRA mutation (T6741)Detected by FISH.Homologous to the resistance-inducing T3151 mutation in BCR-ABL.t(4q12)Several PDGFRA fusions?rareStem cell leukemia- lymphoma syndromet(8;13)(p11;q11-12)FGFR1-ZNF198 fusionUnknownFeatures of both lymphoma and eosinophilic MPD.t(8p11)Several FGFR1 fusionsRareClassic MPDPolycythemiaJAK2V617F95%JAK2 exon 12 mutation5%Essential thrombocythemiaJAK2V617F50%MPLW515L/K1%Primary myelofibrosisJAK2V617F50%MPLW515L/K5%Unclassified MPDt(9;21)(p24;p13)ETV6-JAK2t(9;22)(p24;q11.2)BCR-JAK2 fusiont(8;9)(p22;p24)PCM1-JAK2 fusionSystemic mastocytosisc-KIT point mutations (Asp816Val)100%CD117 (c-kit) is detected by IHC in normal and abnormal mast cells. The most common mutations do not result in proteins sensitive to imatinib.Cryptic del(4)(q12) -- interstitial 800 kb deletionFIP1L1-PDGFRA fusion\~60% of patients with eosinophiliaFound in mastocytosis with associated eosinophilia. These patients do not have the typical c-KIT mutation. Excellent response to treatment with imatinib [a](#tblfn98){ref-type="table-fn"}.Acute Myeloid LeukemiaAMLNormal karyotype40-50%FLT3 (13q12) internal tandem duplications (ITD, 20%) or point mutations (7%)20 -30%More common in monocytic AML (M5), less common in myeloblastic leukemia with maturation (M2) or erythroleukemia (M6). Less common in AML with cytogenetic changes (10%). Poor prognostic factor.Results in an activated tyrosine kinase. Current trials are evaluating response to a kinase inhibitor -- PKC412.Partial tandem duplication MLL (11q23)10%Exon 2 through 6 also carry FLT3-IDT mutation.High expression BAALC (8q22.3)Adult younger than 60 yrs with de novo AML, unfavorable prognostic impact Independent adverse prognostic factor for resistance to initial induction chemotherapy.CEBPA (19q13.1) mutation4-15%Favorable prognostic significance.NPM1(5q35) mutation45-62%Cytoplasmic localization of nucleophosmin 956dupTCTG in exon 12 (type A).Female, higher WBC, low/absence CD34+, 40% also carry FLT3-IDT or TKD mutation.Patients with NPM1 mutations lacking FLT3-IDT had significantly better CR rates.Overexpression ERG (21q22)Adverse prognosis.AML (M1, M2, or M4)t(6;9)(p23;q34)DEK-CAN fusion1% of all AMLPoor prognosis.FLT3 ITDs90% of this AML typeAML with t(8;21) (M2)t(8;21)(q22;q22)AML1(RUNX1)-ETO fusion5-12% of AML30% of cases of AML with karyotypic abnormalities and maturation in neutrophilic lineage.Usually younger patients, good prognosisc-KIT mutations\~50% of this AML typeResponse to imatinib[a](#tblfn98){ref-type="table-fn"} untested.Other RUNX1 fusionToxic exposure.Acute promyelocytic leukemia (M3, M3v.)t(15;17)(q22;q11-12)PML-RARA fusion5-8% of AML (95-100% of APML)Abnormal promyelocytes predominate. Usually occurs in adults in mid life. Treatment with all trans-retinoic acid acts to differentiate the cells. Favorable prognosis.t(11;17)(q23;p21)PLZF-RARA fusiont(5;17)(q34;q12)NPM1-RARA fusiont(11;17)(p13;q21)NUMA-RARA fusionFLT3 ITDs32% of APMLAML with inv(16) or t(16;16)inv (16)(p13)(q22)t(16;16)(p13;q22)del(16q)Other rare variants or cryptic translocationsCBFB-MYH11 fusion10-12% of AML (100% of M4EO)Monocytic and granulocytic differentiation and abnormal eosinophils in the marrow. Usually younger patients. Favorable prognosis.c-KIT mutations\~50% of this AML typeResponse to imatinib[a](#tblfn98){ref-type="table-fn"} untested.AML with 11q23 abnormalities11q23 abnormalitiesMLL fusion with numerous different partners (86)5-6% of AMLUsually associated with monocytic features. Occurs in infants and in patients after therapy with topoisomerase II inhibitors. Intermediate prognosis.AML and MDS, therapy related5q-/7q-/12p-/20q-Occurs after alkylating agents and/or radiation, usually 5 to 6 years after treatment. Poor prognosis.t(9;11), t(11;19), t(6;11)MLL balanced translocationsOccurs after DNA-topoisomerase II inhibitors, usually 3 years after treatment. Long-term prognosis unknown.t(21q22)Other RUNX1 fusion**B Cell**B lymphoblastic leukemia/ lymphoma (ALL)t(9;22)(q34;q11.2)BCR-ABL fusion(usually p190 \[esp. in children\], but also p210 protein)5% of childhood ALL, 20-25% of adult ALLPhiladelphia chromosome.Poor prognosis.t with 11q23MLL rearrangementsPoor prognosis. Usually infants.t(12;21)(p13;q22)ETV6(TEL)-AML1 fusion\> 50% of childhood ALL or hyperdiploidGood prognosis. This translocation is not detected by standard cytogenetics.Detected by FISH.t(1;19)(q23;p13.3)PBX1-E2A fusion5-6%Pre-B-ALL; most common translocation in childhood. Unfavorable but modified by therapy.HypodiploidPoor prognosis.Hyperdiploid \>50Good prognosis (= DNA Index 1.16 to 1.6).t(5;14)(q31;q32)IL3-IGH fusionPoor prognosis.t(8;14)(q24;q32)MYC-IGH fusionGood prognosis.t(2;8)(p12;q24)IGK-MYC fusionGood prognosis.t(8;22)(q24;q11)MYC-IGL fusionGood prognosis.t(17;19)(q21;p13)HLF-E2A fusionPoor prognosis.t(4;11)(q21;q23)MLL-AF4 fusionPoor prognosis.ALL, therapy relatedSimilar to therapy-related AML.Small lymphocytic lymphoma/CLLtrisomy 1216%Usually do not have I~g~V~H~ mutations.Aggressive clinical course.del(11q22-23)ATM deletion18%Poor prognosis.Detected by FISH.del(13q14)D13S319 deletion55%Usually do have I~g~V~H~ mutations.Long term survival.Detected by FISH.del(17p)P53 deletion7%Worse prognosis.Detected by FISH.I~g~V~H~ not mutated40-50%Worse prognosis (\< 8 year median survival).I~g~V~H~ (mutated, \> 2% difference in nucleotide sequence) ZAP7050-60%Better prognosis (median survival \> 24 years).Lymphoplasmacytic lymphoma (Waldenström macroglobulinemia)6q deletion50% if in bone marrowDetected by FISH. Not specific for LPL.Mantle cell lymphomat(11;14)(q13;q32)CCND1-IGH fusionATM point mutations\>95%Overexpression of cyclin D1 detected by IHC.Marginal zone lymphoma (MALT)+360%t(1;14)(p21;q32)BCL10-IGH fusiont(11;18)(q21;q21)API2-MALT1 fusion25-50%t(11;14)(q21;q32)MALT1-IGH fusionSplenicdel(7q21)Follicular lymphomat(14;18)(q32;q21)IGH-BCL-2 fusion70-95%t(2;18)(p12;q21)IGK-BCL-2 fusionRareBurkitt lymphoma and Burkitt-like lymphomat(8;14)(q24;q32)MYC-IGH fusion85%t(2;8)(p12;q24)MYC-IGK fusionRaret(8;22)(q24;q11)MYC-IGL fusionRaret(8q24)Other MYC fusionMediastinal (thymic) large B-cell lymphoma9p+REL amplificationDiffuse large B-cell lymphomat(3q27)BCL6 translocations with many partners30%BCL6 is detected by IHC in most cases, BCL2 in some cases.t(14;18)(q32;q21)trisomy 18BCL2-IGH fusion20-30%Hairy cell leukemiaNo consistent changes.Hodgkin lymphomaNo consistent changes.Primary effusion lymphomaNo consistent changes.Plasmacytoma/myelomat(11;14)(q13;q32)CCND1-IGH fusionBest prognosis.t(6;14)(p21;q32)CCND3-IGH fusiont(4;14)(p16;q32)FGF23-IGH fusionAdverse prognosis.t(14;16)(q32;q23)IGH-MAF fusionAdverse prognosis.Monosomy 13/13q-15-40%**T Cell**Precursor lymphoblastic leukemia/lymphoblastic lymphomaTranslocations involving TCR alpha, beta, delta, and gamma and partner genes MYC, TAL1, RBTN1, RBTN2, HOX11, and LCK30%del(1)TAL1 (small deletion)25%Adolescents.t(1;14)TAL1-TCRdelta fusion\>30%Adolescents.t(5;14)HOX11L2-TCRdelta fusionYoung children.del(9p)CDKN2A deletionT-cell prolymphocytic leukemiainv(14)(q11;q32)TCRα/β-TCL1 & TCL1b fusion80%t(14;14)(q11;q32)TCRα/β-TCL1 & TCL1b fusion10%t(7;14)(q35;q32.1)TCRβ-TCL 1A fusion70-80%Chrom 8 abnormalitiesAdult T-cell lymphoma/leukemiaNo consistent changes.Mycosis fungoides and Sezary syndromeNo consistent changes.Peripheral T-cell lymphoma, NOSNo consistent changes.Hepatosplenic T-cell lymphomai(7q)(q10)100%Panniculitis-like T-cell lymphomaNo consistent changes.Angioimmunoblastic lymphomaTrisomy 3, trisomy 5, + XEnteropathy-type T-cell lymphomaNo consistent changes.Anaplastic large cell lymphoma (CD30+)t(2;5)(p23;q35)NPM1-ALK fusion protein (p80)70-80%ALK detected by IHC in nucleus, nucleolus, and cytoplasm.t(2p23)Several ALK fusionsALK detected by IHC in cytoplasm.Extranodal NK/T-cell lymphoma, nasal typeNo consistent changes.Blastic NK-cell lymphomaNo consistent changes.[^25][^26][^27]

Tumors and Diseases Associated with Germline Mutations ([TABLE 7--49](#t0250){ref-type="table"}, [TABLE 7--50](#t0255){ref-type="table"} {#s0445}
----------------------------------------------------------------------------------------------------------------------------------------

The following features are suggestive of hereditary susceptibility to cancer:•Two or more close relatives on the same side of the family with cancer•Evidence of autosomal dominant transmission•Early development of cancer in the patient and relatives (in general, \<50 years of age)•Multiple primary cancers•Multiple types of cancers•Unusual pathologic features of tumors ([Table 7-49](#t0250){ref-type="table"} )TABLE 7--49PATHOLOGIC FEATURES OF TUMORS AND DISEASES SUGGESTIVE OF A GERMLINE MUTATIONTYPE OF TUMOR% OF CASES RELATED TO KNOWN GERMLINE MUTATIONSSYNDROMES/GENES INVOLVEDCLUES FOR THE PATHOLOGISTAdrenocortical carcinoma in children50% to 100%Li-Fraumeni, Beckwith-Wiedemann, MEN1Unusual occurrence in a child.Angiomyolipoma of kidney20%Tuberous sclerosisPatients may be screened for other features of tuberous sclerosis.Basal cell carcinomaRare if solitaryNevoid basal cell carcinoma syndromeRisk of a mutation is increased if multiple or if tumor occurs at \<30 years of age.Breast cancer, poorly differentiated, ER negative[∗](#tblfn51){ref-type="table-fn"}\>25% if \<35 years old, \<10% if \>35 years oldBRCA1BRCA1 cancers are more likely to have "medullary" features, and be ER- PR- HER2/neu -. BRCA1 mutation more likely if patient has a family history or has bilateral cancer.Breast cancer, male4% to 14%BRCA2Cancers are of no specific type.Colorectal carcinoma, poorly differentiated, mucinous, or with prominent lymphocytic infiltrate\~10--15% overall, \~80% if patient is \<40HNPCCHNPCC carcinomas are more likely right -sided (two-thirds), poorly differentiated ("medullary"), mucinous, signet ring, lymphocytic infiltrate.IHC for MSH2 and MLH1 can be used to detect many, but not all, cases, but MLH1 may also be absent in sporadic cases.GI neuroendocrine tumors:SomatostatinomaPPomaNon-functioningGastrinomaGlucagonomaVIPomaInsulinomaCarcinoid45%18-44%18-44%20-25%1-20%6%4-5%RareMEN1 mutationsMEN1 mutations are also found in 15% to 70% of sporadic neuroendocrine tumors.Hirschsprung disease20-40%MEN2A (RET mutations in codons 609, 618, 620)Juvenile (hamartomatous) polypsRare if solitaryJuvenile polyposis syndromeSuspect JPS if there are \>5 polyps, if present throughout the GI tract, or if there is a family history of juvenile polyps.Medullary carcinoma of the thyroid25%MEN2A, MEN2B, familial medullary carcinoma (RET mutations)May be multiple and associated with C cell hyperplasia.Cancers in occur in children in MEN2B and in young adults in MEN2A.MedulloblastomaRare (?)Nevoid basal cell carcinoma syndromeIf \<3 years of age or of desmoplastic type, risk of mutation is increased.Myxoma, cardiac\<5%Carney complexIncreased likelihood if multiple, right-sided, and/or recurrent and in young patients (\<30).Neurofibromas\~10% if solitary but \>90% if plexiformNeurofibromatosis type 1Increased risk if there are ≥2 neurofibromas or one plexiform neurofibroma.Ovarian carcinomaRareBRCA1, BRCA2Increased risk if there is a history of breast cancer.BRCA1-associated carcinomas are more likely to be serous in type.Pheochromocytoma30% of all cases, 59% if patient is \<18, 84% if bilateralMEN2A, MEN2B, VHL, Isolated familial pheochromocytomaMultiple tumors, hyperplasia of the medulla.Primary pigmented nodular adrenocortical disease (PPNAD)\>90%Carney complex (25% have PPNAD)May present with Cushing syndrome.Most are associated with germline mutations, but patients may not have other manifestations of the Carney complex.Retinoblastoma40% of all cases, 100% if bilateral or with a positive family historyRB mutations (13q14.1-q14.2)Rhabdomyoma of heart in infants50%Tuberous sclerosisSarcoma, children7--33%Li-Fraumeni, basal cell nevus syndrome, neurofibromatosis type 1, pleuropulmonary blastoma syndromeSebaceous carcinoma\~10% if ocular, 40% if above the chin, 80% if elsewhereHNPCCIncreased likelihood if the tumor has cystic degeneration or features of keratoacanthoma.Usually due to germline MSH2 mutations.Schwannoma, psammomatous melanotic\>50%Carney complexHigher likelihood if patient is young (\<30 years) and/or multiple tumors present.Schwannoma, vestibular5%Neurofibromatosis type 2Risk is increased if the patient is \<30 or if there is bilateral involvement.Sporadic cases almost all have somatic NF2 mutations.Sertoli cell tumor, large-cell calcifying25--35%Carney complex, Peutz-JeghersMost are bilateral and multifocal in young patients. Rarely malignant. Present in 30% of males with Carney complex.Trichilemmoma, facial, multiple\~80%PTENSporadic tumors also have loss of PTEN which can be shown by IHC.Wilms tumor10-15%Germline mutations in WT1 (11p13)Nephrogenic rests are present and may be extensive.5%to 10% of cases associated with germline mutations are multicentric or bilateral.Associated with WAGR syndrome (Wilms tumor, aniridia, GU anomalies, mental retardation) and Denys-Drash syndrome.[^28]•A constellation of tumors suggestive of a specific syndrome ([Table 7-50](#t0255){ref-type="table"} )TABLE 7--50HEREDITARY SYNDROMES ASSOCIATED WITH MULTIPLE TUMORSSYNDROMEGERMLINE MUTATIONSTUMORS (% OF PATIENTS DEVELOPING TUMOR)COMMENTSBeckwith-Wiedemann syndrome11p15 abnormalities (loss of methylation, uniparental disomy, mutations in CDKN1C)Wilms tumor, neuroblastoma, hepatoblastoma, adrenocortical carcinoma, rhabdomyosarcomaMacrosomia, macroglossia, visceromegaly, ear creases and pits, omphalocele, hypoglycemia.Bloom syndromeBLM (RecQL3), 15q26.1Acute leukemia, lymphoma, gastrointestinal adenocarcinoma (20% of patients develop a malignancy)Characteristic appearance, café-au-lait spots, telangiectasias.Carcinomas do not have a specific appearance.BRCA1 and 2BRCA1 (17q21), BRCA2 (13q12.3)Breast (85%), ovary (BRCA1 63%, BRCA2 27%), prostate carcinoma, othersBRCA1 breast cancers are more often poorly differentiated, have medullary features, are ER- PR- HER2/neu -, and have p53 mutations. Ovarian carcinomas are generally serous (90%), high grade, and bilateral. BRCA2 cancers do not have specific pathologic features.Carney complexType 1 (CNC1) (30% of patients): PRKAR1A (17q23-24)Type 2 (CNC2) (40% of patients): locus at 2p1630% of patients do not have identified mutationsMyxomas (cardiac, cutaneous, breast), primary pigmented nodular adrenocortical disease (25%), large-cell calcifying Sertoli cell tumors (\> 90% males), multiple thyroid nodules or carcinoma (75%), growth hormone producing pituitary adenoma (10%), psammomatous melanotic schwannoma (10%), breast duct adenomas, osteochondromyxoma of bonePigmented skin lesions (lentigos, blue nevi (especially epithelioid blue nevus), café-au-lait spots)The skin lesions characteristically involve the vermillion border of the lip and the intercanthal portion of the eye.Myxomas of the heart can involve all chambers (sporadic tumors usually involve the left atrium) and frequently recur.Carney triadUnknownGastric gastrointestinal stromal tumor, pulmonary chondroma, extra-adrenal paragangliomaAlso esophageal leiomyomas and adrenocortical tumorsMost patients are young and female. Only 22% have all three tumors. Most family members are not affected.Familial adenomatous polyposis (FAP; including Gardner syndrome and Turcot syndrome)APC (5q21-22)Colorectal carcinoma, upper GI carcinoma, desmoid, Gardner fibroma, osteoma, thyroid, brain (1/3 to 2/3 are medulloblastomas -- Turcot syndrome)Familial gastrointestinal stromal tumor syndromeKIT (4q12)PDGFRAGIST, often multiple (\> 90% lifetime risk), hyperplasia of the interstitial cells of CajalGIST may occur at younger ages.Familial medullary thyroid carcinomaRET mutations in codons 10, 11, 13, 14 (10q11.2)Medullary thyroid carcinomaCancers usually occur in adults.Hereditary diffuse gastric cancer syndromeCDH1(e-cadherin) (16q22.1)Signet ring cell carcinoma of the stomach (67% men, 83% women), lobular carcinoma of the breast (39% women)50% of sporadic signet ring cell carcinomas have CDH1 somatic mutations and all show loss of e-cadherin by IHC.Hereditary non-polyposis syndrome[∗](#tblfn72){ref-type="table-fn"} ("Lynch syndrome" but first patients were described by Warthin)Mismatch repair genes: MSH2 (2p22-p21) (40%), MLH1 (3p21.3) (40%), MSH6 (2p16) (5 to 7%), PMS2 (7p22) (rare)Colon carcinoma (80%), endometrial carcinoma (20 to 60%), ovarian carcinoma (9 to 12%), stomach carcinoma (11 to 19%), hepatobiliary tumors (2 to 7%), transitional cell carcinoma (4 to 5% - esp ureter and renal pelvis), small bowel tumors (1 to 4%), lymphoma (rare)Sebaceous skin tumors, adenomas, epitheliomas, carcinoma, keratoacanthomas (Muir-Torre -- usually MSH2)Colon carcinomas are more likely (overall, 66%) to be on the right side, poorly differentiated ("medullary"), mucinous, signet ring, or undifferentiated, with a prominent lymphocytic infiltrate.IHC can be used to detect the absence of MSH2 (usually due to germline mutations) and MLH1 (can be due to germline mutations, epigenetic changes (methylation), or less commonly, somatic mutations) in many patients. IHC is 92% sensitive for MSI and 100% specific.MSI testing is also used.Juvenile polyposis syndromeMADH4 (or SMAD4) (18q21.10 (15%) or BMPR1A (10q22.3) (25%)Hamartomatous (juvenile) polyps, GI carcinomasLi-Fraumenip53 (17p13.1), rarely CHEK2 (22q12.1)Sarcomas, breast cancer, leukemia, osteosarcomas, brain tumors, adrenocortical carcinoma, othersMEN1MEN 1 (11q13)Pituitary adenoma, pancreatic islet cell tumors, parathyroid adenomas, adrenocortical tumors, carcinoids, lipomasMEN1 mutations also occur in 15 to 70% of sporadic neuroendocrine tumors.MEN2ARETexon 10 and 11 missense mutations (10q11.2)Medullary thyroid carcinoma (95%), hyperplasia of the parathyroids (15-30%), pheochromocytoma (50%), ganglioneuromatosis of GI tract.Subsets of patients have Hirschsprung disease or cutaneous lichen amyloidosisSpecific mutations correlate with age at development of medullary thyroid carcinoma.MEN2BRETmissense mutation in exon 16 (10q11.2)Medullary thyroid carcinoma (100%), pheochromocytoma (50%)Mucosal neuromas of lips and tongue,Marfanoid habitus, distinctive facies.Nevoid basal cell carcinoma syndrome (Gorlin syndrome)PTCH (9q22.3)Basal cell carcinomas (90%), odontogenic keratocysts (90%), cardiac or ovarian fibromas (20%), medulloblastoma in childhood (5%)Macrocephaly, skeletal anomalies, palmar or plantar pits, calcification of falx (90%).Neurofibromatosis type 1NF1 (17q11.2)Neurofibromas (esp plexiform) (100%), optic gliomas, adrenal ganglioneuromas, pheochromocytoma (0.1 -- 6%), MPNST (10%), leukemia, ganglioneuromatosis of the GI tractCafé-au-lait macules (95%), iris hamartomas (Lisch nodules), axillary freckling.Neurofibromatosis type 2NF2 (22q12.2)Bilateral vestibular schwannomas (100%, 40% have lobular pattern), schwannomas of other nerves, meningiomas (50%, often fibroblastic)Peutz-Jeghers (Hamartomatous polyp syndrome)LKBI/STK11 (19p13.3)Colon, breast, stomach, pancreas, small bowel, thyroid, lung, uterus, sex cord stromal tumors, calcifying Sertoli cell tumorsHamartomatous polyps of GI tractPerioral pigmentation.Pheochomocytoma or paraganglioma, familialSDHB (1p36.1-p35)\
\
SDHD (11q23)\
\
SDHC (1q21) (paragangliomaPheochromocytoma, paragangliomaPatients are more commonly young (\< 40), with multifocal adrenal tumors, or extra-adrenal disease.SDHD is imprinted and only confers susceptibility after paternal transmission.PTEN hamartoma syndrome (including 80% of Cowden's syndrome, 50-60% of Bannayan-RIley-Ruvalcaba syndrome)PTEN (10q23.31)Breast cancer (25 to 50%), thyroid carcinoma (10% - especially follicular), endometrial carcinoma (5 to 10%), hamartomatous polyps of GI tractMultiple facial trichilemmomas, acral keratosis, oral papillomatous lesions, mucosal lesionsMacrocephaly (megalencephaly, 97^th^ percentile), Lhermitte-Duclos disease.Tuberous sclerosisTSC1 (9q34),\
\
TSC2 (16p13,3)Subependymal glial nodules (90%), cortical or subcortical tubers (70%), angiomyolipoma of kidney (70%), lymphangiomyomatosis of lung (1 to 6%), rhabdomyoma of heart (47 to 67%)Skin lesions (100%, including myomelanotic macules, multiple facial angiofibromas, shagreen patch, fibrous facial plaque, ungual fibroma)Seizures (80%), developmental delay or retardation (50%).Von Hippel-Lindau (VHL)VHL (3p26-p25)Hemangioblastomas (retinal, cerebellar, spinal cord) (80%), renal cell carcinoma (40%), renal cysts, pancreatic cysts, pheochromocytoma, endolymphatic sac tumors (10%), epididymal cystadenomas[^29][^30]

Pathologists can aid in the detection of hereditary carcinomas by being aware of the types and pathologic characteristics of carcinomas associated with these syndromes. Patients with germline mutations are important to identify in order to:•Screen patients for other common tumors or other components of the disease•Consider prophylactic surgery or preventive interventions•Offer screening to family members at risk and genetic counseling

Although the sporadic forms of cancers, in general, far outnumber cases associated with germline mutations, in some cases the appearance or site of a carcinoma is highly suggestive of a known syndrome and further investigation may be warranted.

ANALYTICAL CYTOLOGY (FLOW CYTOMETRY) {#s0450}
====================================

Flow cytometers analyze populations of thousands of dissaggregated cells as they pass by stationary detectors. Cell size and cytoplasmic granularity can be measured as well as DNA content and the presence or absence of immunohistochemical markers added to the cell suspension. Newer techniques can analyze three or more features simultaneously to divide cells into unique populations. DNA content can be used to determine the number of cells in S-phase (a measure of proliferation - S-phase fraction). Because cells are not visualized by this technique, one must be sure to submit only lesional tissue.

 {#s0455}

###  {#s0460}

####  {#s0465}

##### Indications for Ploidy and S-Phase Analysis {#s0470}

•Hydatidiform moles -- complete (diploid), partial (triploid)•Some carcinomas -- DNA ploidy and S-phase have been reported to be of prognostic significance for some carcinomas (e.g., colon, breast, and prostate) but is not routinely performed at all institutions or used by all oncologists.

##### Indications for Cell Surface Marker Analysis {#s0475}

•Lymphomas and leukemias

##### Method for Submitting Tissue {#s0480}

Single cell suspensions are necessary for analysis. For fresh tissues, cells must be viable. Fresh tissue (approximately 0.3 to 0.5 cm3) is placed in a specimen container and kept moist with HBSS. Tissues can be held overnight in a refrigerator.

Formalin-fixed paraffin-embedded sections may also be used for DNA ploidy analysis by the Hedley method, although the results are not as satisfactory due to nuclear fragmentation.

##### Results {#s0485}

The results are usually incorporated into the final surgical pathology report.

CYTOLOGIC PREPARATIONS FROM SURGICAL SPECIMENS {#s0490}
==============================================

Cytologic preparations of surgical specimens often add additional information.•**Intraoperative diagnosis:** Touch preps or smears are especially valuable for:•Infectious cases (to avoid contamination of the cryostat and aerosolization of infectious agents)•Neuropathology cases -- for diagnosis and for the performance of cytogenetic (FISH) analysis.•Tumors (for excellent cytologic detail, especially lymphomas and papillary carcinomas of the thyroid)•**Special stains:** Stains for microorganisms can be performed the same day on cytologic smears of specimens from critically ill patients. Do not submit air-dried smears of infectious cases for staining as the unfixed material may constitute a hazard to laboratory personnel. Fat is dissolved during routine processing, but can be demonstrated with fat stains on air dried slides.•**Genetic studies (FISH):** In touch preparations nuclei are intact, unlike tissue sections in which only partial nuclei are present. This feature makes these preparations superior for techniques such as FISH and image analysis.

Comparing cytology preparations and the corresponding surgical specimen is always a useful exercise in learning the comparative morphology of these techniques.

SPECIMEN RADIOGRAPHY {#s0495}
====================

Specimen radiographs are often preferable over patient radiographs:•A permanent record of the radiograph can be kept with the case.•A radiograph of the specimen may reveal more details of the underlying process (e.g., fewer structures may be present to complicate the appearance).•There may have been a significant time interval between the patient radiograph and the surgical excision.•The radiograph will often indicate important sites to examine histologically (tumor invasion into a rib or microcalcifications in a breast biopsy).•The specimen radiograph can confirm that the clinical lesion was removed.

 {#s0500}

###  {#s0505}

####  {#s0510}

##### Indications {#s0515}

•Tumors of bone and cartilage•Tumors invading into bone•Avascular necrosis•All bioprosthetic heart valves (to document the degree of calcification)•Breast biopsies or mastectomies performed for mammographic lesions that cannot be located grossly. Paraffin blocks of breast tissue can be radiographed if microcalcifications were seen by specimen radiography but not in histologic sections and were not identified prior to processing. Clips placed after core needle biopsy are also easily identified.

Calcifications can dissolve in formalin over several days. If the demonstration of calcifications is important (e.g., mammographically detected calcifications) it is preferable to process the tissue within 1 to 2 days. If processing is to be delayed, the tissue can be stored in ethanol.

##### Method {#s0520}

Radiographic equipment is available in radiology departments and in some pathology departments. The specimen may be placed on a piece of wax paper (to keep the surfaces clean) lying on the film. Specimens can be radiographed after decalcification (not all calcium is removed) but best results are obtained on fresh undecalcified specimens. Lungs should not be inflated prior to radiography.

If the specimen is small, two exposures at different settings or at different angles may be useful. Lead sheets can be used to allow two exposures on one piece of film.

If the film is too dark (overexposed), the exposure is too high and a lower setting should be tried. If the film is too light (i.e., unexposed) the exposure is too low and a higher setting is indicated.

Special injection techniques with radiocontrast media are available for unusual specimens (e.g., a recipient lung with pulmonary hypertension, vascular ectasia of the bowel).

###### Octreotide and Sentinel Nodes {#s0525}

Labeled compounds are sometimes used to localize certain types of tumors (generally neuroendocrine) or sentinel lymph nodes. The patient is injected with the isotope prior to surgery and the surgeon uses a hand held probe to identify the labeled tissue. The amount of radioactivity in the tissue is small and generally does not pose a hazard to pathologists handling the tissue and does not need special disposal methods. However, each pathology department should consult with their radiation safety department to ensure appropriate handling of such tissues. In some cases, if a gross lesion is not present corresponding to the area of octreotide uptake, specimens can be imaged using a gamma camera.

##### Results {#s0530}

The radiographs are documented in the gross description and any information gained from the radiograph is incorporated into the surgical pathology report.

TISSUE FOR RESEARCH --- TUMOR BANK {#s0535}
==================================

The pathology department is a unique resource for researchers who need human tissues. The pathologist plays a key role as patient advocate and diagnostician in order to provide appropriate human tissues for biologic research. Most hospitals have a policy that allows the release of tissue for research **if it would otherwise be discarded**. Therefore, tissue is never provided for research until all necessary tissue has been taken for diagnosis. Tissue from primary diagnostic breast biopsies and open lung biopsies without gross lesions must not be given away. It is in the best interest of the patient that a pathologist evaluate the specimen rather than have tissue given away by nonpathologists who are not aware of what is needed for diagnosis.

 {#s0540}

###  {#s0545}

####  {#s0550}

##### Indications {#s0555}

By request of researchers who have obtained permission from the hospital Institutional Review Board (IRB). Patients must provide specific consent. In some cases, all patient identification will need to be removed from the specimen.

MICROBIOLOGICAL CULTURE AND SMEARS {#s0560}
==================================

The investigation of infectious disease by culture is complementary to its investigation by histologic sections ([TABLE 7--51](#t0260){ref-type="table"}, [TABLE 7-52](#t0265){ref-type="table"}, [TABLE 7-53](#t0270){ref-type="table"} ).TABLE 7--51IDENTIFICATION OF INFECTIOUS DISEASESCULTUREHISTOLOGIC SECTIONSCan be performed on aspirates, swabs, fluids, or tissues.Requires surgical excision of tissues.Cultures amplify the number of organisms present, allowing them to be recognized.Organisms may be rare, or not seen in tissue sections.The specific organism can be identified and tested for drug susceptibility.Categories of organisms can be recognized but specific identification may not be possible.Some organisms cannot be cultured.Many organisms can be identified that will not grow in culture or that require long culture times (e.g., TB).It may be difficult to exclude contamination for a positive culture.Morphologic evidence of an inflammatory response provides evidence for a clinical infection. The location of the infection may be of diagnostic importance (e.g., cellulitis vs. necrotizing fasciitis or superficial colonization of devitalized tissue vs. deep infections involving viable tissues).The use of special studies, such as PCR and other molecular assays, may be warranted if the tissue pattern of injury is indicative of a potential organism despite lack of culture evidence and/or lack of organisms seen on tissue sections.TABLE 7-52FUNGI: HISTOLOGIC APPEARANCE IN SURGICAL SPECIMENSHISTOLOGIC APPEARANCE OF FUNGUSSTAINSUSUAL SITES OF INFECTION (PATIENT GROUPS)TISSUE RESPONSE*CANDIDA* SPECIES (*C. ALBICANS*, 60%; *C. TROPICALIS, C. PARAPSILOSIS, C. KRUSEI*)![](fx1.gif)3- to 4-μm round yeast formsTrue hyphae with acute angle branching (5-10 μm)Budding yeast (single bud)ExtracellularMSS (+)PAS (+)Gram (+) (unlike most other fungi)Skin/oral: superficialLarynx (thrush) (immunocompromised; newborn)Vagina (pregnancy; DM; antibiotic use)Esophagus (HIV; malignancy)Invasive/systemic: kidney, liver, lung, heart valves (immunocompromised)Oral, vaginal, disseminated (immunocompromised; antibiotic therapy; elderly; denture wearing)Fungi on surface of epithelium, Cl, +/− eosinophilsUlcer, pseudomembrane, dirty necrosis, PMNs, MP, GC, occasional GRANAI*CANDIDA GLABRATA* ("TORULOPSIS")Similar to other Candida but no true hyphaeOnly small yeast forms are usually presentUrogenital tract (immunocompromised)Bloodstream (immunocompromised)Similar to *C. albicansHISTOPLASMA CAPSULATUM*![](fx2.gif)2- to 5-μm yeast formsUnequal buddingOften intracellular in histiocytes or PMNs (looks like leishmania but with no kinetoplast---one dot only)Very rare short pseudohyphaeGiemsa may give false impression of a capsuleMSS (+)PAS (+)Mucicarmine (−)FM (−)Giemsa (+)Lung (Mississippi and Ohio River valleys): usually an incidentally found fibrocaseous nodule in lung, lymph node, liver, or spleen (patients are not immunocompromised)Disseminated (e.g., gastrointestinal, lung, lymph node) (immunocompromised)NEC GRAN or old resolved GRAN with calcifications, degenerate fungal formsPredominantly intracellular organisms, MP, GRAN, not AIZYGOMYCETES (INCLUDING THE GENERA *MUCOR, RHIZOPUS, RHIZOMUCOR, ABSIDIA*, AND *CUNNINGHAMELLA*)![](fx3.gif)Large hyphae, irregular in width, infrequently septate hyphae, 6-50 μmRight angle branchingBudlike or bulbous projectionsNo yeast formsUsually seen without stainsMSS (weak)PAS (weak)H&E (+)Skin (primary or hematogenous) (DM)Rhinocerebral (DM, leukemia, dialysis)Lung (immunocompromised)GI or bladderInvasion of BVs with infarction, hemorrhage, perineural invasion, little host response or AI (all patients are immunocompromised)*ASPERGILLUS* SPP. (*A. FUMIGATUS*, 90%; *A. FLAVUS, A. NIGER, A. TERREUS, A. NIDULANS*)![](fx4.gif)Septate hyphae, 45-degree branching, 3-8 μm, evenly contouredFruiting bodies (pigmented) seen only in necrotic tissue with air exposure (rarely in invasive lesions)Dilated and distorted hyphae are present in chronic lesionsMSS (+)PAS (+)Gram (weak)IHC and ISH availableNose/sinus:Invasive (immunocompromised)NoninvasiveAllergic mucinBronchopulmonary:Superficial (allergic bronchopulmonary aspergillosis)Bronchocentric granulomatosisAspergilloma: fungal ball in preexisting necrotic cavity (not immunocompromised)Invasive: target lesions (necrotic areas with peripheral hemorrhage) (immunocompromised)Skin: usually secondary to hematogenous spreadUlceration, AI, fungi in viable tissueMat of fungal hyphae, little or no inflammationEosinophils and hyphae in mucin, Charcot-Leyden crystalsBronchiolitis or alveolitis, eosinophils, mucoid impaction with fragmented fungal hyphaeCircumferential GRAN of small airways, mucin impaction with fragmented fungal hyphae, eosinophilsLittle tissue response, Cl. Conidiophores (fruiting bodies) may be present if in contact with air. *Aspergillus niger* is associated with calcium oxalate production causing thrombosis and ischemic necrosisInvasion of arteries with thrombosis and infarction, may be +/− host response; may resolve with GRANMicroabscesses and NEC GRAN*CRYPTOCOCCUS NEOFORMANS*![](fx5.gif)2-15 μm, spherical or oval narrow-based unequal buds, prominent capsule (mucicarmine positive); variable size and shape is characteristicSingle or multiple buds, rare pseudohyphae. Capsule-deficient forms (mucicarmine negative) may be present. However, FM is usually positive.PAS (+)Gram (weak)MSS (+)FM (+)AB (+ capsule)Mucicarmine (+ capsule)ICH availableLungs: symptomatic pneumonia that may affect both lungs. Can also form residual fibrocaseous granulomas (rarely calcify).Meningoencephalitis (soap-bubble lesions): CSF (India ink positive, but antigen test is better) (immunocompromised); the antigen test cross-reacts with *Trichosporon* species.Disseminated (any organ) (immunocompromised)Solitary, well-circumscribed focus of yeast forms surrounded by GRAN and GCFungi in Virchow-Robin space, little host responseLittle host response*BLASTOMYCES DERMATITIDIS*![](fx6.gif)8-20 μm spheres with broad-based buddingDouble contour thick capsuleOften in giant cellsMultiple nucleiNo hyphaeMSS (+)PAS (+)Mucicarmine (+/−)FM (−)Lung (Mississippi and Ohio River valleys) (residual nodules are much rarer than for *Histoplasma* or *Coccidioides* species)Skin: fleshy fungating ulcers, may be verrucousDisseminated (bones, GI, CNS, prostate, liver, spleen, kidney)Usually solitary focus of GRAN, rarely calcifiedPseudoepitheliomatous hyperplasia hyperkeratosis, microabscesses, AI (intraepithelial), GRANDEMATIACEOUS FUNGI (BROWN PIGMENTED; \>100 SPECIES)![](fx7.gif)1.5- to 5-μm brown to black yeast "copper penny," may be present in giant cells, often in pairsSclerotic bodies (septated cells) and septate hyphaeH&E (+)MSS (+)PAS (+)Chromoblastomycosis usually due to traumatic introduction of fungi by thorn or splinterPhaeohyphomycosis (cutaneous phaeomycotic cyst) usually due to traumatic introduction of fungi by thorn or splinterMycetoma (chronic tumor-like lesion with draining sinuses)Systemic (cerebral)---rareHyperkeratosis, microabscesses, PMNs, and GRAN; verrucous appearance, sclerotic bodies presentSubcutaneous cystic granulomatous nodule, surface not involved, hyphae usually presentGRAN, AI, hyaline granulesAbscessesDERMATOPHYTES (*TRICHOPHYTON, MICROSPORUM, EPIDERMOPHYTON* SPECIES)![](fx8.gif)Septate hyphae and yeast forms ("spaghetti and meatballs")MSS (+)PAS (+)FM (+)Skin (tinea corporis or "ringworm," tinea pedis or athlete's foot), hair (tinea capitis), and nails (tinea unguium or onychomycosis)Disseminated (immunocompromised)---very rareChronic dermatitis and spongiosis, little host response, superficial fungal forms*PARACOCCIDIOIDES BRASILIENSIS* (SOUTH AMERICAN BLASTOMYCOSIS)![](fx9.gif)5- to 25-μm double-walled yeast forms that reproduce by gemmulation: 10- to 60-μm "ship's wheel"MSS (+)PAS (+)Skin ulceration (trauma with soil, residency in South America)Upper and lower respiratory tractDisseminated (lymph nodes, liver, spleen, gastrointestinal, genitourinary, bones, adrenal, CNS)Ulcers or vegetations, AI, GRAN, eosinophilsUlcers or vegetations, AI, GRAN, eosinophils, followed by fibrosisUlcers or vegetations, AI, GRAN, eosinophils*SPOROTHRIX SCHENCKII*![](fx10.gif)Round or oval 2- to 6-μm yeast, often in GCUnequal narrow-based buddingElongated cigar-shaped formsNo hyphaeMSS (+)PAS (+)Skin (nodular lymphangitic cutaneous sporotrichosis): red papule that ulcerates and local lymphadenitis (farmers and gardeners, exposure to cats)Extracutaneous: bones and joints, lung---very rareAI and NEC GRAN, hyperkeratosis, pseudoepitheliomatous hyperplasia, intraepithelial abscesses (looks like blastomycosis)Cavitary pneumonitis in one upper lobe*COCCIDIOIDES* SPECIES (*C. IMMITIS, C. POSADASII*)![](fx11.gif)20- to 200-μm nonbudding thick-walled spherules containing 2- to 5-μm endosporesHyphae may rarely be found in pulmonary cavitiesMSS (+)PAS (+)Mucicarmine (−)FM (−)Lung (San Joaquin valley, SW and W): often seen as residual fibrocaseous nodules---organisms may be rare or absentSystemic (meninges, bone, adrenal CNS, liver) (immunocompromised, DM, elderly, pregnant)Single focus, may calcify, AI or GRAN (no GCs)GRAN: if spherules are unrupturedAI: if spherules ruptured and endospores releasedMay be hazardous to laboratory workers if cultured[^31]Data from Lerone DH. Medically Important Fungi: A Guide to Identification, 4^th^ ed. Washington, DC: ASM Press, 2004; and Chandler FW, Watts JC. Pathologic Diagnosis of Fungal Infections. Chicago: ASCP Press, 1987.TABLE 7-53VIRUSES: HISTOLOGIC APPEARANCE AND ASSOCIATED NEOPLASMSHISTOLOGIC APPEARANCE OF VIRUSHOST REACTIONCOMMON SITES (OR CELLS) OF INVOLVEMENTASSOCIATED NEOPLASMS/VALUE OF TESTING FOR VIRUSTESTS TO IDENTIFY VIRUSHERPES SIMPLEX VIRUS (HSV I AND II) (ds DNA)![](fx12.gif)Multinucleated squamous cells, hepatocytes, pneumocytes, microglial cells, or placentaGlassy nuclei with chromatin compressed at nuclear membraneIntranuclear eosinophilic inclusions with a clear halo and thick nuclear membrane (Cowdry A[∗](#tblfn96){ref-type="table-fn"})Vesicles or ulcerated surface with CI and AINecrosis of organs in neonates or immunocompromised patientsSquamous mucosa of esophagus, cervix, or anusSkinLungTemporal lobe (diagnosed by PCR of CSF)No associated neoplasmsIHC for viral proteins (does not distinguish types I and II)ISH/PCRVARICELLA-ZOSTER VIRUS (VZV, ds DNA)Similar to HSVSimilar to HSVSkin: rarely biopsiedLungNo associated neoplasmsIHC (can distinguish VZV from HSV)SMALLPOX VIRUS (ds DNA)![](fx13.gif)Eosinophilic cytoplasmic inclusions (Guarnieri bodies), ballooning degeneration of epithelial cells[†](#tblfn97){ref-type="table-fn"}Multilocular vesicles that coalesce, perivascular lymphocytic infiltrate, AISkinGI tractAll organs in severe formsNo associated neoplasmsIHCelectron microscopy: fluid from vesicles can be used to detect viral particlesPCRReport immediately to the CDC!CYTOMEGALOVIRUS (CMV; ds DNA)![](fx14.gif)Enlarged cells with amphophilic intranuclear (with a surrounding halo) and basophilic intracytoplasmic inclusionsUlcerated mucosa with CI and AIEndothelial cells with thrombosis and infarctionInterstitial pneumonitisEsophagus, colon, lung, adrenal, heart, liver, placentaNo associated neoplasmsIHC (\>40% of U.S. population is infected; significance of \[+\] in normal-appearing cells is unclear)ISH/PCRHUMAN PAPILLOMAVIRUS (HPV, MORE THAN 200 TYPES; ds DNA)![](fx15.gif)Koilocytosis (irregular nuclear enlargement with perinuclear clearing), disrupted keratohyaline granules, hyperkeratosis, parakeratosisSquamous cells with acanthosis, papillomatosis, and coarse clumped keratohyaline granulesVerruca vulgaris: hands, oral cavity, larynx (HPV 2), EV (HPV 5 and 8)Verruca plana: foot (HPV 5 and 8)Condyloma acuminatum: external genitalia (HPV 6 and 11)Cervix: LSIL, HSIL, cancer (HPV 16 and 18)Head and neck cancer (especially tonsil) (HPV 16)SCC of cervix, tonsil, anogenital, papillomas of skin and other sites, cervical adenocarcinomaValue of viral testing: cervical cancer screeningMetastatic SCC: probable primary site[‡](#tblfn98){ref-type="table-fn"}HPV+ tonsillar carcinomas have a better prognosisISH/PCRIHC for p16 (cellular protein overexpressed in \>90% of HPV infections, especially HPV 16 and 18)EPSTEIN-BARR VIRUS (EBV; ds DNA)No diagnostic featuresInfected B cells may have a plasmacytoid immunoblastic appearanceIn oral hairy leukoplakia, the epithelial cells have a foamy balloon cell appearanceLymphocytic infiltrate, peripheral lymphocytosisB cells, oropharyngeal epithelial cells, gastric mucosa, smooth muscleLymphomas,[§](#tblfn99){ref-type="table-fn"} nasopharyngeal carcinoma, lymphoepithelioma-like gastric carcinoma, EBV-associated smooth muscle tumors, IPFDTValue of viral testing:diagnosis of HD; diagnosisof nasopharyngeal carcinomaEBV+ gastric carcinoma has a better prognosisIHC for LMP-1 (nasopharyngeal carcinomas, HD \[not LP\], transplant lymphomas, AIDS-related lymphomas, endemic Burkitt lymphoma) and EBNA 2 (transplant lymphomas, AIDS-related lymphomas)ISH/PCR for EBER-1 and -2 RNAMOLLUSCUM CONTAGIOSUM (ds DNA)![](fx16.gif)Intracytoplasmic molluscum bodies in squamous cells of granular layerAcanthosis of skinSkin: umbilicated nodulesNo associated neoplasmsADENOVIRUS (ds DNA)![](fx17.gif)Alveolar lining cells and bronchial epithelial cells with inclusions filling enlarged nuclei ("smudge cells")Necrotizing bronchiolitis and pneumoniaDiffuse alveolar damageNo GCsLung and other organsNo associated neoplasmsISH/PCR (rarely biopsied; may be cultured)PARVOVIRUS B19 (ss DNA)![](fx18.gif)Large glassy nucleus of nucleated red blood cellsNoneBone marrow, placenta, fetus, and sites of EMHNo associated neoplasmsISH/PCRRABIES VIRUS (ss RNA)![](fx19.gif)Negri bodies: cytoplasmic round to oval or bullet-shaped eosinophilic inclusionsLittle inflammation presentNeurons or Purkinje cellsNo associated neoplasmsISH/PCRIHCMEASLES VIRUS (ss RNA)![](fx20.gif)GC with eosinophilic nuclear and cytoplasmic inclusions, Warthin-Finkeldey cells (multinucleated giant cells)GCs in tracheobronchial mucosa, alveoli, and lymphoid tissueLung: diffuse alveolar damageBrain: subacute sclerosing panencephalitis or measles inclusion body encephalitisNo associated neoplasmsISH/PCR(rare in vaccinated populations; rarely biopsied)RESPIRATORY SYNCYTIAL VIRUS (RSV; ss RNA)![](fx21.gif)Intracytoplasmic eosinophilic inclusionsSyncytial GCs, diffuse alveolar damage, CILungNo associated neoplasmsRarely biopsied; clinical tests are availableMERKEL CELL POLYOMA VIRUS (MCV, MCPYV; ds DNA)No specific featuresNo specific host responseSkinMerkel cell carcinomaClinical tests not yet availableJC VIRUS, POLYOMAVIRUS (ds DNA)Intranuclear basophilic inclusions in oligodendrogliaDemyelination without inflammationSubcortical white matter (progressive multifocal leukoencephalopathy)No associated neoplasmsIHCISH/PCR (can be performed on CSF)BK VIRUS, POLYOMAVIRUS (ds DNA)Decoy cells (tubular or urothelial cells with inclusions) in urineNuclear enlargement in tubules in late phase of infectionPVANTubular cell necrosis, interstitial inflammation, fibrosisUrinary tract (transplanted kidneys)No associated neoplasmsIHCISH/PCR (can be used on urine or bladder washings)Electron microscopy--specific intranuclear inclusionsHEPATITIS B VIRUS (HBV; ds DNA)![](fx22.gif)Cells with ground-glass cytoplasm displacing the nucleusChronic active hepatitis, cirrhosisApoptotic bodiesHepatocytesHepatocellular carcinomaIHC for core antigen (HBcAg) and surface antigen (HbsAg)ISH/PCRHEPATITIS C VIRUS (ss RNA)No diagnostic featuresChronic active hepatitis, steatosis, intralobular inflammation, plasma cells, cirrhosisHepatocytesHepatocellular carcinomaIHCISH/PCRKAPOSI SARCOMA--ASSOCIATED HERPESVIRUS (KSHV, HUMAN HERPESVIRUS-8 \[HHV-8\]; ds DNA)No diagnostic featuresNoneVascular endothelial cells, lymphocytesKaposi sarcoma, multicentric Castleman disease, HHV-8--related lymphomas, primary effusion lymphomaValue of testing for virus: diagnosis of Kaposi sarcomaISH/PCRNote: most primary effusion lymphomas are also EBV+HUMAN T-CELL LEUKEMIA VIRUS (HTLV-1; ds DNA)Lymphocytes with condensed chromatin and a convoluted polylobated nucleus ("flower cells")No specific reactionT cellsAdult T-cell leukemiaValue of testing for virus: diagnosis in patients seronegative for HTLV-1ISH/PCRHuman Immunodeficiency Virus (HIV; ss RNA)No specific changesNo specific reactionCD4+ T cellsImmunosuppression increases risk for other virus-associated neoplasmsDiagnosis usually made by serology[^32][^33][^34][^35][^36]Data from Eyzaguirre E, Haque AK: Application of immunohistochemistry to infections. Arch Pathol Lab Med 132:424-431, 2008; McLaughlin-Drubin ME, Munger K: Viruses associated with human cancer. Biochim Biophys Acta 1782:127-150, 2008; Nuovo GJ: The utility of in situ-based methodologies including in situ polymerase chain reaction for the diagnosis and study of viral infections. Hum Pathol 38:1123-1136, 2007; Slifka MK, Hanifin JM: Smallpox: the basics. Dermatol Clin 22:263-274, 2004.
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###  {#s0570}

####  {#s0575}

##### Indications {#s0580}

•Suspected infectious processes, either by clinical data or by frozen section•Suspected sarcoid to exclude an infectious process

##### Method {#s0585}

Tissue is kept as sterile as possible. Suture removal kits are a convenient source of sterile scissors and forceps. Serially section the specimen to determine if there are focal lesions. Place representative sections in a sterile specimen container making sure to retain a duplicate piece of tissue for histology. Label with the patient's name and unit number, patient's physician, type of specimen, collection date, and time of collection (required for Joint commission accreditation).

##### Results {#s0590}

The results are generally reported by the microbiology laboratory. Communication with the microbiology laboratory and staff is essential to correlate histologic results with microbiology results from the same specimen.

##### Reports {#s0595}

The results of culture of surgical specimens are usually reported in a separate report.

[^1]: Trastuzumab (Herceptin) = a monoclonal antibody directed against the HER2/neu receptor.

[^2]: Imatinib mesylate (STI571, Gleevec™, Glivec™) is a small molecule tyrosine kinase inhibitor used for CML, ALL (Ph+), and GIST.

    The KIT protein is encoded by the c-kit proto-oncogene and is a transmembrane receptor protein with tyrosine kinase activity. Mutated proteins may or may not respond to therapy with Imatinib. Mutations that render KIT independent of its ligand, SCF (stem cell factor), have been found in GIST, AML, germ cell tumors and systemic mastocytosis. Wild-type KIT and KIT with mutations in the juxtamembrane domain (the intracellular segment between the transmembrane and tyrosine kinase domains) are found in GISTs and are sensitive to imatinib. Other tumor types are associated with mutations in the enzymatic domain and the altered protein is generally not sensitive to imatinib.

[^3]: Gefitinib (Iressa) = a tyrosine kinase inhibitor effective against a small subset of lung adenocarcinomas with specific activating mutations.

[^4]: Patients with a ratio of 2.0 or greater have been eligible for Herceptin trials.

[^5]: ^a^Light chains are detected best by immunofluorescence (IF) on unfixed frozen tissue. IF and IHC can be performed on paraffin sections, but with less specificity. Only 50% of cases of light chain disease amyloid will be positive because the amyloid protein is often derived from the variable domain whereas antibodies detect the common domain.

[^6]: Serum amyloid protein A can only be detected by IF on unfixed frozen tissue.

[^7]: Notes:

[^8]: NAME: The most common name used to refer to the marker. The name may refer to the antigen, a CD number, or a specific antibody raised to the antigen. In some cases more than one name is commonly used. Underlined antibodies appear in the tables. Most CD numbers correspond to a specific gene product. However, some correspond to antigens from post-translational modifications. For example, CD15 (LeuM1) is a carbohydrate side chain linked to a protein.

[^9]: ALTERNATE NAME: This list includes abbreviations, antibody names (sometimes recognizing different epitopes), or other terms for the marker.

[^10]: ANTIGEN: The antigen recognized by the antibody.

[^11]: LOCATION: The normal location of the antigen. In some cases, only certain locations of the antigen are considered a positive result (e.g., nuclear immunoreactivity for estrogen receptor, membrane immunoreactivity for HER2/neu).

[^12]: NORMAL CELLS AND TISSUES: The presence of the marker in normal cells and tissues. These cells serve as important internal positive controls. Abnormal positive immunoreactivity is also an important control for the specificity of the study.

[^13]: TUMORS: The tumors in which immunoreactivity is typically expected. Refer to the Tables for additional information.

[^14]: USES: The most common uses for the marker. Different pathologists and institutions will often have preferences for the use of certain markers.

[^15]: COMMENTS: Additional comments regarding the marker.

[^16]: Additional information on CD antigens can be found at <http://www.ncbi.nlm.nih.gov/prow/guide/45277084.htm>.

[^17]: Abbreviations: AD, Alzheimer's disease; AIDS, acquired immunodeficiency syndrome; ALL, acute lymphocytic leukemia; AML, acute myelogenous leukemia; APML, acute promyelogenous leukemia; BM, basement membrane; CML, chronic myelogenous leukemia; CMV, cytomegalovirus; DFSP, dermatofibrosarcoma protuberan; EBV, Epstein Barr virus; FISH, fluorescence in situ hybridization; GIST, gastrointestinal stromal tumor; HCC, hepatocellular carcinoma; HD, Hodgkin's disease; HNPCC, hereditary non-polyposis colorectal cancer; ID, identification; KS, Kaposi's sarcoma; LP HD, lymphocyte predominant Hodgkin's disease; MF, mycosis fungoides; MPNST, malignant peripheral nerve sheath tumor; NK, natural killer; PIN, prostatic intraepithelial neoplasia; PNET, primitive neuroectodermal tumor; RCC, renal cell carcinoma; RS, Reed Sternberg; TCC, transitional cell carcinoma.

[^18]: G, general markers; H, hematopathology markers.

[^19]: See [TABLE 7--28](#t0145){ref-type="table"}, [TABLE 7--9](#t0050){ref-type="table"}, [TABLE 7--22](#t0115){ref-type="table"}, [TABLE 7--47](#t0240){ref-type="table"} for additional information.

[^20]: ^b^Cetuximab (C225, Erbitux) = a monoclonal antibody directed against the EGFR receptor. A test has been approved by the FDA for the determination of EGFR (DakoCyomation, EGFR PharmDX). This test is not used for lung carcinomas.

[^21]: ^ca^Imatinib mesylate (STI571, Gleevec, Glivec) is a small molecule tyrosine kinase inhibitor that may be used for the treatment of tumors overexpressing tyrosine kinases:Bcr-Abl tyrosine kinase: CML, ALL (Ph+)KIT tyrosine kinase: GIST, systemic mastocytosis, some types of AMLPDGFR kinase: CMML, chronic eosinophilic leukemia, rare cases of GIST

[^22]: The KIT protein (CD117) is encoded by the c-kit proto-oncogene and is a transmembrane receptor protein with tyrosine kinase activity. Mutations may render KIT independent of its ligand, SCF (stem cell factor). Mutated proteins may or may not respond to therapy with Imatinib. Wild-type KIT and KIT with mutations in the juxtamembrane domain (the intracellular segment between the transmembrane and tyrosine kinase domains) are found in GISTs and are sensitive to imatinib. Other tumor types are associated with mutations in the enzymatic domain and the altered protein is generally not sensitive to imatinib. Overexpression of the protein is detected by IHC.

[^23]: Trastuzumab (Herceptin) = a monoclonal antibody directed against the HER2/neu receptor. Patients are selected for treatment by testing carcinomas with IHC or FISH.

[^24]: Gefitinib (Iressa) = a tyrosine kinase inhibitor effective against a small subset of lung adenocarcinomas with specific activating mutations in EGFR. IHC for EGFR is not helpful for identifying carcinomas likely to respond to treatment.

[^25]: The KIT protein is encoded by the c-kit proto-oncogene and is a transmembrane receptor protein with tyrosine kinase activity. Mutations may render KIT independent of its ligand, SCF (stem cell factor). Mutated proteins may or may not respond to therapy with Imatinib. Wild-type KIT and KIT with mutations in the juxtamembrane domain (the intracellular segment between the transmembrane and tyrosine kinase domains) are found in GIST's and are sensitive to imatinib. Other tumor types are associated with mutations in the enzymatic domain and the altered protein is generally not sensitive to imatinib.

[^26]: For additional information on specific genes, see Online Mendelian Inheritance in Man (OMIM; [www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov){#interref4}).

[^27]: Imatinib mesylate (STI571, Gleevec, Glivec) is a small molecule tyrosine kinase inhibitor that may be used for the treatment of tumors overexpressing tyrosine kinases:Bcr-Abl tyrosine kinase: CML, ALL (Ph+)KIT tyrosine kinase: GIST, systemic mastocytosis, some types of AMLPDGFR kinase: CMML, chronic eosinophilic leukemia, rare cases of GIST

[^28]: See Lakhani SR, et al, The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20:2310-2318, 2002, for additional information relating pathologic characteristics to risk of a BRCA1 mutation.

[^29]: For additional information on most syndromes, see <http://www.genetests.org/>and Online Mendelian Inheritance in Man (OMIM; [www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov){#interref6}).

[^30]: MSI-H is found in 11% of sporadic colon carcinomas and has histologic features similar to patients with germline mutations. There is reduced response to 5-FU but better survival. \>5 fold increased risk of metachronous cancers.

[^31]: AB, Alcian blue; AI, acute inflammation; BV, blood vessel; CNS, central nervous system; CSF, cerebrospinal fluid; DM, diabetes mellitus; FM, Fontana Masson; GC, giant cell; GI, gastrointestinal; GRAN, granulomas; IHC, immunohistochemical methods; ISH, in situ hybridization methods; MP, macrophage; MSS, silver stain (similar to GMS---Grocott-Gomori methenamine silver); NEC GRAN, necrotizing granulomas; PAS, periodic acid--Schiff; PMNs, polymorphonuclear leukocytes; (+), positive; (-), negative.

[^32]: AI, acute inflammation; CI, chronic inflammation; CDC, Centers for Disease Control and Prevention; CSF, cerebrospinal fluid; ds, double-stranded; EBER, EBV-associated nonpolyadenylated early RNAs; EBNA 2, EBV nuclear antigen 2; EMH, extramedullary hematopoiesis; EV, epidermodysplasia verruciformis; GC, multinucleated giant cells; GI, gastrointestinal; HD, Hodgkin disease; HSIL, high-grade squamous intraepithelial lesion; IHC, immunohistochemistry uses antibodies to visualize either viral proteins (e.g., LMP-1 or HBcAg) or cellular proteins increased during infection (e.g., p16) on tissue sections; IPFDT, inflammatory pseudotumor-like follicular dendritic cell tumor; ISH/PCR, viral nucleic acids are amplified by polymerase chain reaction (PCR) and either quantified or visualized on tissue sections (in situ hybridization); LMP-1, latent membrane protein 1; LNA-1, latency-associated nuclear antigen (or LANA1); LP, lymphocyte predominant HD; LSIL, low-grade squamous intraepithelial lesion; PVAN, polyomavirus-associated nephropathy; SCC, squamous cell carcinoma; ss, single-stranded.

[^33]: Cowdry type B inclusions were described as smaller inclusions associated with polio. However, this finding has not been validated and is not currently used for diagnosis.

[^34]: Monkeypox has a similar appearance. Intracytoplasmic inclusions are characteristic of smallpox and are not seen in HSV or VZV infections. It may be difficult to distinguish smallpox, HSV, and VZV by H&E alone (Nuovo GJ, Plaza JA, Magro C: Rapid diagnosis of smallpox infection and differentiation from its mimics. Diagn Mol Pathol 12:103-107, 2003).

[^35]: The presence of HPV in metastatic carcinoma to a lymph node suggests a primary in the tonsil (if in the head and neck) or cervix (if abdominal).

[^36]: Burkitt lymphoma, classic Hodgkin lymphoma (but not lymphocyte-predominant Hodgkin lymphoma), AIDS-associated B-cell lymphoma, plasmablastic lymphoma, post-transplantation lymphoproliferative disorder, lymphomatoid granulomatosis, methotrexate-associated B-cell lymphoma, severe combined immunodeficiency--associated B-cell lymphoma, Wiskott-Aldrich syndrome--associated B-cell lymphoma, X-linked lymphoproliferative disorder--associated B-cell lymphoma, EBV-positive diffuse large B-cell lymphoma of the elderly, peripheral T-cell lymphoma, extranodal NK/T-cell lymphoma, nasal type, virus-associated hemophagocytic syndrome T-cell lymphoma. Angioimmunoblastic T-cell lymphoma is associated with EBV+ B cells. However, the neoplastic T cells are negative for EBV.
